

**Studies of Oral Vaccination against Infectious Pancreatic Necrosis in Atlantic salmon:
Focus on Antigen Production, Antigen Kinetics, and Immune Responses**


**Studier av oral vaksinerings mot infeksjøs pankreas nekrose hos atlantisk laks: Fokus på
antigen produksjon, antigen kinetikk, og immunrespons**

Philosophiae Doctor (PhD) Thesis

Lihan Chen

Department of Basic Sciences and Aquatic Medicine
Faculty of Veterinary Medicine and Biosciences
Norwegian University of Life Sciences

Ås/Adamstuen 2015



Thesis number: 2015:15
ISSN: 1894-6402
ISBN: 978-82-575-1940-7

Contents

1	Acknowledgements	1
2	Summary	2
3	Sammendrag	4
4	Acronyms/Abbreviations	5
5	Papers	7
6	Introduction	8
6.1	General background	8
6.2	Oral vaccines	8
6.3	Vaccine types	11
6.3.1	Inactivated viral vaccine	11
6.3.2	Subunit viral vaccines	11
6.3.3	Attenuated viral vaccine	12
6.3.4	DNA vaccine	12
6.4	Challenges of oral vaccines for IPN	13
6.4.1	Antigen production	13
6.4.2	Antigen Kinetics	15
6.4.3	Immune response	17
6.4.4	Immune tolerance	19
7	Objectives	21
8	Methodology	22
8.1	Overview	22
8.2	Cells, virus, vaccines, and fish	23
8.3	Virus detection and quantification	24
8.4	Gene expression	25
8.5	Cellular antiviral activity test	25
8.6	Humoral Antibody quantification	25
9	Summary of separate papers	27
	Paper I: Delayed protein shut down and cytopathic changes lead to high yields of infectious pancreatic necrosis virus cultured in Asian Grouper cells	27
	Paper II: IPNV antigen uptake and distribution in Atlantic salmon following oral administration	27
	Paper III: Augmentation of the antibody response of Atlantic salmon by oral administration of alginate-encapsulated IPNV antigens	28
10	Results and Discussion	30
10.1	Overview	30
10.2	High yield of infectious pancreatic necrosis virus produced by Asian grouper cell strain K (AGK)	30
10.2.1	The effects at cell population level	30
10.2.2	The effects at individual cell level	30
10.3	The IPNV antigen uptake kinetics	33
10.4	IPNV antigen distribution in the organs	34
10.5	The immune responses following oral vaccination with IPNV in Atlantic salmon	36
10.6	The local humoral responses	37
10.7	Immune tolerance	38
10.8	The correlation between antigen kinetics and immune responses	39
11	Conclusion	41
12	Perspectives	42
	Reference List	43

1 Acknowledgements

I would like to thank the Research Council of Norway (FUGE project no. 187848) and Schweitzer Biotech Company (Taiwan) for the financial support and the Department of Basic Sciences, Section of Aquatic Medicine at the Norwegian University of Life Sciences for supporting my studies.

The major appreciation goes to my supervisors, Professor Øystein Evensen and Associate Professor Stephen Mutoloki for their help, critical supervision, and patience throughout this period. I have learnt a lot because they guided me through experimental design and insightful discussions to ultimately become independent in scientific research.

Further I am grateful to my colleagues at the Aquatic Medicine lab at BASAM, NMBU for making a scientific and harmonious environment. Especially I want to thank Hetron Mweemba Munang'andu, Cheng Xu, Sunghyun Kim, Amr Gamil, and Tz-Chun Guo for cheering me up when I was in the depressing situation during the last year of my PhD study.

To my co-authors, thanks for your contribution to this thesis, particularly Goran Klaric for the sampling and producing the feed vaccines using with marine alginate encapsulated IPNV.

I also want to thank all my friends, John Chung, Fan-Ching Lin, Fu WanRong, Yi-Man Gao, Hao-jhong Lee, I-Hsiang Tsai, Wan-Zih Chen, Chao-Ling Liao, Naoki Kubota, David Hsu, Pei-Yuan Hsu, Te-Fu Wu, Endymion Chejen Jiang and Wendy Shu. They gave me strength to finish my study with tight budget and enriched my life in Norway.

Last but not least, I must appreciate my dear parents, Lin-Gu Chen and SU-Yi Wu, my brother, Li-Hsin Chen, and my girlfriend, Ching-Hung Chan, for unlimited support and encouragement. You are the most precious possession to me.

Thank you all! Hsieh Hsieh Da Ja!

2 Summary

Infectious pancreatic necrosis has been one of the serious diseases that cause large economic loss every year in salmonid aquaculture. Although commercial injection vaccines against IPN are used regularly in several salmon-producing countries, oral vaccines are the preferred option from a fish farmer's perspective, because oral administration is less labor-intensive, stress-free, and applicable to smaller fish. The development of oral vaccines is confronted by three challenges: (1) inefficient antigen production since huge quantities are required, (2) limited knowledge of antigen kinetics related to antigen uptake, and (3) equivocal immune responses, local and systemic, as regards humoral immune responses and immune tolerance.

In this thesis, three studies were performed to investigate those three challenges of oral vaccination. The antigen chosen for the oral vaccine was an inactivated antigen (IPNV), considered safer than attenuated virus and plasmid DNA as well as more immunogenic than subunit protein vaccines. In paper I, AGK cells showed better ability to support IPNV production compared to the other available cell lines such as RTG-2. Improved production efficacy is likely associated with low antiviral responses in AGK cells and high cell productivity. The rapid growth of AGK cells (two passages per week at 1:4 split ratio), and high viral titer (10^9 TCID₅₀/ml) obtained with these cells could supply large quantities of antigen for vaccine production. In the second study, the antigen kinetics including uptake, delivery, and distribution were investigated. Orally delivered, inactivated IPNV was taken up efficiently and detected in immune organs, at levels similar or higher than those of the other three groups: orally intubated live IPNV, orally intubated live IPNV, and orally intubated inactivated IPNV, suggesting that oral vaccination using inactivated antigen can be an effective strategy against IPN. Finally, immune responses following oral boost demonstrated that when inactivated IPNV is encapsulated with marine-alginate and used as a boost vaccine, local and systemic humoral immune responses were up-regulated (mRNA) such as IgT and IgM. However, it appeared that immune tolerance, not humoral immune response, was induced if only inactivated IPNV (non-formulated) was used for boost.

Overall, this thesis provides insights to the three major challenges of oral vaccine for IPNV: (1) antigen production, (2) antigen kinetics, and (3) induction of immune responses. Furthermore, the results imply that the oral alginate encapsulated inactivated vaccine would have a potential to

protect Atlantic salmon against IPN, although challenge trials are needed to confirm this in lab and in field studies.

3 Sammendrag

Infeksiøs pankreasnekrose har vært en av de alvorlige sykdommer som forårsaker store økonomiske tap hvert år i akvakultur over de siste tiårene. Det finnes injeksjonsvaksiner mot IPN, men orale vaksiner er den foretrukne varianten sett fra et oppdretterperspektiv av den grunn at oral administrasjon er mindre arbeidskrevende, stress-fri, og kan appliseres for liten fisk (som i dag ikke kan injiseres). Utviklingen av orale vaksiner er konfrontert med tre utfordringer: (1) kostbar antigen produksjon, (2) mekanismene og kinetikken for antigen opptak fra tarmen er lite kjent, og (3) tvetydige immunresponser som inkluderer humorale immunresponser og immuntoleranse.

I denne avhandlingen ble tre studier utført for å adressere disse utfordringene. Vi valgte å studere IPN hos laks og baserte studiene på inaktiverte antigener, som er sikrere enn attenuert virus, og plasmid DNA, og gir generelt bedre immunrespons enn subenhets-proteiner (rekombinante proteiner). I artikkel I, fant vi at AGK gir bedre celler IPNV titer i forhold til andre tilgjengelige cellelinjer som RTG-2 og CHSE. AGK gir høyere titer på grunn av de lave antivirale responser og høy replikeringsrate. Rask vekst for AGK-celler (to passasjer med 1 til 4 split ratio hver uke), og et høyt virustiter (opp til 10^9 TCID₅₀ / ml) gjør at man kan produsere store mengder antigen i løpet av relativt kort tid. I den andre studien, ble antigen-kinetikk studert med vekt på opptak og systemisk distribusjon undersøkt. Inaktivert IPNV levert via oral rute ble tatt opp effektivt fra tarmen og påvist i immunorganer, og de nivåer som ble påvist var høyere enn for de tre andre gruppene: oral, levende IPNV, analt intubert levende IPNV, og analt intubert inaktivert IPNV. Dette tyder på at oral vaksinasjon med inaktivert antigen kan være en effektiv strategi mot IPN. I den tredje studien fant vi at immunresponsen etter oral boost med inaktivert IPNV innkapslet i marint alginat, opp-regulerte lokale og systemiske humorale immunresponser som IgT og IgM. Hvis inaktivert IPNV antigen (alene, ikke-formulert) ble det påvist immuntoleranse.

Samlet gir denne avhandlingen innsikt til de tre store utfordringene for orale vaksiner; (1) antigen produksjon, (2) antigen kinetikk, og (3) induksjon av immunresponser. Resultatene gir gode indikasjoner for at oral levert antigen, innkapslet i marint alginat har en mulighet for å beskytte laks mot IPNV smitte. Framtidige studier bør inkluderesmitteforsøk for å bekrefte beskyttelse.

4 Acronyms/Abbreviations

IPNV	-	Infectious pancreatic necrosis virus
VP	-	Variable protein
DNA	-	Deoxyribonucleic acid
ISAV	-	Infectious salmon anemia virus
SAV	-	Salmonid Alphavirus
SVCV	-	Spring viraemia of carp virus
VLP	-	Virus like particle
SVP	-	Subviral particle
MHC	-	Major histocompatibility complex
IHNV	-	Infectious hematopoietic necrosis virus
VNNV	-	Viral nervous necrosis Virus
IFN	-	Interferon
Mx	-	Interferon-induced GTP-binding protein Mx
RTG-2	-	Rainbow trout gonad cells-2
CHSE-214	-	Chinook salmon embryo 214
AGK	-	Asian grouper cell strain K
TCID	-	Tissue culture infective dose
M cell	-	microfold cell
³ H-LPS	-	³ H-labeled Lipopolysaccharide
MMC	-	Melanomacrophage center
Ig	-	Immunoglobulin
GALT	-	Gut-associated lymphoid tissue
Treg	-	Regulatory T cell
TGF- β	-	Transforming growth factor β
IL-10	-	Interleukin 10
FOXP3	-	Forkhead box P3
Th	-	T-cell helper
qRT-PCR	-	Quantitative reverse transcription polymerase chain reaction
IHC	-	Immunohistochemistry
ELISA	-	Enzyme linked immunosorbent assay
UNENCAP	-	Group given feed containing unencapsulated IPNV antigens

ENCAP	-	Group given feed containing alginate-encapsulated IPNV antigens
FBS	-	Deoxyribonucleic acid
MOI	-	Multiplicity of infection
IFAT	-	Indirect fluorescent antibody technique
RNA	-	Ribonucleic Acid
d.p.i.	-	Day post intubation
SDS-PAGE	-	Sodium dodecyl sulfate polyacrylamide gel electrophoresis
PVDF	-	Polyvinylidene fluoride
OD	-	Optic density
CD	-	Complementary determinant
GATA-3	-	Transcription factor that recognize (A/T)GATA(A/G) motifs in DNA

5 Papers

- I. Lihan Chen, Øystein Evensen, and Stephen Mutoloki. Delayed protein shut down and cytopathic changes lead to high yields of infectious pancreatic necrosis virus cultured in Asian Grouper cells. *J. Virol. Methods*, 195, 228–235, 2014
- II. Lihan Chen, Øystein Evensen, and Stephen Mutoloki. IPNV antigen uptake and distribution in Atlantic salmon following oral administration (Manuscript).
- III. Lihan Chen, Goran Klaric, Simon Wadsworth, Suwan Jayasinghe, Tsun-Yung Kuo, Øystein Evensen and Stephen Mutoloki. Augmentation of the antibody response of Atlantic salmon by oral administration of alginate-encapsulated IPNV antigens. *PLoS One*, in press.

6 Introduction

6.1 General background

Infectious pancreatic necrosis disease (IPN) is a serious problem in the aquaculture industry affecting a number of fish species [1]. It was first reported as an acute catarrhal enteritis infecting brook trout (*Salvelinus fontinalis*) in Canada in 1940 [2], and the infectious agent was isolated and named infectious pancreatic necrosis virus (IPNV) by Wolf *et al.* in 1960 [3]. Currently it has a world-wide distribution, and has been isolated from more than 32 fish species, 11 molluscs and four crustacean species [4]. The disease has been a major concern in brook trout, rainbow trout, and Atlantic salmon initially in North America and subsequently in Europe since the early 20th century [2;5;6].

The economic importance of IPN is mainly due to the mortality that it causes and the high morbidity associated with the virus [7]. In salmonids, IPNV infection causes more than 70% mortality in hatchery stocks over a period of two months [8]. Survivors of infection may become asymptomatic carriers and shed virus in their feces and reproductive products throughout the whole life [9]. From the 1990s, IPN became significant in terms of mortality and economic impact in the marine environment, when acute losses in post-smolts were reported shortly after their introduction to sea water [10-12]. The general observation was that IPN occurred 5–8 weeks after seawater transfer [13], and a decline in losses normally started after the peak summer months [14]. As the salmonid aquaculture industry has expanded extensively in recent decades, economic losses due to IPNV were estimated to be over \$60 million in 1996 [15;16]. Although injectable vaccines have been developed and licensed [17], the incidence of IPNV remains high particularly in Chile while in Norway we have seen a declining trend over the last 3-4 years [10]. Moreover, these vaccines are limited by the size of fish due to the reliance on injection for vaccination.

6.2 Oral vaccines

Three major routes of IPN vaccine delivery are used for aquatic vaccination: injection (intraperitoneal and intramuscular), immersion, and oral administration. Each delivery route has its own advantages and limitations. In this thesis, oral administration was selected as the delivery method under study.

Oral vaccination is the most desirable method from a fish farmer's perspective. The advantages are stress-free vaccination with no handling of the fish, possibilities for multiple boost and the possibility for boost immunization in open water [18]. Unlike the injection delivery route, fish are not handled individually during oral delivery and therefore oral vaccination can be applied to small fish in order to reduce the cost and mortality associated with handling of the fish caused by delivery of injectable vaccine. Although immersion vaccination also offers the advantage of zero handling stress [19], it usually requires a combination of other strategies to improve efficacy, such as reduced water level, use of ultrasound, hyperosmotic infiltration, or attenuated bacterial delivery, which also stress the fish. Because of low stress, reduced labor-costs, and no restriction on fish size, oral vaccines can be used repetitively in the lifespan of a fish. Oral vaccines can be delivered to juvenile fish just developing immunity, to fish prior to release in seawater. Recently, oral administration has been shown to induce antigen-specific antibodies with immune cells in the skin mucus, bile or intestine in several fish species [20;21]. Since both intestine and skin have been suggested as possible routes of entry for IPNV and other pathogens, building local defense mechanisms involving the mucosal immune system is probably important [22]. Allnutt *et al.* (2007) suggested that fish vaccinated orally against IPN had an immune response greater than that observed in naïve and control rainbow trout after an 8 weeks induction period [23]. Therefore, vaccination via mucosal surfaces such as the intestine is an attractive delivery mode for protection against IPN [24].

Antigens delivered orally are delivered as an in-feed formulation, top-coated or incorporated into the pellet. Unlike the injection vaccine, it has to pass through the gastric juice and be exposed to digestive enzymes before reaching intestine (foregut and/or hindgut). Hindgut has been considered the prime site of antigen uptake [25]. Many novel methods have been reported to ensure the dose and quality of the antigens are maintained by the time they arrive in the hindgut. The antigen protection strategies include nano- or micro- particles and bio-encapsulation. The antigens are either encapsulated within the particles or covalently linked to the particles. Often the compounds used to form these particles are acid resistant and biodegradable. They help protect the antigens through the stomach to the intestine thus making them attractive for immunization. For example, alginates which are polysaccharides found naturally in brown algae have been used to encapsulate antigens in several oral vaccine studies. Marine alginates are ideal polymers for use in the oral vaccine delivery systems with protective features. Alginate encapsulation provides an effective method to protect bioactive compounds from acidic and

proteolytic degradation in gastrointestinal tract, because alginates shrink at low pH and dissolve at high pH. Therefore, most antigens are shielded through the stomach, and after they have passed the acidic part of the digestive tract and reach the hindgut (with pH>7), a release from the alginate matrix occurs. Joosten *et al.* (1997) were the first to employ the alginate encapsulated technology to deliver a commercial *V. anguillarum* vaccine in both carp and rainbow trout [26]. Although the vaccine was taken up by both species, the antibodies were only significantly induced in carp but protection was not measured. Romalde *et al.* (2004) successfully administered an alginate encapsulated *Lactococcus garvieae* bacterin to rainbow trout, with 50% protective level by oral immunization while the alginate-encapsulated vaccine used as booster immunization strategy showed 87% relative protection against lactococcosis. These results suggested that while the vaccine may not be suitably immunogenic itself, it may be suited to boost fish previously vaccinated by injection [27]. Recently, Leal *et al.* (2010) examined various delivery routes of a *Flavobacterium columnare* bacterin in Nile tilapia (*Oreochromis niloticus*), including formalin-killed bacteria in alginate microparticles delivered orally and bacterin delivered by intramuscular injection, intraperitoneal injection and immersion. Unfortunately, none of these delivery methods resulted in protection. Additionally, a significant humoral immune response was only detected in fish immunized by i.p. or i.m. methods [28]. In contrast, De las Heras *et al.* (2010) showed that alginate microsphere encoding DNA plasmid made from VP2 of IPNV showed high protection in immunized fish (80%) challenged 15 and 30 days after vaccine delivery [29].

Bioencapsulation has been utilized for vaccines and other materials in aquaculture such as for microalgae, artemia, and plant expressed vaccines. The microalgae *Chlamydomonas reinhardtii* was used as an oral vaccine delivery system for fish [30]. When *Renibacterium salmoninarum* protein 57 gene was transformed and expressed in the algae and given to the fish, the observation of systemic antibody response indicated the acid resistant cell wall of *Chlamydomonas* enabled the proteins to reach the posterior gut. Similarly, Companjen *et al.* (2006) delivered the transgenic potato tubers that expressed part of the *E. coli* gut adhesion molecule (LBT) fused to either green fluorescent protein (GFP) or viral peptides to carp and this resulted in an antibody response [31]. Artemia was also used to bioencapsulate antigens or rather as a vehicle. When Artemia was fed to fish following exposure to the antigen, the immune response against the pathogen was induced in older carp and gilthead sea bream [32] with 81% of vaccinated fish surviving compared to 31% of the controls post challenge in zebra fish [33].

6.3 Vaccine types

Four types of antigens are usually used for vaccination against viral diseases namely; (i) inactivated virus, (ii) recombinant viral protein (subunit), (iii) attenuated virus, and (iv) plasmid DNA. In addition comes virus-like particles (VLP), replication deficient viruses various fusion-proteins of protective antigen and an immunomodulator. Not all these technologies are applied for fish and in addition there are a limited number of reports that focus on the use of oral vaccines for fish. Therefore, the discussion here is not confined to oral vaccines, but includes other vaccine delivery systems.

6.3.1 Inactivated viral vaccine

Inactivated virus preparations are commonly used in vaccine preparations/formulations. In fish, they were the earliest type of vaccines and are still a reliable and popular strategy of immunization, and they constitute a great opportunity for studying vaccine responses in fish. Many inactivated vaccines for fish are commercially available, such as the Alpha Ject[®] series from PHARMAQ AS against IPNV, Micro-1 against ISA, an experimental vaccine against pancreas disease (PD), and a vaccine against spring viremia of carp (SVCV). Compared to attenuated and DNA vaccines, inactivated viral vaccine are safe for use as they are not infectious and do not cause horizontal transfer like live virus which could cause adverse ecological effects to the aquaculture environment unless well controlled. Inactivated vaccines can also induce strong immune responses since they allow use of adjuvants and also retain all exposed antigens of the virus that are important to stimulate the host immune responses. Previous studies have shown that inactivated whole viral vaccines gave better protection than recombinant subunit vaccines for IPN [34;35]. The weak points of inactivated vaccine are the short protection period if adjuvants are not included and high expense and time of antigen production. Therefore, efficient virus culturing systems are important for inactivated vaccine in addition to adjuvants.

6.3.2 Subunit viral vaccines

Subunit, protein-/peptide-based vaccines are also used to some extent. Specific viral proteins, usually capsid proteins with good immune-stimulating ability, are produced in a recombinant

system allowing rapid production of a single or small number of viral antigens. Subunit vaccines can include a non-native form of the antigen with little secondary structure and no tertiary structure formed or recombinant proteins can self-assemble and make virus like particles (VLPs) and subviral particles (SVPs) that attain the form of the virus or a smaller version. As an example of subunit IPN vaccines, VP2 and VP3 were expressed in vitro and formed VLPs [36] because of the intrinsic ability of viral structural proteins to self-assemble [37-39]. These VLPs were similar in size to the native virus and induced a strong immune response in salmon [36;40]. A more recent study described an IPN vaccine based on a SVP made from the VP2 of IPNV [23]. In this study, the subunit vaccine induced a strong immune response against IPNV [41]. Three other vaccines based on the VP2 of IPNV are already marketed under the trade names IPNV (licensed in Chile, Centrovet, Chile), Norvax (Intervet-International BV, The Netherlands), SRS/IPNV/*Vibrio* (licensed in Canada and Chile, Microtek International Inc., British Columbia, Canada). However, previous studies are indicative of the protection of subunit vaccine being weaker than inactivated vaccine when the doses were comparable [34].

6.3.3 Attenuated viral vaccine

Attenuated viral vaccines were the first type of vaccines to be used in the history of vaccinology. These vaccines are live viruses that have been selected for non-virulence and cross reactivity (against the pathogenic strains) and/or cultured under conditions that disable viral virulence. Therefore, the virus replicates at much lower rate and are less pathogenic than the wild type virus. Attenuated viral vaccines typically induce a strong and sustained immune response against the target disease, but few commercial vaccines are based on this mode of vaccine production nowadays because of safety issues. The only commercial attenuated viral vaccine in aquaculture is found in Israel for cyprinid herpes virus 3 in koi carp [42].

6.3.4 DNA vaccine

DNA viral vaccines are among the promising vaccine preparations for easy delivery by injection or through feed using naked plasmid DNA encoding a selected gene/part of a gene of the pathogen. Upon injection using the intramuscular route, the antigen is expressed and presented via both MHC I and MHC II to lymphocytes. Therefore, a DNA vaccine can induce not only humoral immunity but also cell-mediated immunity [43]. Ballesteros *et al.* also reported that oral

DNA vaccine induced MHC II, IgM⁺, IgT⁺, and CD3⁺ in the digestive tract of rainbow trout [44]. In aquaculture, the first commercial DNA vaccine was used against infectious hematopoietic necrosis virus (IHNV) in 2005 in Canada (New-Brunswick) [45]. Since then all Atlantic salmon have been vaccinated against IHN and no disease outbreaks have been seen in vaccinated populations. Under experimental conditions, DNA vaccines have been tested for their efficacy against a number of fish viruses, including Infectious Hematopoietic Necrosis Virus [46;47], Viral Nervous Necrosis Virus (VNNV) [48], Infectious Pancreatic Necrosis Virus (IPNV) [29;49] and Spring Viremia Carp Virus (SVCV) [50;51] with variable efficacy, mainly providing good protection against viruses of the family *Novirhabdoviridae*. It should be added that the production cost of these vaccines is high and there are still concerns related to the safety of the use of DNA vaccines such as induction of immune tolerance in the vaccinated animal, end-consumer safety (and GMO labeling of vaccinated fish), and the transparency/regulatory difficulties for European and many Asian markets [52].

6.4 Challenges of oral vaccines for IPN

6.4.1 Antigen production

Since it is difficult to guarantee the safety of live attenuated and DNA vaccines while inactivated vaccines show better protection than subunit vaccines, the inactivate IPNV vaccines would be the best choice for oral vaccination against IPN. It is important to produce the inactivated virus efficiently in culture systems yielding high viral concentration, especially for oral vaccines where the “consumption” of antigen is high. Previous studies suggested that a higher antigen dose of oral vaccines induced a stronger immune response than the lower antigen dose [35]. Cell culture is the best way to produce high concentrations of fish viruses so far, but cell line selection and production conditions often require optimization and the output is highly variable for the different species of virus. Therefore, a culture system that can efficiently produce high concentrations of virus is the first challenge in the production of oral vaccine.

To establish the best criteria of a good virus production system, knowledge of the viral infection process and the cellular responses post infection is necessary. Viral infection entails attachment, penetration of the cell membrane and transfer to cellular compartments, release of viral genome and initiation of transcription, protein translation, viral replication, assembly and release. Viruses

attach to the cell by viral surface antigens that bind to specific host receptors. Therefore, a cell cannot be infected without carrying a receptor for that particular virus on its outer surface. This process starts as an extracellular protein-to-protein interaction although carbohydrates and lipids are occasionally used. Once the virus gains entry into host cell, the viral genome is released and makes its way to the site of transcription, translation and replication. This can be in the cytoplasm, in organelles, or in the nucleus. Thus, the cells chosen for virus propagation should have the receptor for the virus in order to get the virus penetrate and deposit its genome in the host cell.

After entry in the host cell, the early gene products of the viral genome are translated in the cell. Most of the early proteins produced regulate the transcription of later viral genes and viral genome replication, but some of them influence the activities of host cells. For example, some translated proteins are used to induce antiviral immune responses or to control the life cycle of host cells, and subsequently to help the viral replication smoothly. For example, VP5 of IPNV serotype Ab was found to counteract the defense mechanisms that trigger apoptosis before necrosis in the host [53]. It does so by affecting the cellular gene encoding "suicide" of the early replication phase and can thus enhance the replication of the virus [53].

The later genes products are normally structural proteins required for the construction of new capsids have the viral epitopes required for the next infection. The last step is the packaging of the newly produced viral genome and virion proteins followed by the release of viral particles by budding-out, necrosis, or apoptosis. On the other hand, infected cells usually have some anti-viral reaction following virus infection. The production of interferon (IFN) by some cell types has been linked to decrease in virus replication [54]. Galligan *et al.* (2006) suggested that cellular IFN is produced by infected cells and acts on neighboring cells by inducing the production of many IFN stimulated genes including Mx to create an antiviral state [55]. In addition, apoptosis and protein shutdown are also well-known mechanisms employed by cells to protect themselves against virus infections [56-58]. These responses are also used by viruses to subvert the host antiviral responses in some cases [59;60]. Based on the infectious process described above, the following are some of the requirements needed good virus producing systems; (1) cells must provide the appropriate conditions that virus can enter the host cell, unpackage the viral genome and allow the virus to reach the area of replication, (2) cells must have a high growth rate and high confluent density that supply more resource to virus required by the virus to synthesize its own protein and genome, and (3) cells must induce a weak antivirus response following infection,

(4) the cells should also not enter into apoptosis and/or necrosis to allow sustained production and release of virus progeny and (5) facilitate release of virus from the cell.

For IPNV, although several cell lines have been tested for their suitability to propagate the virus [61] and some of them are indeed used for IPNV propagation by several scientists that include rainbow trout gonad 2 (RTG-2) and Chinook salmon embryo 214 (CHSE-214) cells, the cell culture systems are not economically viable since typical yield for IPNV Sp serotypes, which causes most outbreaks in Europe, are 10^6 – 10^7 pfu/ml in RTG-2 cells [62]. Further to this, RTG-2 and CHSE-24 require many days in culture before they have reached a sufficient confluence to be infected and for large volumes, these characteristics are prohibitive. Recently, a new cell line Asian Grouper strain K (AGK) has shown the capacity to grow rapidly in culture becoming confluent at with 3 days post split, and it yields a virus titer of 10^9 – 10^{10} TCID₅₀/ml depending on virus strain used [34]. Therefore, this cell-line represents a better solution for production of high concentration of IPNV antigen. These cells are derived from the skin of a crossbreed between Orange-spotted grouper (*Epinephelus coioides*) and Malabar grouper (*Epinephelus malabaricus*). The cell line is not a mono-clone but is composed of different cell types. AGK cells grow at a higher temperature, can be split at high ratios and have a much shorter turn-around time making them a very valuable resource for easy production of IPNV in large quantities within a short period of time. However, the investigation and documentation of the factors that permit the production of high titers and high volumes of IPNV are absent. Better understanding of the dynamics of IPNV infection in AGK cells will contribute to a better vaccines being used for aquaculture.

6.4.2 Antigen Kinetics

Oral vaccination is a popular topic these years and has shown good protective efficacy under experimental conditions. Although elements of the protective immune response against IPNV in Atlantic salmon have been discussed by various scientists [63-65], there is no any evidence that categorically shows that viral vaccines really passing through the gut barrier and that viral antigen reach the immune organs of fish such as head kidney and spleen. The missing of antigen uptake and delivery in these studies is a crevice of oral vaccination studies and probably accounts for the reason of the inconsistent efficacy of oral vaccines in fish farm. In mammals, the mucosal

system of the intestine is highly organized in form of Peyer's patches and lymphoid follicles [66]. The Peyer's patches possess microfold cells (M cells) that do not contain lysosomes and can therefore transport foreign antigens intact across the cells to enable an integration of innate and adaptive mechanisms [67;68]. This property has not conclusively been shown in any epithelial cells of fish. However, the existence of M-cell like cells has been proposed for salmonids [69]. For IPNV, elements of the protective immune response against IPNV in Atlantic salmon have been elucidated by various scientists [63-65] but the initial IPNV invasion of the host is still disputed. The dispute leaves a demand for understanding the uptake and organ distribution of antigens in Atlantic salmon following oral and anal administration. Several scientists have studied the uptake of various types of antigens in fish following oral and anal intubation. Dalmo *et al.* (1998) showed that the spleen and liver contained high amounts of radioactivity in turbot, but the intestine only in Atlantic cod after oral treatment with ³H-LPS [70]. In rainbow trout and carp, the gastro-intestinal tract was suggested as one of the primary areas where bacterial antigens are take-up after exposure followed by presentation to central immune organs involved in the final antigen processing [65;71]. In salmonid, the second segment of the mid-intestine also represents evolutionary early antigen-sampling enterocytes [69] and the anal administration induces stronger immune response against bacteria than oral administration does [72]. Only a few studies have been concerned with IPNV uptake and organ distribution following vaccination from intestine. IPNV was detected in the cow's gut up to 72 h after feeding a silage mixture containing IPNV [22]. Both proximal and distal intestines were suggested sites of IPNV antigen uptake in Atlantic salmon [73].

Once the antigen crosses the intestine barrier, it is transported to immune organs i.e. head kidney and spleen where an antibody response is induced. The head kidney of teleost fish is equivalent to the bone marrow in other vertebrates [74]. The head kidney is composed of a network of reticular fibers that provide support for the lymphoid tissue and are found scattered among hematopoietic system cells that line the sinusoid reticuloepithelium [75]. The main immune cells are macrophages, which aggregate into melanomacrophage centers (MMCs), and lymphoid cells, which exist mostly as B cells [75]. Components of the spleen include splenic ellipsoids, MMCs and lymphoid tissue in fish. The ellipsoids are thick-walled capillaries that open in the pulp and are around the other two components. The emerging ellipsoids are involved in the capture of antigen in several species such as Atlantic salmon, grouper, catfish, and zebrafish. The antigen is engulfed by macrophage along the wall and may be detained for long periods of time, which has

an important role in immunological memory [76;77].

6.4.3 Immune response

A good oral vaccine has to induce both humoral and mucosal antibody response. After fish have been vaccinated with an inactivated antigen, naïve T-cells differentiate into effector T-helper 2 (Th2) cells. The activated Th2 cells stimulate B-cell proliferation, which induce the production of antibodies. Thus far, only three Ig isotypes have been characterized in salmonid B lymphocytes namely IgM [78;79], IgD [78;80], and IgT [81], and it is still an unclear but important topic to understand their functional roles in systemic and local immune responses following vaccination from the oral route.

IgD

IgD exists as a membrane bound Ig although it is also secreted into serum. The knowledge of IgD is still limited whether in mammal or fish. Some studies showed >90% of IgD secreting plasma cells were in the kidney and spleen in rainbow trout and the levels of IgD in the blood were generally low accounting for <2% in rainbow trout and <3% in human [82;83]. Their results also displayed IgD level correlated with increase in several viral infections [84-88] and vaccinations such as the DNA vaccine against IPNV [89]. However, this isotype was not affected by viral hemorrhagic septicemia virus infection [90]. Although Chen *et al.* (2009) suggested the secreted form of IgD bound to basophils and mast cells leading these cells to produce antimicrobial factors involved in immune defenses in mammal [83], IgD's function remains a puzzle.

IgM

IgM is the most abundant Ig isotype in serum and secreted mainly by plasmablasts and plasma-like cells that are located mostly within the head kidney, where they play a key role in eliciting IgM responses [91]. This Ig subtype plays a major role in conferring protective immunity against systemic infections. For example, Frost and Ness (1997) and Munang'andu *et al.* (2013) vaccinated fish with IPNV vaccine and reported higher levels of IgM in serum before challenge resulting in lower viral infection rate and stronger protection after challenge compared to the control fish [35;92]. Besides in the serum, IgM has been detected on mucosal surface of the intestine, skin, and gills [93-95]. Recently, Ballesteros *et al.* (2013) observed that the membrane

form of IgM was highly expressed in the pyloric caeca of fish that were vaccinated with a DNA vaccine encapsulated in alginate beads than fish exposed to empty plasmids or alginate beads alone, and they also suggested that IgM secreting B-cell maturation correlate with increase in antigen levels expressed on mucosal surfaces of orally vaccinated fish [89]. Some studies also demonstrated that IgM plays a role in mucosal response, because of the presence of antigen-specific IgM albeit with low level. However, the protective mechanism at viral entry sites has not been studied in detail.

IgT

IgT is the only known member of the gut-local immune response in fish possibly mirroring the function of IgA in mammalia. Zhang *et al.* (2010) detected responses of rainbow trout immunoglobulin T (IgT) to an intestinal parasite only in the gut, whereas IgM responses were confined to the serum [95]. Further studies indicated that this isotype was mainly involved in mucosal immune responses both in the gut and skin [95;96], and thus its titer in mucus and mucosal surfaces are estimated to be >100 fold higher than those detected in serum [93]. IgT also was suggested to have a role comparable to IgA that acts as a mucosal antibody and had specialization into mucosal responses [97]. Moreover, IgT⁺ B cells could be observed in the lamina propria and epithelium of the gut, suggesting a role of these cells in producing Ig locally [95]. Local production of immunoglobulins in the GALT probably occurs in other species as a number of studies have found B cells in the GALT of fish [98]. However, only few studies have examined the anti-viral properties of IgT in the gut post oral vaccination, such as the studies of regulation of IgT in the gut post oral or immersion viral vaccination by Cain *et al.* (1996) and Sato and Okamoto (2010) [99;100]. For IPNV, the IgT secreting cells were reported to migrate toward the peritoneal epithelial surface after IPNV exposure [101], and high level of IgT was expressed in the gut of Atlantic salmon following IPNV oral DNA vaccination [89;102]. In more recent study, Ballesteros *et al.* (2013) have shown a high correlation between the levels of VP2 transcribed from an oral DNA vaccine and the levels of IgT in the pyloric caeca suggesting that the expression pattern of this Ig isotype could be highly influenced by the quantity of antigen expressed on mucosal surfaces of vaccinated fish. Although there is no hard evidence of antiviral properties of this isotype, IgT is conceivable that it plays a role protecting surfaces against pathogens that infect through mucosal surfaces [89] like IPNV.

6.4.4 Immune tolerance

The intestine is the place where immune tolerance plays a role in avoiding food allergy and to maintain the gut microbiota. Therefore, oral immune suppression is another important coordinate element that influences oral vaccine efficiency, but few studies have been done in fish. This phenomenon has been shown to decrease specific antibody production against antigens in rainbow trout [9], salmon [103] and common carp [103-105]. Only in common carp, the oral administration of proteins could result in a genetic dependent suppression of antibody responses after systemic administration of the same antigen [105], which was comparable with oral tolerance studies in mammals. In mammals, the regulatory T cells (Treg) cells play essential roles in immune tolerance [106] (Fig 1). Treg distinctively expresses the FOXP3 transcription factor, in addition to producing inhibitory cytokines TGF- β and/or IL-10. Whether these subsets exist in fish is unknown, but many associated molecular homologies have been identified in teleost fish [107]. FOXP3 which is a member of the forkhead box (FOX) gene family is currently the most intensively studied forkhead family member in immunological research and such studies show that FOXP3 is a major regulator of development and suppressive function of Tregs in mammal [108]. Quintana *et al.* (2010) reported FOXP3 showed similar immune-regulation in zebrafish to mammalian [109], and Yang *et al.* (2012) also suggested the FOXP3 probably had the similar function in grass carp [110]. TGF- β and IL-10 are the well-known cytokines as main factors in the control of the oral immune tolerance in mammal [111]. The anti-inflammatory cytokine IL-10 and the Th3-associated anti-inflammatory cytokine TGF- β have been identified in several species of teleost fish [112-123]. Although their functions in Atlantic salmon are not clearly understood, more and more studies suggest that TGF- β and IL-10 modulate pro-inflammatory cytokines and T and B cells proliferation in goldfish, grass carp, rainbow trout and Atlantic salmon as well [123-127].




Figure 1. Treg cell development and suppression

7 Objectives

The overall aim of this work was to optimize IPNV production for use in inactivated vaccine preparations on one side and to gain knowledge of antigen uptake as well as host response following oral vaccination against IPN in Atlantic salmon. Specifically, the following objectives were examined;

- To investigate and document the factors that permit reproducible high titers and volumes of IPNV in AGK cells. A good understanding of these factors will contribute to more efficient production of antigens that are required in the development of protective vaccines against IPN.
- To determine the antigen uptake and organ distribution of inactivated vaccines given orally using different administration routes in Atlantic salmon and assess the potential of systemic distribution of inactivated IPNV antigens.
- To determine the immune response including the systemic and local antibody response of an oral IPN vaccine used as a boost in Atlantic salmon immunized with a prime injection vaccine.


8 Methodology

8.1 Overview

For investigating the oral vaccine for IPN, the steps of research in this thesis followed the stream of oral vaccine process to vaccination. The knowledge gaps of antigen production, antigen kinetics, and immune response were explored by three studies. For the vaccine especially administered by oral route, efficient production of antigen with high titer is desired. AGK cell line was chosen to produce for paper II and paper III, due to its property of generating high titers of IPNV and ability to proliferate rapidly. AGK and RTG-2 cells were used to grow IPNV as a basis for understanding the mechanisms underlying differences in yields. CHSE-214 cells were used to quantify virus yields from both cell lines in all trials. The stream of IPNV titer change and several anti-viral activities were detected from genome level to protein level.

Although many viral vaccines were reported to give good protection in laboratory trials, the efficacy of vaccines under field conditions is still equivocal. For oral vaccines there are very few studies documenting the efficacy and also with little information provided as regards details of antigen uptake, antigen delivery, and local adaptive immune response. The results of antigen kinetics in paper II and systemic and local immune response in paper III can surmount the gaps and provide an approach for the development of an oral vaccine against IPN. For papers II and III, the vaccines made of the AGK produced IPNV were given to the Atlantic salmon. In paper II, we studied the administration of 0.3 ml of live and inactivated IPNV (10^9 TCID₅₀/ml) was intubated into stomach and hindgut. The antigen was detected by qRT-PCR, immunohistochemistry (IHC), and ELISA at 1, 24, 72 hrs post vaccination in serum, foregut, hindgut, head kidney, spleen, and liver (Fig. 2A). In paper III, the boosts included: 1) untreated feed (control); 2) feed containing unencapsulated IPNV (in suspension) (UNECAP); 3) feed containing alginate-encapsulated IPNV antigens (ENCAP). The boost vaccines were given every day for 7 days. The antigen was detected by qRT-PCR in head kidney and hindgut, and immune response was detected by ELISA and qRT-PCR at 7 weeks post the first boost and at 4 weeks post the second boost in serum, head kidney, spleen, and hindgut (Fig. 2B).

A.



B.




Figure 2. The design of studies: A) Paper II; B) Paper III

8.2 Cells, virus, vaccines, and fish

Rainbow trout gonad 2 cells (RTG-2), Asian Grouper strain K (AGK) cells [34], Chinook salmon embryo cells (CHSE-214) were used in this thesis. RTG-1 and CHSE-214 are widely used in IPNV studies and AGK can produce IPNV efficiently.

A recombinant IPNV strain (rNVI-15PT) having amino acids Proline (P), Threonine (T) and Alanine (A) in positions 217, 221 and 247 in the VP2 protein, respectively [35], was used to infect 80% confluent cells. This recombinant IPNV strain replicates as fast as the wild type IPNV (T₂₁₇A₂₂₁T₂₄₇) but has lower mutation rate than the wild type IPNV in cells. The AGK and RTG-2 cells were infected in triplicates by first adsorbing the virus for 2 hrs on a rocking board. Thereafter, the infected monolayer cells were washed using phosphate buffered saline (PBS) before replacing the old growth media with maintenance media followed by incubation at 15°C. AGK cells maintained using 2% FBS of L-15 growth media were inoculated with IPNV using MOI=0.1 followed by incubation at 15° C to produce IPNV..Virus samples from both intact cells and culture supernatants were harvested in parallel, on daily basis until full CPE. The virus yield in these samples was assessed by titration in CHSE-214 cells. The virus for inactivated vaccine was incubated with formalin (0.5%) at room temperature for 48 hrs with continuous stirring using a magnetic stirrer. Thereafter formalin was removed by dialysis against PBS. Inactivation was confirmed by inoculating confluent CHSE-214 cells while formalin residual effects were tested by incubating cells with excessive inactivated virus and assessing for toxicity. Inactivated antigen encapsulated by marine alginate and inactivate antigen with PBS were mixed with other feed components to make the oral vaccine in paper III. Once the antigen was ready, a trial was carried out in which Atlantic salmon parr (n = 90) approx. 25 g and (n=180) approx. 200 g were used in the studies reported in paper II and paper III, respectively.

8.3 Virus detection and quantification

Several techniques were used to detect and quantify the amount of IPNV such the Kärber's method of determining the tissue culture infective dose (TCID₅₀/ml), qRT-PCR, western blotting, ELISA, IFAT, and IHC. Kärber's method is used to determine TCID₅₀/ml. This is a method with good sensitivity for infectious virus the titer is determined by the number of wells having cytopathic effect (CPE). The TCID₅₀/ml titration method is time consuming and requires one week to be completed (after inoculation). qRT-PCR and western blotting were also used to quantify the virus used for studies in paper I. Those techniques have good sensitivity and resolution and require less time. qRT-PCR detection will not estimate the number of replicating virus particles. qRT-PCR was used for determining the presence of IPNV antigen in head kidney and hindgut samples in paper III. The indirect enzyme linked immunosorbent assay (ELISA) is a tool that can be used to quantify virus at protein level especially in serum because of its ease of

use, although sensitivity is moderate ($\approx 10^4$ virus particles per ml). ELISA was used for studies in paper II. Besides quantification, it was important to visualize the distribution of IPNV in internal organs and for this purpose immunohistochemistry (IHC) was used.

8.4 Gene expression

Gene expression analysis can provide insight into how the organism responds to infection and vaccination. Genes are up-regulated or down-regulated in response to different antigen or vaccine components. By quantifying mRNA levels of transcripts like cytokines, immunoglobulin and immune regulatory molecules, a transcript profile can be generated [128-132]. In this way, immune gene expression can be used to provide a fingerprint of a protective response. In the thesis, qRT-PCR was used to track and quantify several immune genes for the purpose of understanding the immune response following vaccination for studies reported in paper III. This can be used and extended in future studies including with the purpose to create correlates of protection.

8.5 Cellular antiviral activity test

Cellular antiviral responses are parameters that influence the efficiency of virus production (at cell level). Protein synthesis shutdown, antiviral ability of interferon pathway cascades and apoptosis are believed to be important antiviral responses induced by cells in response to infection. For quantification of protein synthesis, ^{35}S methionine was incubated with the cells for one hour to label the new proteins synthesized during incubation. After the protein is isolated from the cells, separated, blotted onto the membrane, and scanned by an imager, level of protein synthesis can be assessed. While the IFN sequence of grouper is still not determined, the antiviral responses induced through IFN pathways was approached by using poly (I:C) for induction of IFN. Also overexpression of Mx protein and its effect on IPNV growth/replication was also studied (Paper I). Further, apoptosis responses in infected cells were also examined (Paper I) using flow cytometry to visualize Annexin V positive cells (a marker of apoptosis).

8.6 Humoral Antibody quantification

Sandwich ELISA was used to assess antibody levels obtained at different time points in paper III. Compared to indirect ELISA, sandwich ELISA is more sensitive and with higher specificity. Since the sandwich ELISA quantifies proteins between two layers of antibodies, the protein is

specifically captured and detected. The performance followed a previous description [133] with minor modifications. An IPNV concentration of 10^7 TCID₅₀/well was used (as bait) while serum samples were diluted at 1:40 in phosphate buffered saline.

9 Summary of separate papers

Paper I: Delayed protein shut down and cytopathic changes lead to high yields of infectious pancreatic necrosis virus cultured in Asian Grouper cells

Inactivated whole virus vaccines represent the majority of commercial preparations used to prevent against infectious pancreatic necrosis (IPN) in salmonids today. The production of these vaccines requires high virus concentrations and is resource-demanding.

In this study, we describe the cultivation of high yields of IPN virus in Asian Grouper strain K (AGK) cells. The mechanism by which this is achieved was investigated by comparison with commonly used salmonid cell lines (RTG-2 and CHSE-214 cells). The cells were counted before and sequentially after infection. Thereafter, protein shut down, virus yields and apoptosis were assessed. The effects of poly(I:C) pre-treatment and Mx expression on IPNV concentrations were examined and the results show that high virus yields were associated with high cell numbers per unit volume, delayed cell death and apoptosis in AGK cells while the opposite was observed in RTG-2 cells. Poly(I:C) treatment and Mx expression resulted in a dose-dependent inhibition of virus multiplication. The production capacity of AGK and CHSE-214 cells were compared and higher split ratio and shorter split interval of AGK cells documents dramatic differences in virus antigen production capacity.

Collectively, the results suggest that high cell numbers and prolonged survival of AGK cells are responsible for the superior virus yields over RTG-2 and higher split ratio/shorter split interval makes AGK superior over CHSE cells.

Paper II: IPNV antigen uptake and distribution in Atlantic salmon following oral administration

One of the difficulties facing the success of oral vaccination in fish is the hostile stomach environment that antigens must cross. Further, uptake of antigen from the gut to systemic distribution is required for induction of systemic immunity, the dynamics of which are not well understood. In the present study, groups of Atlantic salmon parr were intubated with live or inactivated IPNV either orally or anally. At 1, 24 and 72hrs post infection (p.i.) the fish were

sacrificed and serum, head kidney, spleen, liver, anterior and posterior intestinal tissues were sampled. The serum was used for assessing IPNV by ELISA while tissues were used for antigen distribution by immunohistochemistry. Both live and inactivated IPNV antigens were observed in enterocytes of the intestines and in immune cells of the head kidneys and spleens of all groups. In the liver, no antigens were observed in any of the groups. Significantly higher serum antigen OD values ($p<0.04$) were observed in orally compared to anally intubated fish. By contrast, no difference ($p=0.05$) was observed in tissue antigens between these groups by immunohistochemistry. No significant difference ($p=0.05$) was observed in serum antigens between groups intubated with live and inactivated IPNV while in tissues, significantly more antigens ($p<0.03$) were observed in the latter compared to the former. These findings demonstrate that both live and inactivated IPNV is taken up by enterocytes in the intestines of Atlantic salmon likely by receptor mediated mechanisms akin to those of HRP or ferritin. Higher IPNV uptake by the oral compared to anal route suggests that both the anterior and posterior intestines are important for the uptake of the virus and that IPNV is resistant to gastric degradation of the Atlantic salmon stomach.

Paper III: Augmentation of the antibody response of Atlantic salmon by oral administration of alginate-encapsulated IPNV antigens

Atlantic salmon (*Salmo salar* L.) growers often face infectious pancreatic necrosis virus (IPNV) challenge during the first few months following transfer to sea. To be protected, fish needs high antibody titers at the start of the challenge and it is questionable whether sufficient antibody titers are induced by commercially available injection vaccines. Thus boosting with oral vaccines would be a good alternative. The effect of orally boosting fish with IPNV antigens however remains poorly understood.

The objective of the present study was to assess if alginate-encapsulated whole IPNV antigens would stimulate a booster response of Atlantic salmon post-smolt. One year after intraperitoneal vaccination with an oil-adjuvant vaccine, the fish (growers) were boosted either by 1) alginate-encapsulated IPNV antigens (ENCAP); 2) soluble antigens (UNENCAP) or 3) no antigens in feed (control). This was done twice in seven weeks intervals. The first sampling was done 7 weeks post the 1st oral boost (just before the second oral boost) while the second sampling was at 4 weeks after the 2nd oral boost. Samples collected were serum, head kidney, spleen and

hindgut. Antibodies in the serum were analyzed by ELISA while the remaining tissues were used to assess the expression of IgM, IgT, CD4, GATA3, FOXP3, TGF- β and IL-10 genes by qRT-PCR. Compared to controls, fish fed with ENCAP had a significant increase ($p < 0.04$) in serum antibodies following the 1st boost but no difference was observed after the 2nd boost. This coincided with significant up-regulation of CD4 and GATA3 genes. In contrast, serum antibodies in the UNENCAP group decreased both after the 1st and 2nd oral boosts. In the second samples, this was associated with significant up-regulation of FOXP3, TGF- β and IL-10 genes suggesting the induction of tolerance. The expression of IgT was not induced in the hindgut after the 1st oral boost but was significantly up-regulated following the 2nd one. CD4 and GATA3 gene expression exhibited a similar pattern to IgT in the hindgut. IgM mRNA expression on the other hand was not differentially regulated at any of the times examined.

Our findings suggest that 1) Parenteral prime with oil-adjuvant vaccines followed by oral boost with ENCAP results in augmentation of the systemic immune response; 2) Symmetrical prime and boost (mucosal) with ENCAP results in augmentation of mucosal immune response and 3) Symmetrical priming and boosting (mucosal) with soluble antigens results in the induction of systemic immune tolerance.

10 Results and Discussion

10.1 Overview

This thesis is composed of three studies. Each focuses on challenges of the oral vaccine preparation and use, including antigen production (paper I), antigen kinetics (paper II), and immune responses (paper III). The sequence of these three studies was performed according to the process of vaccine development. Paper II and paper III would not have been done without the high titer/ high production capacity obtained with AGK cells, i.e. produced by the optimized production system reported in paper I. The results of paper II gave evidence to support that the immune responses observed in paper III were induced by IPNV antigen locally or systemically. Therefore, the findings of this thesis can make contributions to improve the development of IPNV oral vaccines for Atlantic salmon.

10.2 High yield of infectious pancreatic necrosis virus produced by Asian grouper cell strain K (AGK)

10.2.1 The effects at cell population level

AGK cells produced IPNV titers in excess of 10^9 TCID₅₀/ml which is higher than what is obtained for RTG-2 cells and comparable to or above previous records of CHSE-214 and CHH-1 [61;62]. Moreover, the higher split ratio and short interval of AGK cells compared to RTG-2, CHH-1, and CHSE-214 gave a very marked difference in production capacity. The number of AGK cells was more than twice of RTG-2 per unit volume at confluence. This means that AGK supply more “factories” to produce IPNV. AGK cells grow more rapidly compared to salmonid cell lines and are split 2 times a week at 1:4, very different from RTG-2, CHSE-214, and CHH-1 cells (Fig. 3). The effect of higher split ratio and the shorter split interval results in a very high number of flasks available for inoculation and the resulting vaccine volume will differ dramatically. This is a great advantage for vaccine production.

10.2.2 The effects at individual cell level

Although AGK cells have higher cell numbers per unit area than RTG-2 cells, the 100 times higher titer of AGK-produced IPNV suggested that the difference in cell numbers could only account for part of the difference in titer. The production capacity per cells is also important.

Protein shutdown and apoptosis are among the mechanisms cells use for protection against virus infections [56-58;134] but have not been clearly elucidated in IPNV infected cells. In paper I, the delay of protein shutdown (Fig. 4) and delayed/lack of apoptosis in AGK cells was associated with high host cell numbers and virus yields. This is in contrast to the findings of RTG-2 cells where cell multiplication ceased at 1 d.p.i. (MOI = 10) or 2 d.p.i. (MOI = 0.1), coinciding with host cell protein shutdown. Furthermore, apoptosis was detected in RTG-2 cells by 1 d.p.i. unlike in AGK cells where it was absent at this time point. Collectively, these findings suggest that delayed protein shutdown and CPE in AGK cells allows longer replication windows that in turn increase virus yields, opposite to what is seen in RTG-2 cells. The similarities in the trends of protein shutdown of AGK cells infected with different MOI in this study were intriguing given that the final virus concentrations were different. In AGK cells, the virus was inhibited when Mx protein was over-expressed (Fig. 5). Moreover, the induction of Mx was observed when the cells were infected with high MOI leading to low viral titers, but it was absent when cells were inoculated with low MOI, ultimately with higher virus titers. These findings support previous reports that the effect of Mx on IPNV is dose-dependent, the more the expression, the more its antiviral effects [135]. Low MOI allows the virus to multiply without inducing Mx (virus remains “under the radar”) and thus results in high virus yields. The Mx protein inducer, IFN, was also reported to decrease the proliferation of IPNV. For example, Dobos and Roberts (1983) reported that the induction of IFN in RTG-2 resulted in low virus concentrations while the absence in CHSE-214 cells was linked to opposite [54]. We used poly(I:C), a potent inducer of interferon, to stimulate the AGK cells to release IFN because the IFN gene sequence of AGK cells was still unknown (at the time these studies were carried out). While no difference between poly(I:C) treated and untreated groups was observed in RTG-2 cells, poly(I:C) transfection initially inhibited virus replication in AGK cells. These results indicate lower antiviral responses induced and higher virus yield obtained in AGK cells. Moreover, this study clearly shows the potential of the AGK cell line used for production of IPN vaccine antigen.




Figure 3. The split ratio of AGK and Salmonid cell lines (RTG-2 and CHSE-214)




Figure 4. Protein shutdown in RTG-2 and AGK cells following infection with infectious pancreatic necrosis virus. Key: VP2, VP3, VP4 = virus proteins; M=marker; d.p.i. = days post infection; MOI= multiplicity of infection, C = negative control. Newly synthesized proteins were labelled with [³⁵S]Methionine, separated by SDS-PAGE, blotted on PVDF membrane and imaged using a Typhoon imager.




Figure 5. Indirect fluorescence antibody test of overexpressed Mx (A) in AGK cells following infection with infectious pancreatic necrosis virus at 72 h post infection. (B) Negative control transfected with the truncated form of Mx, note the degree of double staining. Fewer cells present the double staining when the cells over expressed Mx (A). Key: green color = Mx; red stain = IPNV; yellow/orange = double staining of IPNV and Mx (A) or its truncated form (B).

10.3 The IPNV antigen uptake kinetics

An ideal vaccine should mimic the natural route of infection and provide enough virus-specific epitopes to induce protective immune responses [136;137]. Therefore, understanding antigen uptake is a first step for developing a good mucosal vaccine. Since the intestine has been suggested to be one of the entry sites of IPNV [22], administrating the oral vaccine via the intestine mucosal surface would be a suitable option of vaccination. Our result shows that the uptake of this virus was from the lumen of the posterior intestines (Fig. 6A) and supports previous reports that the posterior intestine or hindgut is important for absorption of macromolecules in fish [104]. In order to understand the efficiency of IPNV uptake, indirect ELISA was used to detect IPNV antigens in serum. The OD values of all test groups were higher than control group at every sampling time point and significantly higher in anal live, oral live and oral inactivated IPNV groups at 24 h.p.i. and in oral live and inactivated IPNV groups at 72 h.p.i. (Fig. 7). The group intubated orally had comparatively more antigen than anally (by ELISA or IHC), in contrast to the findings reported previously [104;138]. Since IPNV is known to be resistant to chemical and even thermal treatments [139-141], it is not surprising that our results suggest that IPNV is resistant to the low pH and digestive enzymes in Atlantic salmon stomach. We did not observe an obvious difference between live and inactivated IPNV antigen after oral administration. These findings are consistent with previous reports indicating that formalin inactivation of IPNV does not significantly alter the surface structure of the virus [142;143].




Figure 6. Infectious pancreatic necrosis virus (IPNV) in intestine (A); MMC (arrow) (B); head kidney (C); spleen (D) demonstrated by immunohistochemistry.




Figure 7. The relative OD₄₉₀ values of IPNV antigen in serum of live IPNV intubated from anal route (Anal live IPNV), live IPNV intubated from oral route (Oral live IPNV), inactivated IPNV intubated from anal route (Anal inactivated IPNV), and inactivated IPNV intubated from oral route (Oral inactivated IPNV) groups to control group at 1, 24, and 72 hours post intubation. Bars represent mean values of OD + SD values from 2 to 5 individuals. *Depicts statistical significance between boosted fish versus non-boosted control ($p < 0.05$).

10.4 IPNV antigen distribution in the organs

The number of fish per group in which antigens were detected is shown in Table 1. No antigens were detected from the anterior intestine in any of the groups. Although no antigens were demonstrated in the anterior intestine in the present study, the higher serum antigens in orally intubated groups compared to their anal counterparts as assessed by ELISA suggest that the anterior intestine as well as the foregut may be important in the uptake of IPNV as suggested by some [104] while contrasting others [104;138]. In the hindgut, antigen was observed on mucosal surfaces and in macrophages and goblet cells (Fig. 6A). As far as we know, this is the first report

to document the uptake of this virus both live and inactivated from the lumen of the intestines. The anticipation is that the mechanisms involved are similar to that of HRP or ferritin as reported by others [138]. These findings support previous reports that the intestine is important for absorption of macromolecules in fish [104].

Antigens of both live and inactivated virus intubated either orally or anally were observed in the immune organs (head kidney and spleen) of the fish from 1 hr to 72 hrs p.i. Antigens were localized mostly in macrophage-like cells and melanomacrophage centers (MMCs) (Fig. 6B, C, D). To our knowledge, the MMCs were shown for the first time to be at the same location of IPNV positive stain by IHC. MMCs play an important role in the response of fish to pathogen. Ellis & de Sousa [149] showed that circulating small lymphocytes also migrated to the centers and suggested they may be the location where trapped antigen interact with the immune system [144]. Furthermore, the close relationship of MMCs with the lymphoid cells indicate they were the major sites of long-term antigen retention in fish [145]. Therefore, the IPNV and MMCs in the same location implied that live and inactivated IPNV antigen could be recognized by the immune system of Atlantic salmon parr whether intubated orally or or anally. Different from immune organs, no IPNV antigens were observed in the liver of any groups in the present study. Since salmonid liver receives mostly venous blood from the gut [146-148] and plays a role in the digestion and removal of toxins from the blood, all antigen taken up by the intestine would pass through and potentially be taken up in the liver.

Table 1. Number of fish with positive staining for infectious pancreatic necrosis virus antigens in different tissues following intubation.

Tissue	Time (hours p.i.)	Live virus		Inactivated virus	
		Anal intubation	Oral intubation	Anal intubation	Oral intubation
Posterior intestine	1	0*	0**	1	1
	24	0	0	0	0
	72	0	0	1	1
Liver	1	0*	0**	0	0
	24	0	0	0	0
	72	0	0	0	0
Head kidney	1	3*	0**	2	3
	24	0	1	2	0
	72	0	3	3	0
Spleen	1	2*	0**	1	2
	24	0	0	3	1
	72	0	0	2	0

*n=3; **n=2 otherwise n=5.

10.5 The immune responses following oral vaccination with IPNV in Atlantic salmon

10.5.1 The systemic humoral responses

The findings of paper III demonstrate that oral boosting of injection vaccinated Atlantic salmon with alginate encapsulated IPNV antigens induces systemic humoral responses. The induction of higher transcript levels of T-helper 2 (Th2) mRNA in the ENCAP group is likely since there was a significant up-regulation of CD4 and GATA-3 in the head kidney and spleen (Fig. 8) of these fish, and IPNV-specific antibody in the serum. Induction of Th2 response was reported as one of the major immune responses from vaccination using inactivated virus and alginate encapsulated antigens in previous studies [149-152]. These findings are consistent with other reports in which different antigens were used [153;154] and suggest that oral boosting with alginate encapsulated antigens holds promise as a means of augmenting immune responses against IPNV.




Figure 8. Mean relative expression of A) CD4; B) GATA3; C) IgT; and D) IgM genes of fish orally boosted with different antigen preparations compared to un-boosted controls. n=30; *statistically significant $p < 0.05$.

10.6 The local humoral responses

In the present study, the up-regulation of IgT was only observed in the head kidney and the hindgut at the second sampling. IgT is the only known Ig in the gut of fish that resembles the function of IgA in mammalia. However, only few studies have examined the anti-virus properties of IgT in the gut of fish after oral vaccination [99;100;155]. Since IgT is a locally induced antibody response expected to play a role in mucosal immunity, it was up-regulated in head kidney and hindgut, as expected, with the highest levels found in the hindgut (Fig. 8).

Additionally, the results in paper III show that the 1st oral boost did not induce a corresponding change in the mucosal response as measured by gene expression in the hindgut, which suggests that injection vaccination does not activate mucosal immunity, in common with findings of others [154]. Therefore, the first oral boost served as a “prime” to the mucosal response while the 2nd exposure “boosted” it. Interestingly, oral boosting did not result in increased IgM expression in the hindgut, different from what others have observed assessing mucosal antibodies [154]. The ability of orally administered antigens to stimulate both systemic and mucosal immune responses

while parenteral delivery of antigens only inducing a systemic immune response demonstrate the asymmetry seen also for other animal species (mice) [156].

10.7 Immune tolerance

Immune tolerance is one of the challenges of oral vaccination. Soluble antigens have been found to induce tolerance in carp [104]. In the present study, tolerance was induced by two consecutive administrations of unencapsulated IPNV antigen (UNENCAP). The suppression of antibodies aligns well with induction of FOXP3, TGF- β and IL-10. The expressions of FOXP3, a marker of Treg was only slightly different between three groups at first sampling, but was significantly higher in the unencapsulated group a second sampling in head kidney and the hindgut when compared to the other group. In addition, TGF- β and IL-10 showed a similar pattern, but they were significantly up-regulated in both the unencapsulated and encapsulated groups at the second sampling (Fig. 9). TGF- β and IL-10 have been reported to be immunosuppressive cytokines linked to immune tolerance [157-159]. In mammals, TGF- β was secreted by dendritic cells (at low dose) and macrophage (at high dose) to modulate Treg, followed by reducing the activity of Th1 and Th2 cells but inducing gut associated immunoglobulin IgA secretion [111;160;161] while IL-10 was secreted by Treg to suppress the Th1 and Th2 cells and increase IgA production [111]. Induction of tolerance suggests that most of the un-encapsulated IPNV antigens were taken up, meaning they survived the hostile acidic environment in the stomach. This finding underlines the importance of encapsulation as an aid to stimulating the immune response of fish. It is noteworthy that the doses of vaccines administered during the 2nd boost were lower per body weight of fish compared to the 1st boost since the fish had gained weight by the time they received the second boost. The effect of this was not addressed but should be a subject of future studies.




Figure 9. Mean relative expression of A) FOXP3; B) TGF- β and C) IL-10 genes in fish orally boosted with different antigen preparations compared to un-boosted controls. n=30; *statistically significant $p < 0.05$.

10.8 The correlation between antigen kinetics and immune responses

To our knowledge, the correlation between antigen kinetics and immune response following oral administration is in general poorly understood. In this thesis, IPNV antigens were detected in situ in leukocyte-like cells in the hindgut, head kidney and spleen (paper II), and immune responses were induced in these organs (paper III). The results suggest that the oral vaccine can induce not only local but also systemic humoral immune responses since antigens translocate across the gut to systemic distribution/circulation and then transmitted via the circulatory system to the immune organs. The findings are indicative of the immune responses lasting up to the second oral boost (paper III), possibly aligned with the IPNV antigens being associated with MMCs, providing long-term antigen retention (paper II).

There are few studies (to my knowledge) showing uptake of IPNV antigens from the gut (given orally) and the antigen kinetics revealed in paper II thus provide more insight into kinetics of oral vaccination of fish. Further studies of the relationship between antigen kinetics and immune responses would help us improve the efficacy of oral vaccines. For example, the induction of immune tolerance (paper III) was likely influenced by the dose and formulation,.

11 Conclusion

Antigen production

- The high cell numbers and prolonged survival of AGK cells are probably an important factor for the superior virus yields in AGK cells.
- The higher split ratio/shorter split interval makes AGK superior over other available cell lines.

Antigen kinetics

- Inactivation of IPNV by formalin did not influence the IPNV antigen kinetics following oral intubation.
- The hindgut not the foregut is the segment of intestine where IPNV antigen uptake in Atlantic salmon.
- The antigens could indeed be taken and delivered to the immune organs, including the macrophage-like cells and MMCs, which play important roles in immune system of fish.

Immune response

- Parenteral prime with oil-adjuvant vaccine followed by oral boost with ENCAP results in an augmentation of both systemic and mucosal immune responses.
- Oral boost with ENCAP results in transient augmentation of mucosal immune responses.
- Oral boost with UNENCAP results in the induction of immunological tolerance.

12 Perspectives

Antigen production

- Since the characteristics of AGK cell line enhance the production of virus, it may also be useful for producing other virus such as fish alphavirus. Therefore, it will be beneficial to understand if AGK cells can be used to produce other virus with high yield for vaccine.

Antigen Kinetics

- Further understanding of antigen kinetics will be a fascinating subject to study people to develop vaccine or to optimize the method to assess the feasibility of vaccine development.

Efficacy of oral vaccine

- Performing a challenge test will be the next and ultimate test aimed to show the effect of a boost regime. Previous reports indicate that the level of antibody can be used to predict the protection of vaccine [35].
- It will be necessary to detect IgT levels in intestine and other mucosal surface post oral vaccination.
- A very interesting and yet poorly understood mechanism is the contrasting difference in oral immune tolerance in non-formulated and alginate formulated vaccine formulations. To what this applies to other antigens and also will impact protection against challenge remains to be studied and elucidated.

Reference List

- [1] Biering E, Villoing S, Sommerset I, Christie KE. Update on viral vaccines for fish. *Developments in biologicals* 2004;121:97-113.
- [2] M'Gonigle RH. Acute catarrhal enteritis of Salmonid fingerlings. *Transactions of the American Fisheries Society* 1941 Jan 1;70(1):297-303.
- [3] Wolf K, Snieszko SF, Dunbar CE, Pyle E. Virus nature of infectious pancreatic necrosis in trout. *Experimental Biology and Medicine* 1960 May 1;104(1):105-8.
- [4] Besse P, Levaditi JC, Guillon JC, Kinkelin Pd. Occurrence of viral diseases in the rainbow trout hatcheries in France. First histopathological results. *Annals of the New York Academy of Sciences* 1965 Aug 1;126(1):543-6.
- [5] Dorson M, Torchy C. The influence of fish age and water temperature on mortalities of rainbow-trout, *Salmo-gairdneri richardson*, caused by a european strain of infectious pancreatic necrosis virus. *Journal of Fish Diseases* 1981;4(3):213-21.
- [6] McAllister PE, Bebak J. Infectious pancreatic necrosis virus in the environment: Relationship to effluent from aquaculture facilities. *Journal of Fish Diseases* 1997 May;20(3):201-7.
- [7] Perez SI, Rodriguez S. Major viral diseases affecting fish aquaculture in Spain. *Microbiologia* 1997 Jun;13(2):149-60.
- [8] Roberts RJ, Pearson MD. Infectious pancreatic necrosis in Atlantic salmon, *Salmo salar* L. *Journal of Fish Diseases* 2005 Jul;28(7):383-90.
- [9] Davidson GA, Ellis AE, Secombes CJ. A preliminary investigation into the phenomenon of oral tolerance in rainbow-trout (*Oncorhynchus-Mykiss*, Walbaum, 1792). *Fish & Shellfish Immunology* 1994 Mar;4(2):141-51.
- [10] Jarp J, Gjevre AG, Olsen AB, Bruheim T. Risk-factors for Furunculosis, infectious pancreatic necrosis and mortality in post-smolt of Atlantic salmon, *Salmo-salar* l. *Journal of Fish Diseases* 1995 Jan;18(1):67-78.
- [11] Smail DA, McFarlane L, Bruno DW, McVicar AH. The pathology of an IPN-Sp sub-type (Sh) in farmed Atlantic salmon, *Salmo salar* L, post-smolts in the Shetland Isles, Scotland. *Journal of Fish Diseases* 1995 Nov;18(6):631-8.
- [12] Ariel E, Olesen NJ. Finfish in aquaculture and their diseases - A retrospective view on the European Community. *Bulletin of the European Association of Fish Pathologists* 2002;22(2):72-85.
- [13] Jarp J. Epidemiological aspects of viral diseases in the Norwegian farmed Atlantic salmon (*Salmo salar* L.). *Bulletin of the European Association of Fish Pathologists* 1999;19(6):240-4.

- [14] Bruno DW. Changes in prevalence of clinical infectious pancreatic necrosis among farmed Scottish Atlantic salmon, *Salmo salar* L. between 1990 and 2002. *Aquaculture* 2004 Jun 1;235(1-4):13-26.
- [15] Christie KE. Immunization with viral antigens: Infectious pancreatic necrosis. *Fish Vaccinology* 1997;90:191-9.
- [16] Midtlyng P. IPN in salmonids: a review. In: Evensen O, Rimstad E, Stagg R BE, Midtlyng P, Skjelstad B, Johansen LH, et al., editors. *Vaccination*. 2003: p. 85-95.
- [17] Gomez-Casado E, Estepa A, Coll JM. A comparative review on European-farmed finfish RNA viruses and their vaccines. *Vaccine* 2011 Mar 24;29(15):2657-71.
- [18] Adelmann M, Kollner B, Bergmann SM, et al. Development of an oral vaccine for immunisation of rainbow trout (*Oncorhynchus mykiss*) against viral haemorrhagic septicaemia. *Vaccine* 2008 Feb 6;26(6):837-44.
- [19] Nakanishi T, Ootake M. Antigen uptake and immune responses after immersion vaccination. *Fish Vaccinology* 1997;90:59-68.
- [20] Rombout JHWM, Bot HE, Taveme-Thiele JJ. Immunological importance of the second gut segment of carp. II. Characterization of mucosal leucocytes. *Journal of fish biology* 1989;35:167-78.
- [21] Bernard D, Six A, Rigottier-Gois L, et al. Phenotypic and functional similarity of gut intraepithelial and systemic T cells in a teleost fish. *Journal of Immunology* 2006 Apr 1;176(7):3942-9.
- [22] Smail DA, Irwin N, Harrison D, Munro ALS. Passage and survival of infectious pancreatic necrosis (IPN) virus in the cows gut after feeding a silage mixture containing IPN virus. *Aquaculture* 1993 Jun 15;113(3):183-7.
- [23] Allnutt FCT, Bowers RM, Rowe CG, Vakharia VN, LaPatra SE, Dhar AK. Antigenicity of infectious pancreatic necrosis virus VP2 subviral particles expressed in yeast. *Vaccine* 2007 Jun 21;25(26):4880-8.
- [24] Lauterslager TGM, Stok W, Hilgers LA. Improvement of the systemic prime/oral boost strategy for systemic and local responses. *Vaccine* 2003 Mar 28;21(13-14):1391-9.
- [25] Quentel C, Vigneulle M. Antigen uptake and immune responses after oral vaccination. *Fish Vaccinology* 1997;90:69-78.
- [26] Joosten PHM, Tiemersma E, Threels A, CaumartinDhieux C, Rombout JHWM. Oral vaccination of fish against *Vibrio anguillarum* using alginate microparticles. *Fish & Shellfish Immunology* 1997 Oct;7(7):471-85.
- [27] Romalde JL, Luzardo-Alvarez A, Ravelo C, Toranzo AE, Blanco-Wendez J. Oral immunization using alginate microparticles as a useful strategy for booster vaccination against fish lactococcosis. *Aquaculture* 2004 Jun;236(1-4):119-29.

- [28] Leal CAG, Carvalho-Castro GA, Sacchetin PSC, Lopes CO, Moraes AM, Figueiredo HCP. Oral and parenteral vaccines against *Flavobacterium columnare*: evaluation of humoral immune response by ELISA and in vivo efficiency in Nile tilapia (*Oreochromis niloticus*). *Aquaculture International* 2010 Jun;18(4):657-66.
- [29] de las Heras AI, Rodriguez Saint-Jean S, Perez-Prieto SI. Immunogenic and protective effects of an oral DNA vaccine against infectious pancreatic necrosis virus in fish. *Fish & Shellfish Immunology* 2010 Apr;28(4):562-70.
- [30] Siripornadulsil S, Dabrowski K, Sayre R. Microalgal vaccines. *Transgenic Microalgae As Green Cell Factories* 2007;616:122-8.
- [31] Companjen AR, Florack DEA, Sloopweg T, Borst JW, Rombout JHWM. Improved uptake of plant-derived LTB-linked proteins in carp gut and induction of specific humoral immune responses upon infeed delivery. *Fish & Shellfish Immunology* 2006 Sep;21(3):251-60.
- [32] Joosten PHM, Avilestrigueros M, Sorgeloos P, Rombout JHWM. Oral vaccination of juvenile carp (*Cyprinus-Carpio*) and gilthead seabream (*Sparus-Aurata*) with bioencapsulated *Vibrio-Anguillarum* bacterin. *Fish & Shellfish Immunology* 1995 May;5(4):289-99.
- [33] Lin JH, Yu CC, Lin CC, Yang HL. An oral delivery system for recombinant subunit vaccine to fish. *Journal of Developmental Biology* 2005;121:175-80.
- [34] Munang'andu HM, Fredriksen BN, Mutoloki S, et al. Comparison of vaccine efficacy for different antigen delivery systems for infectious pancreatic necrosis virus vaccines in Atlantic salmon (*Salmo salar* L.) in a cohabitation challenge model. *Vaccine* 2012 Jun 8;30(27):4007-16.
- [35] Munang'andu HM, Fredriksen BN, Mutoloki S, Dalmo RA, Evensen O. Antigen dose and humoral immune response correspond with protection for inactivated infectious pancreatic necrosis virus vaccines in Atlantic salmon (*Salmo salar* L). *Veterinary Research* 2013;44(1):7.
- [36] Shivappa RB, McAllister PE, Edwards GH, Santi N, Evensen O, Vakharia VN. Development of a subunit vaccine for infectious pancreatic necrosis virus using a baculovirus insect/larvae system. *Journal of Developmental Biology* 2005;121:165-74.
- [37] Chackerian B. Virus-like particles: flexible platforms for vaccine development. *Expert Review of Vaccines* 2007 Jun;6(3):381-90.
- [38] Garcea RL, Gissmann L. Virus-like particles as vaccines and vessels for the delivery of small molecules. *Current Opinion in Biotechnology* 2004 Dec;15(6):513-7.
- [39] Grgacic EV, Anderson DA. Virus-like particles: passport to immune recognition. *Methods* 2006 Sep;40(1):60-5.

- [40] McKenna BM, Fitzpatrick RM, Phenix KV, Todd D, Vaughan LM, Atkins GJ. Formation of infectious pancreatic necrosis virus-like particles following expression of segment A by recombinant semliki forest virus. *Marine Biotechnology* 2001 Mar;3(2):103-10.
- [41] Dhar AK, Bowers RM, Rowe CG, Allnutt FCT. Expression of a foreign epitope on infectious pancreatic necrosis virus VP2 capsid protein subviral particle (SVP) and immunogenicity in rainbow trout. *Antiviral Research* 2010 Mar;85(3):525-31.
- [42] Ronen A, Perelberg A, Abramowitz J, et al. Efficient vaccine against the virus causing a lethal disease in cultured *Cyprinus carpio*. *Vaccine* 2003 Dec 1;21(32):4677-84.
- [43] Davis HL, McCluskie MJ. DNA vaccines for viral diseases. *Microbes and Infection* 1999 Jan;1(1):7-21.
- [44] Ballesteros NA, RodrA-guez Saint-Jean S, PAcrez-Prieto SI, Aquilino C, Tafalla C. Modulation of genes related to the recruitment of immune cells in the digestive tract of trout experimentally infected with infectious pancreatic necrosis virus (IPNV) or orally vaccinated. *Developmental & Comparative Immunology* 2014;44(1):195-205.
- [45] Garver KA, LaPatra SE, Kurath G. Efficacy of an infectious hematopoietic necrosis (IHN) virus DNA vaccine in Chinook *Oncorhynchus tshawytscha* and sockeye *O. nerka* salmon. *Diseases of Aquatic Organisms* 2005 Apr 6;64(1):13-22.
- [46] Boudinot P, Blanco M, de Kinkelin P, Benmansour A. Combined DNA immunization with the glycoprotein gene of viral hemorrhagic septicemia virus and infectious hematopoietic necrosis virus induces double-specific protective immunity and nonspecific response in rainbow trout. *Virology* 1998 Sep 30;249(2):297-306.
- [47] Lorenzen N, Lorenzen E, Einer-Jensen K, Heppell J, Wu T, Davis H. Protective immunity to VHS in rainbow trout (*Oncorhynchus mykiss*, Walbaum) following DNA vaccination. *Fish & Shellfish Immunology* 1998 May;8(4):261-70.
- [48] Sommerset I, Krossoy B, Biering E, Frost P. Vaccines for fish in aquaculture. *Expert Review of Vaccines* 2005 Feb;4(1):89-101.
- [49] Mikalsen AB, Torgersen J, Alestrom P, Hellemann AL, Koppang EO, Rimstad E. Protection of Atlantic salmon *Salmo salar* against infectious pancreatic necrosis after DNA vaccination. *Diseases of Aquatic Organisms* 2004 Jul 5;60(1):11-20.
- [50] Emmenegger EJ, Kurath G. DNA vaccine protects ornamental koi (*Cyprinus carpio koi*) against North American spring viremia of carp virus. *Vaccine* 2008 Nov 25;26(50):6415-21.
- [51] Kanellos T, Sylvester ID, D'Mello F, et al. DNA vaccination can protect *Cyprinus Carpio* against spring viraemia of carp virus. *Vaccine* 2006 Jun 5;24(23):4927-33.
- [52] Myhr AI, Dalmo RA. Introduction of genetic engineering in aquaculture: Ecological and ethical implications for science and governance. *Aquaculture* 2005 Dec 30;250(3-4):542-54.

- [53] Hong JR, Gong HY, Wu JL. IPNV VP5, a novel anti-apoptosis gene of the Bcl-2 family, regulates Mcl-1 and viral protein expression. *Virology* 2002 Apr 10;295(2):217-29.
- [54] Dobos P, Roberts TE. The molecular-biology of infectious pancreatic necrosis virus - A review. *Canadian Journal of Microbiology* 1983;29(4):377-84.
- [55] Galligan CL, Murooka TT, Rahbar R, Baig E, Majchrzak-Kita B, Fish EN. Interferons and viruses - Signaling for supremacy. *Immunologic Research* 2006;35(1-2):27-39.
- [56] McClintock JT, Dougherty EM, Weiner RM. Semipermissive replication of a nuclear Polyhedrosis-virus of autographa-Californica in a Gypsy-Moth cell-line. *Journal of Virology* 1986 Jan;57(1):197-204.
- [57] Guzo D, Rathburn H, Guthrie K, Dougherty E. Viral and host cellular transcription in *Autographa-Californica* nuclear polyhedrosis virus-infected Gypsy-Moth cell-lines. *Journal of Virology* 1992 May;66(5):2966-72.
- [58] Du XL, Thiem SM. Responses of insect cells to baculovirus infection: Protein synthesis shutdown and apoptosis. *Journal of Virology* 1997 Oct;71(10):7866-72.
- [59] Mazzacano CA, Du XL, Thiem SM. Global protein synthesis shutdown in *Autographa californica* nucleopolyhedrovirus-infected Ld652Y cells is rescued by tRNA from uninfected cells. *Virology* 1999 Aug 1;260(2):222-31.
- [60] Mir MA, Panganiban AT. A protein that replaces the entire cellular eIF4F complex. *Embo Journal* 2008 Dec 3;27(23):3129-39.
- [61] Lannan CN, Winton JR, Fryer JL. Fish cell-lines - Establishment and characterization of 9 cell-lines from Salmonids. In *Vitro-Journal of the Tissue Culture Association* 1984;20(9):671-6.
- [62] Skjesol A, Aamo T, Hegseth MN, Robertsen B, Jorgensen JB. The interplay between infectious pancreatic necrosis virus (IPNV) and the IFN system: IFN signaling is inhibited by IPNV infection. *Virus Research* 2009 Jul;143(1):53-60.
- [63] Sadasiv EC. Immunological and pathological responses of salmonids to infectious pancreatic necrosis virus (IPNV). *Annual Review of Fish Diseases* 1995;5(0):209-23.
- [64] Mcbeath AJA, Snow M, Secombes CJ, Ellis AE, Collet B. Expression kinetics of interferon and interferon-induced genes in Atlantic salmon (*Salmo salar*) following infection with infectious pancreatic necrosis virus and infectious salmon anaemia virus. *Fish & Shellfish Immunology* 2007 Mar;22(3):230-41.
- [65] Azad IS, Shankar KM, Mohan CV, Kalita B. Uptake and processing of biofilm and free-cell vaccines of *Aeromonas hydrophila* in Indian major carps and common carp following oral vaccination - antigen localization by a monoclonal antibody. *Diseases of Aquatic Organisms* 2000 Nov 14;43(2):103-8.

- [66] Debard N, Sierro F, Kraehenbuhl JP. Development of Peyer's patches, follicle-associated epithelium and M cell: Lessons from immunodeficient and knockout mice. *Seminars in Immunology* 1999 Jun;11(3):183-91.
- [67] Fagarasan S, Kawamoto S, Kanagawa O, Suzuki K. Adaptive immune regulation in the Gut: T cell-dependent and T cell-independent IgA synthesis. *Annual Review of Immunology*, Vol 28 2010;28:243-73.
- [68] Wang CH, McDonald KG, McDonough JS, Newberry RD. Murine isolated lymphoid follicles contain follicular B lymphocytes with a mucosal phenotype. *American Journal of Physiology-Gastrointestinal and Liver Physiology* 2006 Oct;291(4):G595-G604.
- [69] Fuglem B, Jirillo E, Bjerkas I, et al. Antigen-sampling cells in the salmonid intestinal epithelium. *Developmental and Comparative Immunology* 2010 Jul;34(7):768-74.
- [70] Dalmo RA, Seternes T, Arnesen SM, Jorgensen TO, Bogwald J. Tissue distribution and cellular uptake of *Aeromonas salmonicida* lipopolysaccharide (LPS) in some marine fish species. *Journal of Fish Diseases* 1998 Sep;21(5):321-34.
- [71] Khimmakthong U, Deshmukh S, Chettri JK, et al. Tissue specific uptake of inactivated and live *Yersinia ruckeri* in rainbow trout (*Oncorhynchus mykiss*): Visualization by immunohistochemistry and in situ hybridization. *Microbial Pathogenesis* 2013 Jun;59-60:33-41.
- [72] Johnson KA, Amend DF. Efficacy of *Vibrio-Anguillarum* and *Yersinia-Ruckeri* bacterins applied by oral and anal intubation of salmonids. *Journal of Fish Diseases* 1983;6(5):473-6.
- [73] Sundh H, Calabrese S, Jutfelt F, Niklasson L, Olsen RE, Sundell K. Translocation of infectious pancreatic necrosis virus across the intestinal epithelium of Atlantic salmon (*Salmo salar* L.). *Aquaculture* 2011 Nov 16;321(1-2):85-92.
- [74] Zapata A, Diez B, Cejalvo T, Frias CG, Cortes A. Ontogeny of the immune system of fish. *Fish & Shellfish Immunology* 2006 Feb;20(2):126-36.
- [75] Press CM, Dannevig BH, Landsverk T. Immune and enzyme-histochemical phenotypes of lymphoid and nonlymphoid cells within the spleen and head kidney of Atlantic salmon (*Salmo-salar* L). *Fish & Shellfish Immunology* 1994 Mar;4(2):79-93.
- [76] dos Santos NMS, Romano N, de Sousa M, Ellis AE, Rombout JHWM. Ontogeny of B and T cells in sea bass (*Dicentrarchus labrax*, L.). *Fish & Shellfish Immunology* 2000 Oct;10(7):583-96.
- [77] Petrie-Hanson L, Ainsworth AJ. Differential cytochemical staining characteristics of channel catfish leukocytes identify cell populations in lymphoid organs. *Veterinary Immunology and Immunopathology* 2000 Feb 25;73(2):129-44.
- [78] Andersson E, Matsunaga T. Complete cDNA sequence of a rainbow-trout IgM gene and evolution of nertebrate IgM constant domains. *Immunogenetics* 1993 Jun;38(4):243-50.

- [79] Hordvik I, Voie AM, Glette J, Male R, Endresen C. Cloning and sequence-analysis of 2 isotypic Igm heavy-chain genes from Atlantic salmon, *Salmo-Salar* l. *European Journal of Immunology* 1992 Nov;22(11):2957-62.
- [80] Hordvik I, Thevarajan J, Samdal I, Bastani N, Krossoy B. Molecular cloning and phylogenetic analysis of the Atlantic salmon immunoglobulin D gene. *Scandinavian Journal of Immunology* 1999 Aug;50(2):202-10.
- [81] Hansen C, Gollub N, Assamagan K, Ekelof T. Discovery potential for a charged Higgs boson decaying in the chargino-neutralino channel of the ATLAS detector at the LHC (vol 44, pg 1, 2005). *European Physical Journal C* 2005 Oct;44:11.
- [82] Brandtzaeg P, Korsrud FR. Significance of different J chain profiles in human tissues: generation of IgA and IgM with binding site for secretory component is related to the J chain expressing capacity of the total local immunocyte population, including IgG and IgD producing cells, and depends on the clinical state of the tissue. *Clin Exp Immunol* 1984 Dec;58(3):709-18.
- [83] Chen K, Xu WF, Wilson M, et al. Immunoglobulin D enhances immune surveillance by activating antimicrobial, proinflammatory and B cell-stimulating programs in basophils. *Nature Immunology* 2009 Aug;10(8):889-U121.
- [84] Brzosko WJ, Mikulska B, Cianciara J, Babiuch L. Immunoglobulin classes of antibody to Hepatitis-B core antigen. *Journal of Infectious Diseases* 1975;132(1):1-5.
- [85] Salonen EM, Hovi T, Meurman O, Vesikari T, Vaheri A. Kinetics of specific IgA, IgD, Ige, IgG, and IgM antibody-responses in rubella. *Journal of Medical Virology* 1985;16(1):1-9.
- [86] Moskophidis D, Moskophidis M, Lohler J. Virus-specific IgD in acute viral infection of mice. *Journal of Immunology* 1997 Feb 1;158(3):1254-61.
- [87] Luster MI, Armen RC, Hallum JV, Leslie GA. Measles virus-specific IgD antibodies in patients with subacute sclerosing panencephalitis. *Proceedings of the National Academy of Sciences of the United States of America* 1976;73(4):1297-9.
- [88] Luster MI, Armen RC, Hallum JV, Leslie GA. IgD antibodies against measles-virus in patients with subacute sclerosing panencephalitis. *Federation Proceedings* 1976;35(3):573.
- [89] Ballesteros NA, Saint-Jean SSR, Perez-Prieto SI, Castro R, Abos B, Tafalla C. The pyloric caeca area is a major site for IgM(+) and IgT(+) B cell recruitment in response to oral vaccination in rainbow trout. *Fish & Shellfish Immunology* 2013 Jun;34(6):1695-6.
- [90] Castro R, Jouneau L, Pham HP, et al. Teleost fish mount complex clonal IgM and IgT responses in spleen upon systemic viral infection. *Plos Pathogens* 2013 Jan;9(1).
- [91] Hoehlig K, Lampropoulou V, Roch T, et al. Immune regulation by B cells and antibodies a view towards the clinic. *Advances in Immunology* 2008;98:1-38.

- [92] Frost PETT, Ness ASLA. Vaccination of Atlantic salmon with recombinant VP2 of infectious pancreatic necrosis virus (IPNV), added to a multivalent vaccine, suppresses viral replication following IPNV challenge. *Fish & Shellfish Immunology* 1997;7(8):609-19.
- [93] Parra D, Takizawa F, Sunyer JO. Evolution of B cell immunity. *Annual Review of Animal Biosciences* 2013;1(1):65-97.
- [94] Olsen MM, Kania PW, Heinecke RD, Skjoedt K, Rasmussen KJ, Buchmann K. Cellular and humoral factors involved in the response of rainbow trout gills to *Ichthyophthirius multifiliis* infections: molecular and immunohistochemical studies. *Fish & Shellfish Immunology* 2011 Mar;30(3):859-69.
- [95] Zhang YA, Salinas I, Li J, et al. IgT, a primitive immunoglobulin class specialized in mucosal immunity. *Nature Immunology* 2010 Sep;11(9):827-U82.
- [96] Xu Z, Parra D, Gomez D, et al. Teleost skin, an ancient mucosal surface that elicits gut-like immune responses. *PNAS* 2013 Aug 6;110(32):13097-102.
- [97] Zhang YA, Salinas I, Sunyer JO. Recent findings on the structure and function of teleost IgT. *Fish & Shellfish Immunology* 2011 Nov;31(5):627-34.
- [98] Salinas I, Zhang YA, Sunyer JO. Mucosal immunoglobulins and B cells of teleost fish. *Developmental and Comparative Immunology* 2011 Dec;35(12):1346-65.
- [99] Cain KD, LaPatra SE, Baldwin TJ, Shewmaker B, Jones J, Ristow SS. Characterization of mucosal immunity in rainbow trout *Oncorhynchus mykiss* challenged with infectious hematopoietic necrosis virus: Identification of antiviral activity. *Diseases of Aquatic Organisms* 1996 Dec 12;27(3):161-72.
- [100] Sato A, Okamoto N. Induction of virus-specific cell-mediated cytotoxic responses of isogenic ginbuna crucian carp, after oral immunization with inactivated virus. *Fish & Shellfish Immunology* 2010 Sep;29(3):414-21.
- [101] Martinez-Alonso S, Vakharia VN, Saint-Jean SR, Perez-Prieto S, Tafalla C. Immune responses elicited in rainbow trout through the administration of infectious pancreatic necrosis virus-like particles. *Dev Comp Immunol* 2012 Feb;36(2):378-84.
- [102] Chen L, Mutoloki S, Evensen O. Oral alginate-encapsulated IPNV antigen booster enhancing both systemic and local antibody responses in Atlantic salmon. *Proceeding of 6th Vaccine and ISV Congress Shanghai, China* 2012 Oct 14.
- [103] Udey LR, Fryer JL. Immunization of fish with bacterins of *Aeromonas-Salmonicida*. *Marine Fisheries Review* 1978;40(3):12-7.
- [104] Rombout JHWM, van den Berg AA, van den Berg CTGA, Witte P, Egberts E. Immunological importance of the second gut segment of carp. III. Systemic and/or mucosal immune responses after immunization with soluble or particulate antigen. *Journal of fish biology* 1989 Aug 1;35(2):179-86.

- [105] Joosten PHM, Engelsma MY, van der Zee MD, Rombout JHWM. Induction of oral tolerance in carp (*Cyprinus carpio* L) after feeding protein antigens. *Veterinary Immunology and Immunopathology* 1997 Dec 12;60(1-2):187-96.
- [106] de Lafaille MAC, Lafaille JJ. Natural and adaptive FOXP3(+) regulatory T cells: More of the same or a division of labor? *Immunity* 2009 May 22;30(5):626-35.
- [107] Laing KJ, Hansen JD. Fish T cells: Recent advances through genomics. *Developmental and Comparative Immunology* 2011 Dec;35(12):1282-95.
- [108] Jonsson H, Peng SL. Forkhead transcription factors in immunology. *Cell Mol Life Sci* 2005 Feb;62(4):397-409.
- [109] Quintana FJ, Iglesias AH, Farez MF, et al. Adaptive autoimmunity and FOXP3-based immunoregulation in zebrafish. *Plos One* 2010 Mar 5;5(3).
- [110] Yang M, Wei H, Zhao TQ, Wang XY, Zhang AY, Zhou H. Characterization of Foxp3 gene from grass carp (*Ctenopharyngodon idellus*): A rapamycin-inducible transcription factor in teleost immune system. *Developmental and Comparative Immunology* 2012 Sep;38(1):98-107.
- [111] Weiner HL, da Cunha AP, Quintana F, Wu H. Oral tolerance. *Immunological Reviews* 2011 May;241:241-59.
- [112] Tafalla C, Aranguren R, Secombes CJ, Castrillo JL, Novoa B, Figueras A. Molecular characterisation of sea bream (*Sparus aurata*) transforming growth factor beta 1. *Fish & Shellfish Immunology* 2003 May;14(5):405-21.
- [113] Zhang DC, Shao YQ, Huang YQ, Jiang SG. Cloning, characterization and expression analysis of interleukin-10 from the zebrafish (*Danio rerio*). *Journal of Biochemistry and Molecular Biology* 2005 Sep 30;38(5):571-6.
- [114] Pinto RD, Nascimento DS, Reis MIR, do Vale A, dos Santos NMS. Molecular characterization, 3D modelling and expression analysis of sea bass (*Dicentrarchus labrax* L.) interleukin-10. *Molecular Immunology* 2007 Mar;44(8):2056-65.
- [115] Inoue Y, Kamota S, Ito K, et al. Molecular cloning and expression analysis of rainbow trout (*Oncorhynchus mykiss*) interleukin-10 cDNAs. *Fish & Shellfish Immunology* 2005 Apr;18(4):335-44.
- [116] Lutfalla G, Crollius HR, Stange-thomann N, Jaillon O, Mogensen K, Monneron D. Comparative genomic analysis reveals independent expansion of a lineage-specific gene family in vertebrates: The class II cytokine receptors and their ligands in mammals and fish. *Bmc Genomics* 2003 Jul 17;4.
- [117] Savan R, Igawa D, Sakai M. Cloning, characterization and expression analysis of interleukin-10 from the common carp, *Cyprinus carpio* L. *European Journal of Biochemistry* 2003 Dec;270(23):4647-54.

- [118] Seppola M, Larsen AN, Steiro K, Robertsen B, Jensen I. Characterisation and expression analysis of the interleukin genes, IL-1 beta, IL-8 and IL-10, in Atlantic cod (*Gadus morhua* L.). *Molecular Immunology* 2008 Feb;45(4):887-97.
- [119] Zou J, Clark MS, Secombes CJ. Characterisation, expression and promoter analysis of an interleukin 10 homologue in the puffer fish, *Fugu rubripes*. *Immunogenetics* 2003 Aug;55(5):325-35.
- [120] Hardie LJ, Laing KJ, Daniels GD, Grabowski PS, Cunningham C, Secombes CJ. Isolation of the first piscine transforming growth factor beta gene: Analysis reveals tissue specific expression and a potential regulatory sequence in rainbow trout (*Oncorhynchus mykiss*). *Cytokine* 1998 Aug;10(8):555-63.
- [121] Harms CA, Kennedy-Stoskopf S, Horne WA, Fuller FJ, Tompkins WAF. Cloning and sequencing hybrid striped bass (*Morone saxatilis* x *M. chrysops*) transforming growth factor-beta (TGF-beta), and development of a reverse transcription quantitative competitive polymerase chain reaction (RT-qcPCR) assay to measure TGF-beta mRNA of teleost fish. *Fish & Shellfish Immunology* 2000 Jan;10(1):61-85.
- [122] Yang M, Zhou H. Grass carp transforming growth factor-beta 1 (TGF-beta 1): Molecular cloning, tissue distribution and immunobiological activity in teleost peripheral blood lymphocytes. *Molecular Immunology* 2008 Mar;45(6):1792-8.
- [123] Haddad G, Hanington PC, Wilson EC, Grayfer L, Belosevic M. Molecular and functional characterization of goldfish (*Carassius auratus* L.) transforming growth factor beta. *Developmental and Comparative Immunology* 2008;32(6):654-63.
- [124] Chettri JK, Raida MK, Holten-Andersen L, Kania PW, Buchmann K. PAMP induced expression of immune relevant genes in head kidney leukocytes of rainbow trout (*Oncorhynchus mykiss*). *Developmental and Comparative Immunology* 2011 Apr;35(4):476-82.
- [125] Lilleeng E, Penn MH, Haugland O, et al. Decreased expression of TGF-beta, GILT and T-cell markers in the early stages of soybean enteropathy in Atlantic salmon (*Salmo salar* L.). *Fish & Shellfish Immunology* 2009 Jul;27(1):65-72.
- [126] Maehr T, Wang T, Vecino JLG, Wadsworth S, Secombes CJ. Cloning and expression analysis of the transforming growth factor-beta receptors type 1 and 2 in the rainbow trout *Oncorhynchus mykiss*. *Developmental and Comparative Immunology* 2012 May;37(1):115-26.
- [127] Holopainen R, Tapiovaara H, Honkanen J. Expression analysis of immune response genes in fish epithelial cells following ranavirus infection. *Fish & Shellfish Immunology* 2012 Jun;32(6):1095-105.
- [128] Ellis AE, Cavaco A, Petrie A, Lockhart K, Snow M, Collet B. Histology, immunocytochemistry and qRT-PCR analysis of Atlantic salmon, *Salmo salar* L., post-smolts following infection with infectious pancreatic necrosis virus (IPNV). *Journal of Fish Disease* 2010 Oct;33(10):803-18.

- [129] Taksdal T, Dannevig BH, Rimstad E. Detection of infectious pancreatic necrosis (IPN)-virus in experimentally infected Atlantic salmon parr by RT-PCR and cell culture isolation. *Bulletin of the European Association of Fish Pathologists* 2001;21(5):214-9.
- [130] Blake S, Ma JY, Caporale DA, Jairath S, Nicholson BL. Phylogenetic relationships of aquatic birnaviruses based on deduced amino acid sequences of genome segment A cDNA. *Diseases of Aquatic Organisms* 2001 Jun 20;45(2):89-102.
- [131] Bowers RM, Lapatra SE, Dhar AK. Detection and quantitation of infectious pancreatic necrosis virus by real-time reverse transcriptase-polymerase chain reaction using lethal and non-lethal tissue sampling. *Journal of Virological Methods* 2008 Feb;147(2):226-34.
- [132] Rodriguez S, Alonso M, Perez-Prietol SI. Comparison of two birnavirus-rhabdovirus coinfections in fish cell lines. *Diseases of Aquatic Organisms* 2005 Nov 28;67(3):183-90.
- [133] Munang'andu HM, Fredriksen BN, Mutoloki S, et al. Comparison of vaccine efficacy for different antigen delivery systems for infectious pancreatic necrosis virus vaccines in Atlantic salmon (*Salmo salar* L.) in a cohabitation challenge model. *Vaccine* 2012 Jun 8;30(27):4007-16.
- [134] Imajoh M, Hirayama T, Oshima S. Frequent occurrence of apoptosis is not associated with pathogenic infectious pancreatic necrosis virus (IPNV) during persistent infection. *Fish & Shellfish Immunology* 2005 Feb;18(2):163-77.
- [135] Lester K, Hall M, Urquhart K, Gahlawat S, Collet B. Development of an in vitro system to measure the sensitivity to the antiviral Mx protein of fish viruses. *J Virol Methods* 2012 Jun;182(1-2):1-8.
- [136] Falcone V, Mihm D, Neumann-Haefelin D, et al. Systemic and mucosal immunity to respiratory syncytial virus induced by recombinant *Streptococcus gordonii* surface-displaying a domain of viral glycoprotein G. *Fems Immunology and Medical Microbiology* 2006 Oct;48(1):116-22.
- [137] Companjen AR, Florack DE, Bastiaans JH, Matos CI, Bosch D, Rombout JH. Development of a cost-effective oral vaccination method against viral disease in fish. *Dev Biol (Basel)* 2005;121:143-50.
- [138] Rombout JH, Lamers CH, Helfrich MH, Dekker A, Taverne-Thiele JJ. Uptake and transport of intact macromolecules in the intestinal epithelium of carp (*Cyprinus carpio* L.) and the possible immunological implications. *Cell Tissue Res* 1985;239(3):519-30.
- [139] Myrnel M, Modahl I, Nygaard H, Lie KM. Infectious pancreatic necrosis virus in fish by-products is inactivated with inorganic acid (pH 1) and base (pH 12). *Journal of Fish Diseases* 2014 Apr;37(4):349-55.
- [140] Christie KE, Hjeltnes B. Infeksios pankreas nekrose-IPN. In: Poppe T, editor. *Fiskehelse-Sykdommer, forebygging behandling*. Fyllingsdalen, Norway, John Grieg Forlag AS, 1990: p. 190-2.

- [141] Nygaard H, Modahl Ir, Myrmel M. Thermal inactivation of infectious pancreatic necrosis virus in a peptone-salt medium mimicking the water-soluble phase of hydrolyzed fish by-products. *Applied and environmental microbiology* 2012;78(7):2446-8.
- [142] Goorha RM, Gifford GE. Comparison of interferon induction by active and inactive Semliki Forest virus. *Journal of General Virology* 1971 Feb;10(2):117-24.
- [143] Liu T, Zhou X, Abdel-Motal UM, Ljunggren HG, Jondal M. MHC class I presentation of live and heat inactivated Sendai virus antigen in T2Kb cells depends on an intracellular compartment with endosomal characteristics. *Scandinavian journal of immunology* 1997;45(5):527-33.
- [144] Ellis AE, Sousa MD. Phylogeny of lymphoid system .1. Study of fate of circulating lymphocytes in plaice. *European Journal of Immunology* 1974;4(5):338-43.
- [145] Lamers CHJ, Dehaas MJH. Antigen localization in the lymphoid organs of carp (*Cyprinus-Carpio*). *Cell and Tissue Research* 1985;242(3):491-8.
- [146] Kryvi H, Totland GK. *Fiskeanatomi*. Kristiansand, Norway: Hoyskoleforlaget AS-Norwegian Academic Press, 1997.
- [147] Petersen LH, Dzialowski E, Huggett DB. The interactive effects of a gradual temperature decrease and long-term food deprivation on cardiac and hepatic blood flows in rainbow trout (*Oncorhynchus mykiss*). *Comp Biochem Physiol A Mol Integr Physiol* 2011 Nov;160(3):311-9.
- [148] Thorarensen H, McLean E, Donaldson EM, Farrell AP. The blood vasculature of the gastrointestinal tract in chinook, *Oncorhynchus tshawytscha* (Walbaum), and coho, *O. kisutch* (Walbaum), salmon. *J Fish Biol* 1991;38:525-31.
- [149] Sarei F, Dounighi NM, Zolfagharian H, Khaki P, Bidhendi SM. Alginate nanoparticles as a promising adjuvant and vaccine delivery system. *Indian Journal of Pharmaceutical Sciences* 2013 Jul;75(4):442-9.
- [150] Salvador A, Igartua M, Hernandez RM, Pedraz JL. Combination of immune stimulating adjuvants with poly(lactide-co-glycolide) microspheres enhances the immune response of vaccines. *Vaccine* 2012 Jan 11;30(3):589-96.
- [151] Maurice S, Nussinovitch A, Jaffe N, Shoseyov O, Gertler A. Oral immunization of *Carassius auratus* with modified recombinant A-layer proteins entrapped in alginate beads. *Vaccine* 2004 Dec 9;23(4):450-9.
- [152] Mutwiri G, Bowersock T, Kidane A, et al. Induction of mucosal immune responses following enteric immunization with antigen delivered in alginate microspheres. *Veterinary Immunology and Immunopathology* 2002 Sep 10;87(3-4):269-76.
- [153] Thinh NH, Kuo TY, Hung LT, et al. Combined immersion and oral vaccination of Vietnamese catfish (*Pangasianodon hypophthalmus*) confers protection against mortality caused by *Edwardsiella ictaluri*. *Fish & Shellfish Immunology* 2009 Dec;27(6):773-6.

- [154] Tobar JA, Jerez S, Caruffo M, et al. Oral vaccination of Atlantic salmon (*Salmo salar*) against salmonid rickettsial septicaemia. *Vaccine* 2011 Mar 9;29(12):2336-40.
- [155] Martinez-Alonso S, Vakharia VN, Saint-Jean SR, Perez-Prieto S, Tafalla C. Immune responses elicited in rainbow trout through the administration of infectious pancreatic necrosis virus-like particles. *Developmental and Comparative Immunology* 2012 Feb;36(2):378-84.
- [156] Berzofsky JA, Ahlers JD, Derby MA, Pendleton CD, Arichi T, Belyakov IM. Approaches to improve engineered vaccines for human immunodeficiency virus and other viruses that cause chronic infections. *Immunological Reviews* 1999 Aug;170:151-72.
- [157] Weiner HL. Oral tolerance: immune mechanisms and the generation of Th3-type TGF-beta-secreting regulatory cells. *Microbes Infect* 2001 Sep;3(11):947-54.
- [158] Letterio JJ, Roberts AB. Regulation of immune responses by TGF-beta. *Annual Review of Immunology* 1998;16:137-61.
- [159] Conti P, Kempuraj D, Kandere K, et al. IL-10, an inflammatory/inhibitory cytokine, but not always. *Immunol Lett* 2003 Apr 3;86(2):123-9.
- [160] Miller A, Lider O, Roberts AB, Sporn MB, Weiner HL. Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of transforming growth factor beta after antigen-specific triggering. *PNAS* 1992 Jan 1;89(1):421-5.
- [161] Chen Y, Kuchroo VK, Inobe J, Hafler DA, Weiner HL. Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. *Science* 1994 Aug 26;265(5176):1237-40.



Delayed protein shut down and cytopathic changes lead to high yields of infectious pancreatic necrosis virus cultured in Asian Grouper cells

Lihan Chen, Øystein Evensen, Stephen Mutoloki*

Norwegian School of Veterinary Science, Department of Basic Science and Aquatic Medicine, P.O. Box 8146 Dep., 0033 Oslo, Norway

ABSTRACT

Article history:

Received 8 July 2013

Received in revised form 7 October 2013

Accepted 11 October 2013

Available online 25 October 2013

Keywords:

Infectious pancreatic necrosis virus

AGK cells

Mx

Protein shutdown

Inactivated whole virus vaccines represent the majority of commercial preparations used to prevent infectious pancreatic necrosis (IPN) in salmonids today. The production of these vaccines requires high virus concentrations that are resource-demanding. In this study, we describe the cultivation of high yields of IPN virus in Asian Grouper strain K (AGK) cells. The mechanism by which this is achieved was investigated by comparison with commonly used salmonid cell lines (RTG-2 and CHSE-214 cells). The cells were counted before and sequentially after infection. Thereafter, protein shut down, virus yields and apoptosis were assessed. The effects of poly(I:C) pre-treatment and Mx expression on IPNV concentrations were examined and the results show that high virus yields were associated with high cell numbers per unit volume, delayed cell death and apoptosis in AGK cells while the opposite was observed in RTG-2 cells. Poly(I:C) treatment and Mx expression resulted in a dose-dependent inhibition of virus multiplication. The production capacity of AGK and CHSE-214 cells were compared and higher split ratio and shorter split interval of AGK cells documents dramatic differences in virus antigen production capacity. Collectively, the results suggest that high cell numbers and prolonged survival of AGK cells are responsible for the superior virus yields over RTG-2 and higher split ratio/shorter split interval makes AGK superior over CHSE cells.

© 2013 Elsevier B.V. All rights reserved.

1. Introduction

Infectious pancreatic necrosis (IPN) is one of the most important diseases of farmed salmonids the world over. Originally known to affect fry at the point of start-feeding and in smolts shortly after sea water transfer, the disease now afflicts fish at all stages of production (Roberts and Pearson, 2005). IPN is caused by an un-enveloped double stranded RNA virus, the IPN virus (IPNV) that is a prototype of the genus Aquabirnavirus in the family Birnaviridae (Cohen et al., 1973; Duncan and Dobos, 1986). The virus genome consists of two segments, A and B, with the former encoding structural proteins VP2 and VP3, and non-structural proteins VP4 and VP5 (Dobos, 1976; Havarstein et al., 1990). Segment B encodes VP1, the RNA dependent RNA polymerase (Duncan et al., 1991).

Disease prevention and control of IPN include vaccination of parr during the fresh water stage with the purpose to protect them against disease during the first 2 months post sea transfer. Several vaccines are available, most of which are based on inactivated whole virus but also on subunit preparations (Sommerset et al., 2005) although their performance is equivocal. At experimental level, inactivated whole virus vaccines have shown better

protection than recombinant subunit vaccines, the former holding promise as effective vaccines for the future (Munang'andu et al., 2012, 2013a). The efficacy of the vaccines relies on inclusion of high antigen content.

Several cell lines have been tested for their suitability in the propagation of IPNV (Lannan et al., 1984) and are indeed in use in several laboratories for example rainbow trout gonad 2 (RTG-2) and Chinook salmon embryo 214 (CHSE-214) cells. The yields of virus that these cell lines give differ between cell lines and even between virus isolates. In general, the Sp serotype yields lower quantities (10^6 – 10^7 pfu/ml) in RTG-2 cells compared to CHSE-214 (10^8 pfu/ml) or even up to 10^{10} TCID₅₀/ml (Skjesol et al., 2009). The difference in yields between RTG-2 and CHSE-214 cells has been attributed to the former's ability to elicit an interferon (IFN) response believed to be absent in the latter (Macdonald and Kennedy, 1979; Jensen et al., 2002). Other factors including apoptosis and necrosis as well as the rates at which they occur may also contribute to the virus yield although this is not well documented. As stated above, vaccine production, challenge models, immunological and biological assays demand the cultivation of virus in large quantities. We report the use of Asian Grouper strain K (AGK) cells that support the cultivation of high titres of IPNV (10^9 – 10^{10} TCID₅₀/ml) (Munang'andu et al., 2012). These cells are derived from the skin of a crossbreed between Orange-spotted grouper (*Epinephelus coioides*) and Malabar grouper (*Epinephelus*

* Corresponding author. Tel.: +47 22 96 47 17; fax: +47 22 59 73 10.

E-mail address: stephen.mutoloki@nvh.no (S. Mutoloki).

malabaricus). The cell line is not a mono-clone but is composed of different cell types. AGK cells grow at a higher temperature, can be split at high ratios and have a much shorter turn-around time making them a very valuable resource for easy production of IPNV in large quantities within a short period of time.

The purpose of the present study was to investigate and document the factors that permit the production of high titres and high volumes of IPNV using AGK cells. A good understanding of these factors will contribute to more efficient production of antigens that are required in the development of protective vaccines against IPNV.

2. Materials and methods

2.1. Cells

Rainbow trout gonad 2 cells (RTG-2; ATCC CCL-55) were maintained at 20 °C with L-15 medium (Invitrogen) supplemented with 10% foetal bovine serum (FBS), 10% L-glutamine and 1 µl/ml of gentamicin. Asian Grouper strain K (AGK) cells (Munang'andu et al., 2012) were maintained at 28 °C with L-15 media of the same composition but supplemented with 7.5% FBS while Chinook salmon embryo cells (CHSE-214; ATCC CRL-1681) were maintained at 20 °C also with the same medium but containing 10% FBS.

2.2. Experimental design

RTG-2 and AGK cells were used to grow IPNV as a basis for understanding the mechanisms underlying differences in yields. CHSE-214 cells were used to quantify virus yields from both cell lines.

2.3. Assessment of IPNV yields in AGK and RTG-2 cells

A recombinant IPNV strain (rNVI-15PT) with amino acids Proline (P), Threonine (T) and Alanine (A) in positions 217, 221 and 247 in the VP2 protein, respectively (Munang'andu et al., 2013b), was used to infect confluent cells. The cells were infected in triplicates by first adsorbing the virus for 2 h on a rocking board, then washing with PBS before replacing fresh maintenance media and incubating them at 15 °C. Virus samples from both intact cells and culture supernatants were harvested in parallel, on daily basis until full CPE. The virus yield in these samples was assessed by titration in CHSE-214 cells.

To assess the effect of virus to cell infection ratio on virus yields, the cells were infected with either MOI=0.1 or MOI=10. Virus yields were assessed as described above. In addition, quantitative RT-PCR was also used to assess virus yields of AGK cells from day 1 to 5.

2.4. Metabolic labelling of newly synthesized proteins

AGK and RTG-2 cells infected with IPNV (MOI=0.1 and 10) were incubated for the required duration (up to 5 days maximum). To harvest the cells, they were first washed with PBS and then incubated for 1 h in Dulbecco's modified Eagle's medium without Methionine and supplemented with 0.1% FBS and 20 Ci [³⁵S]Methionine/ml. After incubation, the cells were washed three times with PBS and then lysed by using Cellytic M reagent (Sigma). The protein was separated by SDS-PAGE and blotted onto a poly(vinylidene fluoride) (PVDF) membrane. The membrane was then kept in a Phosphor cassette over-night prior to scanning using a Typhoon imager (GE Healthcare).

2.5. Transfection of poly(I:C) in AGK and RTG-2 cells followed by IPNV infection

To examine antiviral effects, AGK and RTG-2 cells were grown in 6-well culture plates until near confluence. Thereafter they were transfected with 3 µg of poly(inosinic:polycytidylic) acid (poly(I:C)) and 9 µl of FuGENE® HD Transfection Reagent (Roche) per well according to the manufacturer's instructions. 24 h later, the cells were infected with IPNV at MOI of 0.1. At 48, 72 and 96 h following infection, the viral proteins were assessed by Western blot.

2.6. Assessment of Mx expression following IPNV infection in AGK cells

AGK cells were infected with IPNV (MOI of 0.1 and 10). Sampling was done daily for 6 days. Total RNA was isolated by using the RNeasy Plus mini kit (Qiagen), and the concentration of RNA was determined by spectrophotometry (Nanodrop ND1000). For each sample, 500 ng of total RNA was subjected to cDNA synthesis using Transcriptor first-strand cDNA kit (Roche) in a total volume of 20 µl as described above. Mx expression was determined by quantitative real time PCR (qPCR) and this was performed by using Light-Cycler 480 SYBR green I Master mix on a LightCycler 480 thermocycler (Roche). 2 µl of cDNA was used as a template in a final volume of 20 µl. The mixtures were first incubated at 95 °C for 10 min, followed by 40 amplification cycles (10 s at 95 °C, 20 s at 60 °C, and 8 s at 72 °C).

The sequences of primers (Mx-574 Fwd and Mx-730 Rev) used to assess the expression of Mx are given in Table 1. The specificity of the PCR products from each primer pair was confirmed by melting-curve analysis and subsequent agarose gel electrophoresis. The $2^{-\Delta\Delta CT}$ method was used to calculate the amount of gene products as described previously (Nolan et al., 2006; Schmittgen and Livak, 2008). $2^{-\Delta\Delta CT}$ is the relative mRNA expression representing the fold induction over the control group. All quantifications were normalized to Cathepsin D. This gene has been demonstrated not to be induced in IPNV-persistently infected CHSE-214 cells (Marjara et al., 2010). In the present study, Cathepsin D expression was tested in AGK cells and found not to be induced by infection with IPNV.

2.7. Over-expression of Mx in AGK cells

The full Mx gene sequence (GenBank Accession No. KF148054) was amplified by PCR using the primers pcDNA3.1c-Mx-F and pcDNA3.1c-Mx-R (Table 1) containing BamHI/EcoRI restriction sites. A truncated form of the gene was used as a negative control and was produced using primers pcDNA3.1c-MxN-F and pcDNA3.1c-MxN-R. PCR was done as described above. 3 µg of PCR products and pcDNA3.1c vector were digested by using restriction enzyme BamHI and EcoRI (Promega) for 3 h and were directionally ligated using a ratio of 1:3. The plasmids were sequenced to confirm orientation and position of the gene as well as that of the His-tag.

Transfection of AGK cells was done in 6-well plates using 3 µg of plasmids containing the Mx gene and 9 µl of FuGENE® HD Transfection Reagent (Roche) per well according to the manufacturer's instructions. After 48 h, the cells were infected with IPNV (MOI of 0.1). 24 h post infection, the Mx and viral protein expression were detected by IFAT.

2.8. Simultaneous assessment of Mx over-expression and IPNV infection in AGK cells

AGK cells over-expressing Mx or not (controls), grown in 6 well plates were infected with IPNV as described above. At 72 h post-infection, the culture medium was removed from the cells, washed

Table 1
List of primers used in this study.

Name	D*	Sequence (5'–3')	T _A (°C)
MxC-f	F	MAGGGACARCAGARRACATTGGA	59.7
MxC-r	R	AAYYAAMYSCTGCTGAKGTSCTGT	59.4
Mx3Race		TCC AAC CTA GGC AGC GAT TTC TCA	60.1
Mx5Race		TTG GCC TTG GCA GAT TTG AGC AGA	61.3
Mxfull-f	F	ATGACAACTCAACAGAAGATCAGCTG	57.3
Mxfull-r	R	TTAGGATCCAACTCCAGCAGGTAGCT	61.0
pcDNA3.1c-Mxf	F	GAATTCTGCCGCATGACAACTCAACAGAAGATCAGCTG	65.8
pcDNA3.1c-Mxr	R	GGATCCAACTCCAGCAGGTAGCTGCGTGC	67.1
pcDNA3.1c-MxNf	F	GAATTCTGCCGCATGACAACTCAACAGAAGATCAGCTG	65.8
pcDNA3.1c-MxNr	R	GGATCCAACTCCAGCAGGTAGCTGCGTGC	67.1
Mx-574	F	TTGAAGATGGCACAGGAGGTGAT	60.3
Mx-730	R	TGCACCTGACAAATCATGTAGCCCT	60.5
Cathepsin D-f	F	CAGGCTGTAAGACCATCTGC	57.8
Cathepsin D-r	R	TGTTGTCAGGTCGAACACAG	57.6

T_A, annealing temperature; D*, direction of primer.

with PBS and then fixed for 20 min in 4% paraformaldehyde solution (Sigma, USA) at room temperature. After washing twice for 5 min with PBS, incubation was performed for another 5 min on ice with 200 μ l/well of 0.1% Triton X-100 (Sigma). After washing as described above, the cells were then blocked with 5% BSA for 20 min at room temperature. Following removal of the blocking solution, primary antibodies (mouse anti-polyhistag (Sigma)) or rabbit anti-IPNV (Evensen and Rimstad, 1990) diluted 1:1000 in 2.5% BSA were added and incubated for 30 min at room temperature. The wells were then washed before adding secondary antibodies (IgG goat anti-mouse Alexa Flour 488 or goat anti-rabbit Alexa Flour 594 (Invitrogen)) diluted 1:1000 in 2.5% BSA. The samples were incubated for 30 min at room temperature before the final washing prior to examination by fluorescence microscopy.

2.9. Assessment of apoptosis in AGK and RTG-2 cells following infection with IPNV

Cells were gently trypsinized and washed once with L15 medium containing 7.5% FBS prior to collection in tubes by

centrifugation at 300 \times g for 10 min. They were then re-suspended in 1 \times binding buffer of Annexin-V-FLUOS Staining Kit (Roche). The supernatant was transferred to a 5 ml polystyrene round-bottomed tube (BD Biosciences). Thereafter, 2 μ l of Annexin V-FITC was added and the cells incubated at room temperature for 30 min in the dark. Thereafter the volume was adjusted to 300 μ l. Propidium iodide (PI) was added at 8 μ l/ml just before analysis. The BD FACS Aria cell sorter (BD, San Jose, CA) was used for the analysis with Annexin V-FITC binding with FITC signal detector and PI staining by the phycoerythrin emission signal detector. Data analysis was performed using BD FACS DiVa Software, version 5.0.2 (BD, San Jose, CA). Cell aggregates were identified and excluded by using the width pulse of FSC-A versus area width of SSC-A. The percentage of early and late apoptotic cells were calculated for each sample.

2.10. Statistical analysis

Data were analyzed for statistical significance using a two-tailed Student's *t* test assuming populations of unequal variance. The threshold for significance was $p < 0.05$.




Fig. 1. Infectious pancreatic necrosis virus (IPNV) yields in AGK and RTG-2 cells. Virus concentration in supernatants of AGK and RTG-2 cells infected at MOI=0.1 (A). Time-course concentrations of virus recovered from cells versus supernatants of RTG-2 and AGK cells are shown by (B) and (C), respectively.




Fig. 2. Numbers of AGK and RTG-2 cells over time post infection with infectious pancreatic necrosis virus at MOI of either 0.1 or 10.

3. Results

3.1. Infection of AGK cells with IPNV results in delayed CPE and higher virus yields compared to RTG-2 cells

Full CPE was observed at 7 days post infection (d.p.i.) in RTG-2 cells compared to 10 d.p.i. in AGK cells. The time course assessment of virus yields harvested from cells or supernatants and then titrated in CHSE-214 cells showed higher concentrations of IPNV propagated in AGK compared to RTG-2 cells (Fig. 1A). As expected, the virus concentration was initially higher in intact cells compared to the supernatants but this became reversed towards full CPE (Fig. 1B and C). At full CPE, the virus yield in AGK cells was significantly higher ($p < 0.01$) than in RTG-2 cells (Fig. 1A–C). In order to investigate the basis for this difference, the numbers of cells in infected AGK and RTG-2 cells were counted from day 0 to 6 post infection in parallel wells by using a Countess[®] Automated cell counter (Invitrogen). In both cell types, there were about 1.2×10^6 cells/ml at the time of inoculation (Fig. 2). The highest average number of infected AGK cells attained was about 3.5×10^6 /ml at 3 d.p.i. irrespective of the MOI used. In contrast, the highest average number of RTG-2 cells was only 1.3×10^6 /ml at 1 d.p.i.

3.2. Protein shut down in AGK cells is delayed compared to RTG-2 cells following infection

To find out why it takes longer to achieve full CPE in AGK compared to RTG-2 cells, protein synthesis following infection was examined. [³⁵S]Methionine-labelled host protein synthesis

revealed reductions (shutting down of protein synthesis) in both cell types, but much earlier in RTG-2 cells compared to AGK cells. In the former, protein shut down started as early as 1 d.p.i. in cells infected with virus at MOI=10 (Fig. 3). In these cells, virus synthesis visualized as strong protein bands were observed. At 2 d.p.i., the virus bands were stronger in RTG-2 cells while host proteins were almost completely shut down. In contrast, no reduction in protein synthesis was observed in AGK cells prior to 5 d.p.i., even in cells inoculated with MOI=10 (Fig. 3). However, strong viral protein bands were visible from 3 d.p.i. onwards irrespective of the virus MOI used for infection.

3.3. Poly(I:C) transfection prior to infection delays virus growth in AGK

To address questions of delayed production of viral proteins and prolonged survival of AGK cells, innate antiviral responses were examined. Since recombinant interferon- α (IFN- α) of grouper was not available to us, poly(I:C), a known inducer of IFN- α was used to transfect cells 24 h prior to infection. The response was assessed indirectly by monitoring viral bands sequentially by Western blot. The same was done in RTG-2 cells for comparison. Fig. 4A shows that no difference was observed in the expression of virus bands between poly(I:C) transfected and untreated RTG-2 cells. In contrast, AGK cells transfected with poly(I:C) exhibited delayed virus protein expression, with bands first appearing at 4 d.p.i. compared to 2 d.p.i. in non-poly(I:C)-transfected controls (Fig. 4B). However, from 4 d.p.i. onwards, no differences between groups was observed, suggesting that poly(I:C) delays but does not prevent replication of IPNV in AGK cells.

3.4. Kinetics of Mx expression in AGK cells infected with IPNV

To further examine antiviral responses, the effect of Mx downstream of the IFN response was examined. Mx was constitutively expressed in uninfected control group albeit at low levels (not shown). In infected cells, the expression exhibited a biphasic induction pattern with only cells inoculated with virus at MOI=10 showing significant induction ($p < 0.01$) at 1 d.p.i. (Fig. 5). Notably, significant induction was only observed in cells infected with MOI=10 while significant down-regulation was in cells infected with virus at MOI=0.1 (Fig. 5).

To understand the relationship between Mx expression and IPNV replication better, cells were infected at MOI=0.1 and 10, and the virus was quantified over time post infection. The virus




Fig. 3. Protein shutdown in RTG-2 and AGK cells following infection with infectious pancreatic necrosis virus. Key: VP2, VP3, VP4 = virus proteins; M = marker; d.p.i. = days post infection; MOI = multiplicity of infection, C = negative control. Newly synthesized proteins were labelled with [³⁵S]Methionine, separated by SDS-PAGE, blotted on PVDF membrane and imaged using a Typhoon imager.




Fig. 4. Western blot of infectious pancreatic necrosis virus capsid proteins in AGK cells transfected with poly(I:C) prior to infection. Key: M: marker; 1, 3, 5 = poly(I:C) treated cells and 2, 4, 6 = untreated controls at indicated time points; pVP2-1, pVP2-2 = precursor proteins of the virus VP2; VP2 and VP3 = virus capsid proteins.

yield recovered from intact cells was assessed sequentially by titration in CHSE-214 cells. For RTG-2 cells, a difference (higher yields with MOI = 10 compared to MOI = 0.1) was observed during the first 3 days only (Fig. 6A). Thereafter, no difference in yields was observed. In contrast, there was no difference in yields between groups (MOI = 0.1 or 10) at early times (days 1–5) for AGK cells (Fig. 6B). At later times (days 5–10) however, higher virus yields in cells infected with MOI = 0.1 compared to 10 (which was opposite to the Mx expression (Fig. 5)) was observed. Thus in order to contrast between the virus quantities better, qRT-PCR was used on samples collected from days 1 to 5. Fig. 6C shows that at 1 d.p.i., the virus concentration in intact cells (infected at MOI = 10) was significantly higher ($p < 0.01$) than that of MOI = 0.1, coinciding with the expression pattern of Mx (Fig. 5). However, by day 3, the difference had evened out while as from day 4 onwards, the virus concentration was higher in cells infected with MOI = 0.1 than MOI = 10 (Fig. 6C).

3.5. AGK cells over-expressing Mx are protected against IPNV infection

In order to specifically test the antiviral effects of AGK Mx, the gene was over-expressed in AGK cells prior to infection with IPNV and the effect was assessed by IFAT. The Mx protein was fused with a His tag (detected using anti-polyhistag antibodies) while IPNV was detected by using anti-IPNV antibodies. The transfection efficiency was on average relatively low, however the cells that received the construct were in general protected against IPNV infection (Fig. 7A) although a few cells co-expressing both Mx and IPNV were also observed. In contrast, cells over-expressing the truncated form of Mx (negative control) were not protected (Fig. 7B).



Fig. 5. Relative mRNA levels of Mx in AGK cells following infection with infectious pancreatic necrosis virus at either MOI of 0.1 or 10 as measured by real-time quantitative RT-PCR. *Significantly different (at least $p < 0.05$).




Fig. 6. Infectious pancreatic necrosis virus yields harvested from AGK and RTG-2 cells infected either at MOI 0.1 and 10. Average concentrations of the virus in (A) RTG-2 cells and (B) AGK cells assessed by titration in CHSE-214 cells. (C) Average concentrations of the virus in AGK cells assessed by real time RT-PCR. *Significantly different (at least $p < 0.05$).




Fig. 7. Indirect fluorescence antibody test of overexpressed Mx (A) in AGK cells following infection with infectious pancreatic necrosis virus at 72 h post infection. (B) Negative control transfected with the truncated form of Mx, note the degree of double staining. Key: green colour = Mx; red stain = IPNV; yellow/orange = double staining of IPNV and Mx(A) or its truncated form(B).

3.6. IPNV-infected AGK cells are less apoptotic than RTG-2 cells

Other factors likely to contribute to cell survival or the lack of it following virus infection include apoptosis and necrosis. To determine which one was applicable in AGK and RTG-2 cells infected with IPNV, the cells were subjected to flow cytometry. At 24 h following infection, a higher percentage of infected RTG-2 cells (9.6%) underwent apoptosis compared to AGK cells (0.6%) (Fig. 8).

3.7. AGK yields much higher volumes of virus supernatant than CHSE over the same time period

While the studies above provide some explanation as to why AGK cells yield a higher virus titre than RTG-2 cells, it has been shown that titres equivalent to those offered by AGK cells can be obtained in CHSE-214 cells (Skjesol et al., 2009, own observation). For this reason we extended this study and compared the growth capacity of AGK and CHSE-214 cells in 162 cm² flasks. Both cell lines were seeded onto 162 cm² with 3.7×10^6 cells as a start and incubated at their optimum temperatures (28 °C for AGK and 20 °C for CHSE-214 cells). AGK cells became confluent and were ready to be split after 3 days while CHSE-214 only became confluent after 7 days of incubation. AGK cells have a split ratio (SR) of 1:4 and CHSE are split at 1:3. On this basis we calculated how many flasks can be obtained after 3 weeks of culture, using the following formula; number of flasks = $SR^{(no. \text{ splits})}$. The number of flasks of AGK after 3 weeks (6 splits) will be 4096, for CHSE 27 flasks (3 splits). This will be equivalent to 163 840 ml of supernatant for AGK and 1080 ml for CHSE (40 ml per bottle in a 162 cm² flask). At a virus yield of 1.0×10^9 TCID₅₀/ml of supernatant (for both) and a vaccine dose of 5×10^8 TCID₅₀/fish, AGK cell production will support the vaccination of 327 680 fish while only 2160 fish can be vaccinated from CHSE-grown virus.

4. Discussion

It was shown in this study that AGK cells produce higher yields of IPNV compared to RTG-2 cells. IPNV titres in excess of 10^9 TCID₅₀/ml were obtained from the former (Fig. 1), translating to about 100 times more than the yield of RTG-2 cells and comparable to previous records of CHSE-214 and CHH-1 (Lannan et al., 1984; Skjesol et al., 2009). When comparing production capacity to CHSE cells, the higher split ratio and shorter split interval of AGK cells will give a very marked difference in production capacity. Infected AGK cells had more than twice the number of RTG-2 cells per unit volume at confluence (Fig. 2), a difference probably explainable by their smaller size in comparison with the latter. This means that AGK cells can reproduce more than RTG-2 cells. It is expected that

the large number of AGK cells provide more cells for the virus to multiply leading to higher yields.

AGK cells grow more rapidly compared to salmonid cell lines probably because of their relatively higher physiological and in vitro temperature tolerance (28 °C). Temperature has previously been demonstrated to induce increase growth rate in mammalian cells through its effect on the G1 growth phase (Watanabe and Okada, 1967). AGK cells are split at 1:4, not very different from CHSE-214 cells (1:3), but they grow confluent in 3 days as opposed to 7 days (CHSE-214 cells). The effect of higher split ratio and the shorter split interval demonstrate the advantage these cells have over CHSE-214 and other similar salmonid cell lines. From a vaccine production point of view, the effect of shorter splitting intervals results in a very high number of flasks available for inoculation and the resulting vaccine volume will differ dramatically.

While the difference in cell numbers between AGK and RTG-2 cells can only account for part of the difference in yields, the rest can be attributed to individual cells' virus carrying capacities, likely facilitated by delayed protein shutdown and delayed/lack of apoptosis in AGK cells. Protein shutdown is a well-known mechanism employed by cells to protect themselves against virus infections (McClintock et al., 1986; Guzo et al., 1992; Du and Thiem, 1997). It is also used by viruses to subvert host antiviral responses (Mazzacano et al., 1999; Mir and Panganiban, 2008). IPNV has previously been shown to interfere with host protein synthesis (Skjesol et al., 2009) although the mechanism has not been clearly elucidated. In this study, the delay in protein shutdown of AGK cells (Fig. 3) was associated with high host cell numbers and virus yields. This is in contrast to the findings of RTG-2 cells where cell multiplication ceased at 1 d.p.i. (MOI = 10) or 2 d.p.i. (MOI = 0.1) (Fig. 2), coinciding with host cell protein shutdown. Furthermore, apoptosis was detected in RTG-2 cells by 1 d.p.i. unlike in AGK cells where it was absent at this time point. Collectively, these findings suggest that delayed protein shutdown and CPE in AGK cells allows for longer replication windows that in turn permit increased virus yields, opposite to what is seen in RTG-2 cells.

The similarities in the trends of protein shutdown of AGK cells infected with different MOI in this study (Fig. 3) were intriguing given that the final virus concentrations were different (Fig. 6). This is opposite to what was seen in RTG-2 cells where shutdown was enhanced by high MOI and the virus yield ultimately ending up with the same concentration for both high and low MOI. In AGK cells, the low expression of Mx, while constitutive, did not inhibit IPNV multiplication. Infecting cells with high MOI triggered the induction of Mx leading to reduced final yields. In contrast, inoculation of cells with low MOI induced only marginal non-significant changes in the Mx expression, ultimately with higher virus concentrations. Taken together, these findings support previous reports that the effect of Mx on IPNV is dose-dependent, the more the expression, the more its antiviral effects (Lester et al., 2012). Low MOI allows the virus to multiply without inducing Mx and results in high virus yields.

The production and responsiveness of interferon (IFN) by some cell types, for example RTG-2 has previously been shown to result in low virus concentrations while the absence has been linked to high titres, e.g. in CHSE-214 cells (Dobos and Roberts, 1983). Cellular IFN is produced by infected cells and acts on neighbouring cells by inducing the production and release of many interferon stimulated genes (ISGs) including Mx to create an antiviral state (Galligan et al., 2006). Poly(I:C), a potent inducer of interferon was used in the present study to transfect both AGK and RTG-2 cells (Fig. 4) (Skjesol et al., 2009). While no difference between groups was observed in RTG-2 cells, poly(I:C) transfection initially inhibited virus replication in AGK cells. These results fit well with those of Mx expression following IPNV infection with MOI = 10 (Fig. 5) and strengthen the argument that interferon delays but does not inhibit IPNV multiplication as shown previously (Skjesol et al., 2009). Unfortunately, the




Fig. 8. Flow cytometry analysis of AGK and RTG-2 cells at 24 h post infection with infectious pancreatic necrosis virus. (A) Uninfected AGK control cells; (B) IPNV-infected AGK cells; (C) uninfected RTG-2 control cells and (D) IPNV-infected RTG-2 cells. Apoptotic cells are strong Annexin V positive while necrotic cells have increased propidium iodide stain.

genetic sequence of AGK IFN is not known at present, nor are there tools that can be used to study the interferon response directly although the anticipation is that the IFN response in AGK cells is conserved.

IPNV kills infected cells by lysis, referred to as post-apoptotic necrosis in fish cell lines (Hong et al., 1998, 1999; Santi et al., 2005). It is not very clear however whether apoptosis is part of the virus pathogenesis mechanism. At least one report suggests that it is part of the host cell antiviral mechanisms (Imajoh et al., 2005). In the present study, more apoptosis was observed in RTG-2 compared to AGK cells at 24 h p.i. These results are consistent with those of protein shutdown and support the observation that infected AGK cells remain viable longer than AGK cells following infection. However, additional studies are required to document the contribution of apoptosis or the lack of it to virus yield.

IPNV has been propagated previously in AGK cells in our laboratory for both inactivated whole virus vaccines and challenge models, achieving strong protection against homologous challenge in experimental models where mortalities of 84.6% in naïve fish were obtained (Munang'andu et al., 2012, 2013a,c). This clearly shows the potential of the AGK cell line used for production of IPNV vaccine antigen.

Acknowledgements

This work was funded by the Research Council of Norway (FUGE Project No. 187848). The authors wish to thank the Oslo University Hospital Flow Cytometry Core Facility, especially Hans Christian Dalsbotten Aass for the assistance with flow cytometry. AGK cells

were kindly provided by Schweitzer Biotech Company, Taiwan, ROC.

References

- Cohen, J., Poinsard, A., Scherrer, R., 1973. Physico-chemical and morphological features of infectious pancreatic necrosis virus. *J. Gen. Virol.* 21, 485–498.
- Dobos, P., 1976. Size and structure of the genome of infectious pancreatic necrosis virus. *Nucleic Acids Res.* 3, 1903–1924.
- Dobos, P., Roberts, T.E., 1983. The molecular biology of infectious pancreatic necrosis virus: a review. *Can. J. Microbiol.* 29, 377–384.
- Du, X., Thiem, S.M., 1997. Responses of insect cells to baculovirus infection: protein synthesis shutdown and apoptosis. *J. Virol.* 71, 7866–7872.
- Duncan, R., Dobos, P., 1986. The nucleotide sequence of infectious pancreatic necrosis virus (IPNV) dsRNA segment A reveals one large ORF encoding a precursor polyprotein. *Nucleic Acids Res.* 14, 5934.
- Duncan, R., Mason, C.L., Nagy, E., Leong, J.A., Dobos, P., 1991. Sequence analysis of infectious pancreatic necrosis virus genome segment B and its encoded VP1 protein: a putative RNA-dependent RNA polymerase lacking the Gly-Asp-Asp motif. *Virology* 181, 541–552.
- Evensen, O., Rimstad, E., 1990. Immunohistochemical identification of infectious pancreatic necrosis virus in paraffin-embedded tissues of Atlantic salmon (*Salmo salar*). *J. Vet. Diagn. Invest.* 2, 288–293.
- Galligan, C.L., Murooka, T.T., Rahbar, R., Baig, E., Majchrzak-Kita, B., Fish, E.N., 2006. Interferons and viruses: signaling for supremacy. *Immunol. Res.* 35, 27–40.
- Guzo, D., Rathburn, H., Guthrie, K., Dougherty, E., 1992. Viral and host cellular transcription in *Autographa californica* nuclear polyhedrosis virus-infected gypsy moth cell lines. *J. Virol.* 66, 2966–2972.
- Havarstein, L.S., Kalland, K.H., Christie, K.E., Endresen, C., 1990. Sequence of the large double-stranded RNA segment of the N1 strain of infectious pancreatic necrosis virus: a comparison with other Birnaviridae. *J. Gen. Virol.* 71 (Pt. 2), 299–308.
- Hong, J.R., Lin, T.L., Hsu, Y.L., Wu, J.L., 1998. Apoptosis precedes necrosis of fish cell line with infectious pancreatic necrosis virus infection. *Virology* 250, 76–84.
- Hong, J.R., Lin, T.L., Yang, J.Y., Hsu, Y.L., Wu, J.L., 1999. Dynamics of nontypical apoptotic morphological changes visualized by green fluorescent protein in living cells with infectious pancreatic necrosis virus infection. *J. Virol.* 73, 5056–5063.

- Imajoh, M., Hirayama, T., Oshima, S., 2005. Frequent occurrence of apoptosis is not associated with pathogenic infectious pancreatic necrosis virus (IPNV) during persistent infection. *Fish Shellfish Immunol.* 18, 163–177.
- Jensen, I., Larsen, R., Robertsen, B., 2002. An antiviral state induced in Chinook salmon embryo cells (CHSE-214) by transfection with the double-stranded RNA poly I:C. *Fish Shellfish Immunol.* 13, 367–378.
- Lannan, C.N., Winton, J.R., Fryer, J.L., 1984. Fish cell lines: establishment and characterization of nine cell lines from salmonids. *In Vitro* 20, 671–676.
- Lester, K., Hall, M., Urquhart, K., Gahlawat, S., Collet, B., 2012. Development of an in vitro system to measure the sensitivity to the antiviral Mx protein of fish viruses. *J. Virol. Methods* 182, 1–8.
- Macdonald, R.D., Kennedy, J.C., 1979. Infectious pancreatic necrosis virus persistently infects Chinook salmon embryo cells independent of interferon. *Virology* 95, 260–264.
- Marjara, I.S., Thu, B.J., Evensen, O., 2010. Differentially expressed genes following persistent infection with infectious pancreatic necrosis virus in vitro and in vivo. *Fish Shellfish Immunol.* 28, 845–853.
- Mazzacano, C.A., Du, X., Thieme, S.M., 1999. Global protein synthesis shutdown in *Autographa californica* nucleopolyhedrovirus-infected Ld652Y cells is rescued by tRNA from uninfected cells. *Virology* 260, 222–231.
- McClintock, J.T., Dougherty, E.M., Weiner, R.M., 1986. Semipermissive replication of a nuclear polyhedrosis virus of *Autographa californica* in a gypsy moth cell line. *J. Virol.* 57, 197–204.
- Mir, M.A., Panganiban, A.T., 2008. A protein that replaces the entire cellular eIF4F complex. *EMBO J.* 27, 3129–3139.
- Munang'andu, H.M., Fredriksen, B.N., Mutoloki, S., Brudeseth, B., Kuo, T.Y., Marjara, I.S., Dalmo, R.A., Evensen, O., 2012. Comparison of vaccine efficacy for different antigen delivery systems for infectious pancreatic necrosis virus vaccines in Atlantic salmon (*Salmo salar* L.) in a cohabitation challenge model. *Vaccine* 30, 4007–4016.
- Munang'andu, H.M., Fredriksen, B.N., Mutoloki, S., Dalmo, R.A., Evensen, O., 2013a. Antigen dose and humoral immune response correspond with protection for inactivated infectious pancreatic necrosis virus vaccines in Atlantic salmon (*Salmo salar* L.). *Vet. Res.* 44, 7.
- Munang'andu, H.M., Sandtrø, A., Mutoloki, S., Brudeseth, B.E., Santi, N., Evensen, Ø., 2013b. Immunogenicity and cross protective ability of the central VP2 amino acids of infectious pancreatic necrosis virus in Atlantic salmon (*Salmo salar* L.). *PLoS One* 8 (1), e54263.
- Munang'andu, H.M., Fredriksen, B.N., Mutoloki, S., Dalmo, R.A., Evensen, O., 2013c. The kinetics of CD4+ and CD8+ T-cell gene expression correlate with protection in Atlantic salmon (*Salmo salar* L.) vaccinated against infectious pancreatic necrosis. *Vaccine* 31, 1956–1963.
- Nolan, T., Hands, R.E., Bustin, S.A., 2006. Quantification of mRNA using real-time RT-PCR. *Nat. Protoc.* 1, 1559–1582.
- Roberts, R.J., Pearson, M.D., 2005. Infectious pancreatic necrosis in Atlantic salmon, *Salmo salar* L. *J. Fish Dis.* 28, 383–390.
- Santi, N., Song, H., Vakharia, V.N., Evensen, O., 2005. Infectious pancreatic necrosis virus VP5 is dispensable for virulence and persistence. *J. Virol.* 79, 9206–9216.
- Schmittgen, T.D., Livak, K.J., 2008. Analyzing real-time PCR data by the comparative C(T) method. *Nat. Protoc.* 3, 1101–1108.
- Skjesol, A., Aamo, T., Hegseth, M.N., Robertsen, B., Jørgensen, J.B., 2009. The interplay between infectious pancreatic necrosis virus (IPNV) and the IFN system: IFN signaling is inhibited by IPNV infection. *Virus Res.* 143, 53–60.
- Sommerset, I., Krossoy, B., Biering, E., Frost, P., 2005. Vaccines for fish in aquaculture. *Expert Rev. Vaccines* 4, 89–101.
- Watanabe, I., Okada, S., 1967. Effects of temperature on growth rate of cultured mammalian cells (L5178Y). *J. Cell Biol.* 32, 309–323.

1 **IPNV antigen uptake and distribution in Atlantic salmon following oral administration**

2 Lihan Chen, Øystein Evensen and Stephen Mutoloki*

3 Norwegian University of Life Sciences,

4 Department of Basic Sciences and Aquatic Medicine,

5 Faculty of Veterinary Medicine and Biosciences,

6 P.O. Box 8146 Dep., 0033 Oslo, Norway

7 *Corresponding author

8 email address: stephen.mutoloki@nmbu.no;

9

10 **Abstract**

11 One of the difficulties facing the success of oral vaccination in fish is the hostile stomach
12 environment that antigens must cross. Further, uptake of antigen from the gut to systemic
13 distribution is required for induction of systemic immunity, the dynamics of which are not well
14 understood. In the present study, groups of Atlantic salmon parr were intubated with live or
15 inactivated IPNV either orally or anally. At 1, 24 and 72hrs post infection (p.i.) the fish were
16 sacrificed and serum, head kidney, spleen, liver, anterior and posterior intestinal tissues were
17 sampled. The serum was used for assessing IPNV by ELISA while tissues were used for antigen
18 distribution by immunohistochemistry. Both live and inactivated IPNV antigens were observed in
19 enterocytes of the intestines and in immune cells of the head kidneys and spleens of all groups. In
20 the liver, no antigens were observed in any of the groups. Significantly higher serum antigen OD

21 values ($p < 0.04$) were observed in orally compared to anally intubated fish. By contrast, no
22 difference ($p = 0.05$) was observed in tissue antigens between these groups by
23 immunohistochemistry. No significant difference ($p = 0.05$) was observed in serum antigens
24 between groups intubated with live and inactivated IPNV while in tissues, significantly more
25 antigens ($p < 0.03$) were observed in the latter compared to the former. These findings demonstrate
26 that both live and inactivated IPNV is taken up by enterocytes in the intestines of Atlantic salmon
27 likely by receptor mediated mechanisms akin to those of HRP or ferritin. Higher IPNV uptake by
28 the oral compared to anal route suggests that both the anterior and posterior intestines are
29 important for the uptake of the virus and that IPNV is resistant to gastric degradation of the
30 Atlantic salmon stomach.

31

32 **Key words**

33 Infectious pancreatic necrosis virus, Atlantic salmon, oral, anal, uptake

34

35 **Introduction**

36 Oral vaccines are the most desirable preparations for use in the aquaculture industry for several
37 reasons: they are stress-free, can be mass-applied to fish of any size and are not labour intensive
38 [1-3]. Despite these advantages, only a few commercial preparations are available on the market
39 at the moment including those against infectious pancreatic necrosis virus (IPNV), Spring
40 viremia carp virus (SVCV), infectious salmon anaemia virus (ISAV) and *Piscirickettsia salmonis*
41 [4;5]. This status quo highlights the market potential for oral vaccines in the aquaculture industry
42 but also reflects the challenges faced in their development.

43 One of the problems associated with oral vaccination of fish is the poor induction of local and
44 systemic immunity by the vaccines. Indeed oral vaccines come third after injection and
45 immersion preparations in terms of efficacy [6]. Previous studies suggest that this is a result of a)
46 antigen destruction from exposure to gastric acids and digestive enzymes in the gut of some
47 species of fish, b) poor uptake of antigens over the intestinal epithelium and c) induction of
48 tolerance following oral administration [7;8]. Therefore to resolve some of these obstacles,
49 several encapsulation formulations with the ability to protect the antigens through the hostile
50 environment of the stomach have been developed such as alginate beads or microspheres [6;9].
51 Nevertheless, even with these formulations, variable results in the vaccination of fish have been
52 reported with different antigen preparations [9;10]. It is also noteworthy that the assessment in
53 these studies were done mainly by examining mortalities or survival of fish following challenge
54 (summarized in [6]) whilst antigen uptake remains poorly understood. In the present study, we
55 examined the uptake and distribution of IPNV at early time in selected organs following oral and
56 anal intubation. This has previously not been well documented. Novoa and coworkers attempted
57 to show the uptake and sequential distribution of IPNV in turbot following intraperitoneal
58 injection and immersion infection and drew conclusions at tissue level, but failed to document
59 which cells take up the virus at the portals of entry [11].

60 Infectious pancreatic necrosis is a disease caused by IPNV and affects salmonids especially fry at
61 start feeding, parr during fresh water and post-smolts a few weeks after seawater transfer. IPNV
62 uptake in fish has in general not been studied in detail since the 1990's. Available literature
63 shows that the second gut segment is important for uptake of proteins following both oral and
64 anal administration [10;12;13]. For IPNV however, Sundh and colleagues found that both
65 proximal and distal intestines were routes of uptake in Atlantic salmon [14]. In carp, HRP (solid

66 phase) is taken up by the receptor mediated route and is sorted into the endolysosomal
67 compartment and intercellular spaces [7]. Ferritin and LPS (fluid phase) on the other hand are
68 taken up through the large supranuclear vacuoles and cannot be observed in intracellular spaces
69 [10;12;13]. How IPNV is taken up is yet unknown and this was the focus of the present study.
70 Specifically, we investigated sequentially the up-take of IPNV from the intestinal lumen and its
71 subsequent distribution to lymphoid organs or to the liver of Atlantic salmon.

72

73 **2. Materials and Methods**

74 This study was approved by the Norwegian Animal Research Authority.

75 **2.1 Cell lines and viruses**

76 Asian grouper strain K (AGK) cells [15] were used for the propagation of virus in this study. The
77 cells were grown in L-15 medium (Invitrogen) supplemented by 7.5% fetal bovine serum as well
78 as 10% L-glutamine and were incubated at 28 °C. Chinook salmon embryo cells (CHSE-214)
79 were used for titration of the virus and were maintained at 20 °C in the same medium as AGK
80 cells but with 10% FBS. When infected with IPNV, only 1% FBS was used in the media of both
81 cell lines as well as 1 mg/ml of gentamicin. The incubation temperature was then set to 15 °C
82 until full CPE.

83 **2.2 Fish and rearing conditions**

84 Approximately 90 Atlantic salmon parr weighing about 25 g each were procured from Sørsmolt
85 AS in Sannidal, Norway. The fish were healthy and the hatchery from which they were purchased
86 had had no previous records of IPNV outbreaks in the three years prior to the study. The fish

87 were transported to the Norwegian University of Life Sciences/Veterinary Institute shared wetlab
88 in Oslo by road in oxygenated bags. One week following acclimatization, the fish were treated
89 with formalin (diluted 1:4000 in water) for 30 min against ectoparasites. The fish were then kept
90 for a further week prior to the onset of the experiment. During the entire experiment the water
91 temperature was 12 °C.

92 **2.3 Antigen administration/infection of the fish**

93 Infectious pancreatic necrosis virus grown in AGK cells to a titer of 10^9 TCID₅₀/ml as described
94 above was used. Inactivation of the virus was done as described by Dixon & Hill (1983). Briefly,
95 0.5% formalin (w/v) was added to the virus supernatant followed by incubation at room
96 temperature for 48 hrs with a magnetic stirrer. Formalin was then removed by dialysis against
97 PBS. To test for inactivation and the presence of residual formalin, fresh CHSE cells were
98 incubated with excessive amounts of inactivated virus supernatant. No CPE or cellular toxicity
99 was observed after 7 days.

100 Prior to treatment of the fish, the feed was with-held for 24hrs. Allocation of the fish into 6
101 groups was done sequentially by dip netting. Prior to intubation, the fish were anaesthetized by
102 using Benzocaine at 10mg/L of water. The virus was administered into the fish by using a 1ml
103 syringe and tube. Treatment groups comprising 15 fish each were as follows: 1) Live IPNV
104 administered orally; 2) Live IPNV administered anally; 3) Inactivated IPN administered orally; 4)
105 Inactivated IPNV administered anally; 5) L-15 medium only administered orally; 6) L-15
106 medium only administered anally. Each fish received 0.3 ml of the preparation. Marking of the
107 fish was by fin-clipping and each of the four groups (Live-oral; Live-anal; inactivated-oral;

108 Inactivated-anal) was kept in a separate tank. The controls (media only) were kept together with
109 the inactivated virus groups.

110 **2.4 Sampling**

111 At 1, 24, and 72 hrs post intubation (h.p.i.), 5 fish from each group were sacrificed and sampled.
112 Samples of blood, liver, spleen, kidney, anterior intestine or mid-gut (immediately caudal to the
113 pyloric caeca) and posterior intestine or hindgut (1 cm cranial to the anus) were collected. Blood
114 samples were centrifuged on site and then serum was aspirated and transferred to clean tubes for
115 storage at -80 °C until required. The rest of the samples were preserved in 10% phosphate
116 buffered formalin.

117 **2.5 Enzyme-linked immunosorbent assay (ELISA)**

118 In order to assess the amount of IPNV in the blood of the different groups of fish, 96-well plates
119 were coated with 100 µl serum from experimental fish diluted at 1:40 in coating buffer (0.1 M
120 Carbonate buffer pH9.6). The plates were then incubated at 4 °C overnight. The next morning,
121 the plates were washed before blocking with 100 µl of 5% dry milk for 2 hrs at room temperature.
122 Unless otherwise stated, all washing steps were done using 200 µl of PBST/well. Dry milk was
123 diluted with PBST while antibodies were diluted with 1% dry milk. Following blocking, the
124 plates were washed and then incubated with 100 µl of 1:1000 rabbit anti-IPNV antibodies (K95)
125 [16] at room temperature for 1 hr. Following a washing step, 100 µl of secondary antibody,
126 peroxidase-labelled goat anti rabbit (DAKO; Glostrup, Denmark) diluted at 1:1000 dilution, was
127 incubated in each well at room temperature for 1 hr. After another washing step, 100 µl OPD
128 substrate was added to each well and incubated at room temperature for 15 min. The reaction was

129 then stopped by adding 50 μ l/well 1M H₂SO₄. OD values were detected by using an ELISA
130 reader at 492 nm absorbance.

131 **2.6 Immunohistochemistry**

132 Staining of tissues was carried out as described by Evensen and Lorenzen 1996 [17]. Briefly,
133 after de-paraffinization and rehydration, tissue sections were blocked with 5% BSA (Sigma
134 Aldrich) diluted in 1 M Tris buffer solution (TBS) pH 7.6 for 30 min. Subsequently, 150 μ l of
135 rabbit anti-IPNV serum (K95) diluted at 1:1000 in 2.5% BSA was added to each slide. After
136 incubating for 30 min at room temperature, the slides were washed. All washing steps were
137 carried out using 1 M Tris-buffer pH 7.6 with 1% Tween 20. Biotinylated goat anti-rabbit
138 antibody (DAKO; Glostrup, Denmark) was then added for 30 minutes. After washing,
139 streptavidin alkaline phosphatase (Sigma-Aldrich) was added and incubated for 30 min.
140 Following washing, fast red substrate (Sigma-Aldrich) was added to each slide and incubated for
141 10 min. The reaction was stopped by immersion of slides in running tap water for 5 min.
142 Counterstaining was carried out using Hematoxylin dye for 2 min and then washing in tap water.
143 After mounting with glycerol, the slides were observed under a light microscope.

144 **2.7 Statistical analysis.**

145 Differences in antigen scores as detected by ELISA between groups were analyzed by a two-
146 tailed Student's t test assuming populations of equal variance. To analyze differences between
147 treatment types (live versus inactivated) and routes of intubation (oral versus anal) on the
148 response (antigen present/not present as detected by immunohistochemistry), Fisher's exact test
149 was used with the help of the JMP[®] statistical software [18].

150

151 **3. Results**

152 At 1 hr following intubation with live virus, 2/5 fish in the anally intubated group and 3/5 fish in
153 the orally intubated group died prematurely and were excluded from analysis. Therefore the
154 numbers of samples collected at this time point were reduced accordingly. All five fish from each
155 group were sampled from the rest of the time points.

156

157 **3.1 Higher IPNV antigens were detected in orally- compared to anally-intubated fish by**
158 **ELISA**

159 No antigens were present in the control fish. The OD values for treatment exhibited three trends:
160 1) an increase in IPNV antigens in the serum of all groups from 1 to 24 hrs post intubation (h.p.i.)
161 followed by a decrease; 2) Higher serum antigens ($p < 0.04$) in groups intubated orally (live and
162 inactivated) compared to those intubated anally (Fig. 1); 3) A higher trend of serum antigens in
163 live groups compared to inactivated ones albeit non-significantly. Another notable contrast was in
164 the group intubated anally with inactivated IPNV whose OD values were consistently low at all-
165 time points, being comparable to the negative controls ($p = 0.05$).

166

167 **3.2 Detection of IPNV antigens in different tissues by immunohistochemistry**

168 Table 1 shows the number of fish in which positive antigens were demonstrated by
169 immunohistochemistry in different groups while Table 2 is a summary of the results by organ
170 distribution. Significantly more antigens ($p < 0.03$) were observed in fish intubated with
171 inactivated virus compared to those with live virus when all tissues in each group were summed
172 up.

173

174 The number of fish per group in which antigens were demonstrated is shown in Table 2. No
175 antigens were detected from the anterior intestine of any of the groups. In contrast, antigens were
176 observed in the posterior intestine of some of the fish intubated both orally and anally with
177 inactivated IPNV from 1 hour post intubation (p.i.) onwards. In general, more antigens were
178 observed in fish intubated with inactivated antigens than live virus ($p < 0.03$) although the loss of
179 some fish at the start of the experiment might have affected this result (Table 1). No difference
180 between intubation routes was observed.

181
182 Antigens were observed in the posterior intestine of the inactivated virus groups (both anally and
183 orally) at 1hr and 72 h.p.i. The antigens were located in the cytoplasm of enterocytes and
184 macrophage-like cells (Fig. 3a).

185
186 In immune organs (head kidney and spleen), more antigens were observed in immune organs of
187 fish intubated with inactivated antigens compared to those with live IPNV. The antigens were
188 observed at all-time points and were localized in macrophages and melanomacrophages (Fig. 3b).

189
190 No IPNV antigens were observed in the livers of any of the fish groups.

191
192 **4. Discussion**

193 In the present study, the uptake of IPNV by enterocytes in the posterior intestine, the
194 hematogenous distribution and localization in head kidney and spleen of Atlantic salmon were
195 demonstrated. Both live and inactivated IPNV antigens were observed in the cytoplasm of
196 enterocytes and macrophage-like cells as early as 1 hr post intubation. The antigens were also
197 observed in the named organs at 72 h.p.i. To our knowledge, this is the first report to document

198 the uptake of this virus both live and inactivated from the lumen of the intestines. The
199 anticipation is that the mechanisms involved are similar to that of HRP or ferritin as reported by
200 others [7]. These findings support previous reports that the intestine is important for absorption of
201 macromolecules in fish [13]. Although no antigens were demonstrated in the anterior intestine in
202 the present study, the higher serum antigens in orally intubated groups compared to their anal
203 counterparts as assessed by ELISA suggest that the anterior intestine as well as the foregut may
204 be important in the uptake of IPNV as suggested by some [13] while contrasting others [7;13].

205
206 Orally administered antigens are believed to be depleted by the time they get to the posterior
207 intestine due to the negative actions of the stomach environment [7;13]. In the present study, anal
208 intubation of antigens was included to contrast the oral in order to test this effect. More antigens
209 were observed in fish intubated orally compared to anally ($p < 0.04$) in contrast to the findings of
210 others [7;13]. These results suggest that IPNV is resistant to the low pH and digestive enzymes
211 found in Atlantic salmon stomach. This is hardly surprising given that IPNV is well known to
212 resist chemical and even thermal treatments [19-21].

213
214 The uptake of live IPNV was in general comparable to that of the inactivated virus administered
215 orally as measured either by ELISA or immunohistochemistry. This is despite the fact that the
216 live virus has the capacity to multiply and increase in the fish within the time frame of this study.
217 These findings are consistent with reports of others [22;23], offers support to receptor-mediated
218 uptake suggesting that formalin inactivation of IPNV does not significantly alter its surface
219 structure, thereby allowing the virus to be taken up as efficiently. When it comes to anally
220 administered inactivated IPNV however, it is noteworthy that the serum antigens were low at all-
221 time points.

222

223 In the present study, antigens of both live and inactivated virus intubated either orally or anally
224 were observed in the head kidney and spleen of the fish from 1hr to 72 hrs. Antigens were
225 localized in the cytoplasm of erythrocytes, macrophage-like cells as well as melanomacrophages.
226 The presence of antigens in these cells is in line with previous reports of antigen retention in
227 immune organs [24]. The headkidney and spleen of fish are antigen-trapping organs that filter out
228 systemic antigens with melanomacrophage centres serving as focal repositories and may be
229 primitive analogues of germinal centres of lymph nodes [25;26]. Melanomacrophage centres
230 contain lymphocytes and are probably sites where immune activation of trapped antigens occurs
231 [27].

232

233 No IPNV antigens were observed in the liver of any groups in the present study. These findings
234 are in agreement with our previous work [28] but contrast the report of others [11]. The reason
235 for this difference is likely methodological as immunohistochemistry were used in our studies
236 while virus re-isolation from cellular fractions was used in the latter. Furthermore, the fish
237 species and probably virus strains were also different. Since salmonid liver, unlike the spleen and
238 kidney, receives mostly venous blood from the gut [29-31] and plays a role in the digestion and
239 removal of toxins from the blood, one would expect that all antigens taken up by the intestine
240 would be observed in this organ. This negative result therefore suggests that hepatocytes might
241 not be readily susceptible to IPNV and this view auger well with previous reports that the liver is
242 one of the last organs to be compromised following IPNV infection [28].

243

244 **Acknowledgement**

245 This work was funded by the Research Council of Norway (FUGE project no. 187848). The
246 AGK cells were kindly provided by Schweitzer Biotech Company, Taiwan, R.O.C.

247

248 **Reference List**

249

250 [1] Rombout JH, Abelli L, Picchiatti S, Scapigliati G, Kiron V. Teleost intestinal immunology. Fish
251 Shellfish Immunol 2011 Nov;31(5):616-26.

252 [2] Vandenberg GW. Oral vaccines for finfish: academic theory or commercial reality? Anim Health
253 Res Rev 2004 Dec;5(2):301-4.

254 [3] Adelmann M, Kollner B, Bergmann SM, et al. Development of an oral vaccine for immunisation of
255 rainbow trout (*Oncorhynchus mykiss*) against viral haemorrhagic septicaemia. Vaccine 2008 Feb
256 6;26(6):837-44.

257 [4] Dhar AK, Allnutt FCT. Challenges and opportunities in developing oral vaccines against viral
258 diseases of fish. J Marine Sci Res Development 2011;S7.

259 [5] Centrovet. Inactivated vaccine for salmon rickettsial syndrome and subunit vaccine against
260 infectious salmon anaemia freeze-dried oral powder. Centrovet 2014 [cited 2014 Apr
261 20];Available from: URL: <http://www.centrovet.com/index.php/products-en/fish>

262 [6] Rombout JHWM, Kiron V. Mucosal vaccination of fish. In: Gudding RLA, Evensen O, editors. Fish
263 Vaccination. 1st ed. John Wiley & Sons Ltd., 2014: p. 56-67.

- 264 [7] Rombout JH, Lamers CH, Helfrich MH, Dekker A, Taverne-Thiele JJ. Uptake and transport of intact
265 macromolecules in the intestinal epithelium of carp (*Cyprinus carpio* L.) and the possible
266 immunological implications. *Cell Tissue Res* 1985;239(3):519-30.
- 267 [8] Rombout JHWM, BHEaT-TJJ. Immunological importance of the second gut segment of carp. II.
268 Characterization of mucosal leucocytes. *Journal of fish biology* 1989;35:167-78.
- 269 [9] Maurice S, Nussinovitch A, Jaffe N, Shoseyov O, Gertler A. Oral immunization of *Carassius*
270 *auratus* with modified recombinant A-layer proteins entrapped in alginate beads. *Vaccine* 2004
271 Dec 9;23(4):450-9.
- 272 [10] Joosten PH, Engelsma MY, van der Zee MD, Rombout JH. Induction of oral tolerance in carp
273 (*Cyprinus carpio* L.) after feeding protein antigens. *Vet Immunol Immunopathol* 1997 Dec
274 12;60(1-2):187-96.
- 275 [11] Novoa B, Barja JL, Figueras A. Entry and sequential distribution of an aquatic birnavirus in turbot
276 (*Scophthalmus maximus*). *Aquaculture* 1995;131:1-9.
- 277 [12] Rombout JW, Blok LJ, Lamers CH, Egberts E. Immunization of carp (*Cyprinus carpio*) with a *Vibrio*
278 *anguillarum* bacterin: indications for a common mucosal immune system. *Dev Comp Immunol*
279 1986;10(3):341-51.
- 280 [13] Rombout JHWM, van den Berg AA, van den Berg CTGA, Witte P, Egberts E. Immunological
281 importance of the second gut segment of carp. III. Systemic and/or mucosal immune responses
282 after immunization with soluble or particulate antigen. *Journal of fish biology* 1989 Aug
283 1;35(2):179-86.

- 284 [14] Sundh H, Olsen RE, Fridell F, et al. The effect of hyperoxygenation and reduced flow in fresh
285 water and subsequent infectious pancreatic necrosis virus challenge in sea water, on the
286 intestinal barrier integrity in Atlantic salmon, *Salmo salar* L. J Fish Dis 2009 Aug;32(8):687-98.
- 287 [15] Munang'andu HM, Fredriksen BN, Mutoloki S, et al. Comparison of vaccine efficacy for different
288 antigen delivery systems for infectious pancreatic necrosis virus vaccines in Atlantic salmon
289 (*Salmo salar* L.) in a cohabitation challenge model. Vaccine 2012 Jun 8;30(27):4007-16.
- 290 [16] Evensen O, Rimstad E. Immunohistochemical identification of infectious pancreatic necrosis virus
291 in paraffin-embedded tissues of Atlantic salmon (*Salmo salar*). J Vet Diagn Invest 1990
292 Oct;2(4):288-93.
- 293 [17] Evensen O, Lorenzen E. An immunohistochemical study of *Flexibacter psychrophilus* infection in
294 experimentally and naturally infected rainbow trout (*Oncorhynchus mykiss*) fry. Dis Aquat Organ
295 1996 May 9;25(1-2):53-61.
- 296 [18] JMP [computer program]. Version 10. Cary, NC USA: SAS Institute Inc.; 2012.
- 297 [19] Christie KE, Hjeltnes B. Infeksiøs pankreas nekrose-IPN. In: Poppe T, editor. Fiskehelse-
298 Sykdommer, forebygging behandling. Fyllingsdalen, Norway, John Grieg Forlag AS, 1990: p. 190-2.
- 299 [20] Myrmel M, Modahl I, Nygaard H, Lie KM. Infectious pancreatic necrosis virus in fish by-products
300 is inactivated with inorganic acid (pH 1) and base (pH 12). J Fish Dis 2014 Apr;37(4):349-55.
- 301 [21] Nygaard H, Modahl I, Myrmel M. Thermal inactivation of infectious pancreatic necrosis virus in a
302 peptone-salt medium mimicking the water-soluble phase of hydrolyzed fish by-products. Appl
303 Environ Microbiol 2012 Apr;78(7):2446-8.

- 304 [22] Goorha RM, Gifford GE. Comparison of interferon induction by active and inactive Semliki Forest
305 virus. *J Gen Virol* 1971 Feb;10(2):117-24.
- 306 [23] Liu T, Zhou X, Abdel-Motal UM, Ljunggren HG, Jondal M. MHC class I presentation of live and
307 heat-inactivated Sendai virus antigen in T2Kb cells depends on an intracellular compartment with
308 endosomal characteristics. *Scand J Immunol* 1997 May;45(5):527-33.
- 309 [24] Mutoloki S, Alexandersen S, Evensen O. Sequential study of antigen persistence and concomitant
310 inflammatory reactions relative to side-effects and growth of Atlantic salmon (*Salmo salar* L.)
311 following intraperitoneal injection with oil-adjuvanted vaccines. *Fish Shellfish Immunol* 2004
312 May;16(5):633-44.
- 313 [25] Agius C, Roberts RJ. Melano-macrophage centres and their role in fish pathology. *J Fish Dis* 2003
314 Sep;26(9):499-509.
- 315 [26] Espenes A, Press CM, Dannevig BH, Landsverk T. Immune-complex trapping in the splenic
316 ellipsoids of rainbow trout (*Oncorhynchus mykiss*). *Cell Tissue Res* 1995 Oct;282(1):41-8.
- 317 [27] Ellis AE, Sousa MD. Phylogeny of Lymphoid System .1. Study of Fate of Circulating Lymphocytes
318 in Plaice. *European Journal of Immunology* 1974;4(5):338-43.
- 319 [28] Munang'andu HM, Fredriksen BN, Mutoloki S, Dalmo RA, Evensen O. Antigen dose and humoral
320 immune response correspond with protection for inactivated infectious pancreatic necrosis virus
321 vaccines in Atlantic salmon (*Salmo salar* L). *Vet Res* 2013;44(1):7.
- 322 [29] Kryvi H, Totland GK. *Fiskeanatomi*. Kristiansand, Norway: Høyskoleforlaget AS- Norwegian
323 Academic Press, 1997.

- 324 [30] Petersen LH, Dzialowski E, Huggett DB. The interactive effects of a gradual temperature decrease
325 and long-term food deprivation on cardiac and hepatic blood flows in rainbow trout
326 (*Oncorhynchus mykiss*). *Comp Biochem Physiol A Mol Integr Physiol* 2011 Nov;160(3):311-9.
- 327 [31] Thorarensen H, McLean E, Donaldson EM, Farrell AP. The blood vasculature of the gastrointestinal
328 tract in chinook, *Oncorhynchus tshawytscha* (Walbaum), and coho, *O. kisutch* (Walbaum), salmon.
329 *J Fish Biol* 1991;38:525-31.

330

331

332

333

334

335 **Figure legend**

336 **Figure 1**

337 Infectious pancreatic necrosis virus in the serum of different groups of Atlantic salmon at
338 different time points following intubation. ELISA. *significantly different ($p < 0.05$) from the
339 control.

340 **Figure 2**

341 Contingency table analysis of the response of Atlantic salmon to administration of infectious pancreatic
342 necrosis virus. A) Comparison between routes of administration and B) Comparison between virus
343 treatments. Key: 0= no antigens detected; 1= antigen detected in the fish; Oral: n= 27; Anal: n= 28; Live
344 virus: n= 25; Inactivated virus: n=30.

345 **Figure 3**

346 Infectious pancreatic necrosis virus antigens (red stain) in different tissues of Atlantic salmon at
347 designated time points following oral or anal intubation. Immunohistochemistry. A) Posterior intestine,
348 inactivated IPNV at 72 hrs post oral intubation; B) Head kidney, inactivated IPNV at 72 hrs post oral
349 intubation; Key: E=enterocytes; MØ = macrophages; MMØ= melanomacrophages. X40 magnification.

350

351

Tables

- 1 Table 1.
- 2 Proportion of fish showing infectious pancreatic necrosis virus staining in different organs
- 3 following intubation with either live or inactivated virus.

Treatment	Route of intubation	Time (hours post intubation)		
		1	24	72
Live virus	Oral	0/2	1/5	3/5
	Anal	3/3	0/5	0/5
Inactivated virus	Oral	4/5	1/5	1/5
	Anal	4/5	3/5	4/5

4

5


6 Table 2.

7 Number of fish with positive staining for infectious pancreatic necrosis virus antigens in different
8 tissues following intubation.


Tissue	Time (hours p.i.)	Live virus		Inactivated virus	
		Anal intubation	Oral intubation	Anal intubation	Oral intubation
Posterior intestine	1	0*	0**	1	1
	24	0	0	0	0
	72	0	0	1	1
Liver	1	0*	0**	0	0
	24	0	0	0	0
	72	0	0	0	0
Head kidney	1	3*	0**	2	3
	24	0	1	2	0
	72	0	3	3	0
Spleen	1	2*	0**	1	2
	24	0	0	3	1
	72	0	0	2	0


9 *n=3; **n=2 otherwise n=5.

10




Figures





Figures



Figures

1 **Augmentation of the antibody response of Atlantic salmon by oral**
2 **administration of alginate-encapsulated IPNV antigens**

3

4 Lihan Chen^{1†}, Goran Klaric^{2,3†}, Simon Wadsworth², Suwan Jayasinghe³, Tsun-Yung
5 Kuo⁴, Øystein Evensen¹ and Stephen Mutoloki^{1*}

6

7 ¹Faculty of Veterinary Medicine and Biosciences, Norwegian University of Life
8 Sciences, P.O. Box 8146 Dep., 0033 Oslo, Norway

9 ²EWOS Innovation AS, Hanaveien 17, 4327 Sandnes, Norway

10 ³University College London, Gower Street, WC1E 6BT London, UK

11 ⁴Department of Animal Science/Institute of Biotechnology, National Ilan University,
12 Ilan 26041, Taipei, Taiwan.

13

14 [†]These author contributed equally

15 *Corresponding author

16

17 **Abstract**

18 The objective of the present study was to assess the effect of alginate-encapsulated
19 infectious pancreatic necrosis virus antigens in inducing the immune response of
20 Atlantic salmon as booster vaccines. One year after intraperitoneal injection with an
21 oil-adjuvanted vaccine, post-smolts were orally boosted either by 1)
22 alginate-encapsulated IPNV antigens (ENCAP); 2) soluble antigens (UNENCAP) or 3)
23 untreated feed (control). This was done twice, seven weeks apart. Sampling was done
24 twice, firstly at 7 weeks post 1st oral boost and the 2nd, at 4 weeks after the 2nd oral
25 boost. Samples included serum, head kidney, spleen and hindgut. Serum antibodies

26 were analyzed by ELISA while tissues were used to assess the expression of IgM, IgT,
27 CD4, GATA3, FOXP3, TGF- β and IL-10 genes by quantitative PCR. Compared to
28 controls, fish fed with ENCAP had a significant increase ($p < 0.04$) in serum antibodies
29 following the 1st boost but not after the 2nd boost. This coincided with significant
30 up-regulation of CD4 and GATA3 genes. In contrast, serum antibodies in the
31 UNENCAP group decreased both after the 1st and 2nd oral boosts. This was associated
32 with significant up-regulation of FOXP3, TGF- β and IL-10 genes. The expression of
33 IgT was not induced in the hindgut after the 1st oral boost but was significantly
34 up-regulated following the 2nd one. CD4 and GATA3 mRNA expressions exhibited a
35 similar pattern to IgT in the hindgut. IgM mRNA expression on the other hand was
36 not differentially regulated at any of the times examined. Our findings suggest that 1)
37 Parenteral prime with oil-adjuvanted vaccines followed by oral boost with ENCAP
38 results in augmentation of the systemic immune response; 2) Symmetrical prime and
39 boost (mucosal) with ENCAP results in augmentation of mucosal immune response
40 and 3) Symmetrical priming and boosting (mucosal) with soluble antigens results in
41 the induction of systemic immune tolerance.

42

43 **Keywords:** Oral vaccine, IPNV, alginate, boost, immune response

44 **1. Introduction**

45 Infectious pancreatic necrosis is an important disease of salmonids responsible for
46 great economic losses in the aquaculture industry. It is characterized by loss of
47 appetite, darkened skin pigmentation, distended abdomen and mortalities ranging
48 from negligible to almost 100%. Histopathologically, necrosis of pancreatic acinar
49 cells, multifocal hepatic necrosis and acute catarrhal enteritis are commonly observed
50 [1,2]. The causative agent is infectious pancreatic necrosis virus (IPNV), a double
51 stranded RNA virus belonging to the family *Birnaviridae* and genus *Aquabirnavirus*
52 where it is the type species.

53

54 Control of IPN is by vaccination and oil-based vaccines have earned their place in the
55 market mainly because of their contribution to the control of bacterial diseases in the
56 late 80s and early 90s in Norway. The efficacy of these vaccines against diseases
57 caused by intracellular pathogens such as viruses however remains equivocal, thus the
58 need for the continued search for more effective vaccines.

59

60 The most desirable vaccines for higher vertebrates and even more so for fish are those
61 delivered orally because of the ease with which they are administered; are stress-free;
62 applicable to smaller fish and are less labour-intensive [3]. Their usage in the
63 aquaculture industry has however been under-exploited because of their poor
64 performance in comparison with injectable and immersion counterparts. Some of the
65 challenges associated with orally delivered vaccines include poor antigen delivery and
66 uptake, degradation during passage through the digestive tract and induction of
67 tolerance [4,5]. Nevertheless, a report of good protection in fish vaccinated with
68 encapsulated DNA plasmids has recently been published [6]. Unfortunately,

69 legislation in most countries at the moment precludes the use of DNA vaccines in
70 food animals [7,8].

71

72 One of the challenges faced by vaccination of fish is the duration of protection
73 conferred by different preparations. As already mentioned, oil-based vaccines induce
74 long lasting protection against several bacterial pathogens but this could be at the cost
75 of severe side effects [9]. For viral diseases including IPN, most products on the
76 market do not give satisfactory protection probably because of their failure to induce
77 sufficiently high antibody titers required prior to challenge [10]. Boosting is a good
78 alternative for enhancing or extending protection as shown for lactococcosis [11]. The
79 effect of boosting against IPNV in particular and oral vaccination in general is
80 however not well understood. The main purpose of the present study therefore was to
81 assess the effect of alginate-encapsulated IPNV in stimulating the immune system of
82 Atlantic salmon as a booster vaccine.

83

84 **2.0 Results**

85 **2.1 Intake of oral boost feeds and IPNV antigen dose**

86 The average weight of the fish during the primary and secondary oral boost feeding,
87 the feed intake and antigen dose are shown in Table 1. As targeted, the average
88 antigen dose administered during each of the boost periods was about 1×10^9
89 $TCID_{50}/fish$. However, due to the doubling in the fish weight between the two boost
90 periods, the dose per kg of fish body weight during the second boosting was almost
91 half that during the first (Table 1).

92

93 **2.2 Antigen retention in head kidneys and hindguts**

94 To estimate the amount of antigen taken up and retained both locally and systemically
95 in each group, qPCR was used targeting hindgut and head kidneys tissues to examine
96 retained antigens at the time of sampling (7 weeks and 4 weeks following the 1st and
97 2nd boosts, respectively). The head kidney was used to represent the systemic
98 compartment since this is one of the main antigen trapping organ for blood-borne
99 antigens in fish [12].

100

101 The results show that more mRNA of IPNV (used as a surrogate of antigens) were
102 retained in the encapsulated (ENCAP) versus unencapsulated (UNENCAP) groups at
103 both time points (Fig. 1). In the head kidney, a significant increase in antigens
104 retained from the 1st to the 2nd sampling was observed in both groups. A similar trend
105 in the ENCAP group was observed in hindgut while for the UNENCAP group, no
106 difference between sampling times was observed (Fig. 1).

107

108 **2.3 Oral boosting with alginate-based antigens induces a systemic but transient**
109 **IgM antibody response**

110 Since all experimental fish had previously been vaccinated with an oil-based vaccine
111 that contained IPNV antigens, all the fish had relatively high specific background
112 antibodies as expected. The un-boosted group (control) was used as the baseline for
113 comparison with boosted groups.

114

115 In general, the response of antibodies in boosted groups showed a reverse trend over
116 time compared to that of antigens (Fig. 1&2). In the group boosted with ENCAP, the
117 antibody response was significantly higher ($p<0.04$) than the control following the 1st

118 boost (Fig. 2). At 4 weeks following the 2nd boost however, the antibodies had
119 returned to background levels. In the UNENCAP group, no difference was observed
120 compared to unboosted controls during the 1st sampling while the antibodies were
121 significantly suppressed ($p < 0.02$) following the 2nd boost (Fig. 2).

122

123 **2.4 The systemic immune response is predominantly Th2**

124 The induction of antibodies in the ENCAP group was suggestive of a predominantly
125 humoral response. Thus to verify this, we examined the expression of CD4 and
126 GATA-3 genes that are known to be associated with Th2 responses, in the head
127 kidney and spleen.

128

129 At both 7 weeks post primary- and 4 weeks post-secondary boost, the ENCAP group
130 had significantly higher CD4 expression ($p < 0.04$) in both the head kidney and spleen
131 compared to other groups (Fig. 3a). In contrast, this gene was suppressed in the
132 UNENCAP group at the 1st sampling albeit non-significantly. At the 2nd sampling,
133 this gene was significantly suppressed ($p < 0.01$) in this group. In the ENCAP group,
134 the expression of GATA3 was significantly up-regulated ($p < 0.04$) at both time points
135 in the head kidney and spleen, consistent with the results of CD4 while in the
136 UNENCAP group, these genes were not induced (Fig. 3b).

137

138 **2.5 The gut mucosal response is also Th2 and is primarily primed by the oral** 139 **route**

140 To assess the gut mucosal response, we examined the expression of IgT mRNA since
141 antibodies are not available to us. In addition, mRNA expression of IgM, CD4 and
142 GATA3 genes were also assessed.

143

144 After the 1st oral boost, marginal but non-significant inductions of IgT were observed
145 in both the ENCAP and UNENCAP groups compared to the control (Fig 3c). At 4
146 weeks following the 2nd boost, the expression increased in both groups but more
147 significantly ($p<0.01$) in the ENCAP compared to UNENCAP group. Interestingly,
148 CD4 and GATA3 expression in this organ had a similar pattern to IgT (Fig. 3a&b),
149 especially for the ENCAP group. Conversely, CD4 and GATA3 expression of the
150 UNENCAP group were generally not induced at both time points. The expression of
151 IgM in the hindgut was not differentially expressed in all groups at all-time points
152 examined (Fig. 3d).

153

154 The assessment of IgT expression was extended to the head kidney and spleen where
155 at all-time points and in all groups, this gene was not differentially expressed. The
156 only exception was in the head kidney of the ENCAP group, at 4 weeks following 2nd
157 boost (Fig. 3c), where it was significantly up-regulated ($p<0.03$).

158

159 **2.6 Repeated oral administration of IPNV antigens results in decreased serum** 160 **antibodies but not in the hindgut of Atlantic salmon**

161 The reduction in serum antibodies following administration of antigens can be due to
162 consumption [10,13]. Thus in order to check whether this was the case in the present
163 study, we examined the transcript levels of IgM. Fig. 3d shows significant
164 down-regulation of B cell IgM transcripts both in the kidneys ($p<0.01$) and spleen
165 (0.001) of the UNENCAP group from the 1st to the 2nd samplings. A similar change
166 was observed in the spleen of the ENCAP group ($p<0.01$) but without any differential
167 regulation in the kidney.

168

169 In order to gain insight into the suppression of antibody production by B cells in the
170 UNENCAP group, we examined the expression of forkhead box protein 3 (FOXP3),
171 TGF- β and IL-10.

172

173 Consistent with the reduction/suppression of antibodies in the UNENCAP group at 4
174 weeks following 2nd boost, the expression of FOXP3, TGF- β and IL-10 were all
175 significantly up-regulated ($p < 0.003$, 0.035 and 0.0048, respectively) in the kidneys of
176 this group (Fig. 4a-c). In contrast, no differential expressions of either of these genes
177 were observed in any of the groups after the 1st boost or in the spleen.

178

179 In the hindgut, FOXP3 was only induced in the UNENCAP group after the 2nd boost
180 (Fig. 4a) while both TGF- β and IL-10 were significantly induced in both ENCAP and
181 UNENCAP groups ($p < 0.02$ and 0.01 for TGF- β and $p < 0.01$ and 0.01 for IL-10,
182 respectively).

183

184 **3. Discussion**

185 The findings of the present study demonstrate that oral boosting of Atlantic salmon
186 following parenteral injection with alginate encapsulated IPNV antigens induces both
187 systemic and mucosal (gut) humoral responses. The significant up-regulation of CD4
188 ($p < 0.02$) and GATA-3 ($p < 0.04$) genes in the head kidneys and spleens of the ENCAP
189 group (Fig. 3) fit very well with the induction of serum antibodies and point towards a
190 predominantly T-helper 2 (T_H2) response. In higher vertebrates, the intestinal mucosa
191 contains high basal levels of IL-4, IL-10 and TGF β that are induced shortly after oral
192 vaccination [14]. This micro-environment is thought to tip responses of oral vaccines
193 towards T_H2 [4]. Furthermore, the main mechanism of action of alginate encapsulated

194 antigens has been proposed to be biased towards T_H2 responses [15–18]. These
195 findings are consistent with reports of others using different antigens [19,20] and
196 suggest that oral boosting with alginate encapsulated antigens holds promise as a
197 means of augmenting immune responses against IPN. One limitation of this study is
198 that the fish were not challenged following vaccination and therefore the protective
199 effects of the responses could not be tested but should be a subject for future studies.

200

201 There are conflicting reports when it comes to protection against disease using orally
202 administered vaccines, with some reporting success [6,11,20] while others found little
203 or no difference from controls [17]. Several reasons can be attributed to these
204 variations including the nature of antigens used, formulation of oral preparations,
205 immune response generated versus that desired etc. In the present study, the fish were
206 not challenged following vaccination owing to logistical constraints. While this
207 should be a subject for further studies, it is known from a previous study that high
208 antibody titers against IPNV at the onset of challenge correlate with protection of the
209 fish [10]. It is not unlikely therefore that the augmentation of the immune response in
210 the present study may have been associated with protection.

211

212 It has previously been reported that oral vaccination results in transient antibody
213 response lasting typically 3 weeks post vaccination [20–22], and most of the studies
214 address parenteral/oral combinations or vice-versa. However, very few studies have
215 examined the effect of repeated oral vaccination. In the present study, reductions in
216 serum antibodies following two oral vaccination (7 weeks apart) was observed in the
217 both the ENCAP and UNENCAP groups after the second oral boost. This is
218 consistent with the findings of others who used a similar administration regime (5

219 days of oral vaccine administration per month) [17]. In the same study however,
220 administering the oral vaccine at a rate of 3 days/week for 2 months resulted in
221 progressive increase in antibody titers over time. Together, these findings suggest that
222 modality by which oral vaccines are administered can determine whether a booster
223 effect or tolerance ensues. The low CD4 expression in the UNENCAP group in the
224 kidney and also its decline in the ENCAP group concurrent with the lack of induction
225 of GATA3 and IgM expression in the present study is however intriguing. It is
226 tempting to speculate that this could point towards anergy as discussed further below.

227

228 The induction of the systemic response as measured from serum antibodies and
229 immune gene expression in the kidney of the ENCAP group following the 1st oral
230 boost is in line with previous reports [20,22]. The fact the 1st oral boost did not induce
231 a corresponding change in the mucosal response as measured by gene expression in
232 the hindgut suggests that injection vaccination does not activate mucosal immunity, in
233 common with findings of others [20]. Furthermore, these results (Fig. 3a-c) suggest
234 that in this study, the 1st oral boost served as a “prime” to the mucosal response while
235 the 2nd one “boosted” it. Interestingly, oral boosting had no effect on the IgM
236 expression in the hindgut, a difference from what others have observed assessing
237 mucosal antibodies [20]. The ability of orally administered antigens to stimulate both
238 systemic and mucosal immune responses on one hand and parenteral vaccination
239 inducing only a systemic response demonstrate asymmetrical responses of immune
240 induction as previously observed in mice [23].

241

242 One of the challenges of oral vaccination in fish is the induction of tolerance. This has
243 been shown to be easily induced with soluble antigens [21]. In the present study,

244 tolerance was induced by two booster administration of encapsulated IPNV antigen
245 (UNENCAP) feeds (Fig. 2). In higher vertebrates, tolerance is the default immune
246 pathway in mucosal surfaces and is related to the dose of antigens given, i.e. high
247 doses lead to anergy/deletion while the opposite leads to regulatory T cells (Treg)
248 induction [24]. The suppression of antibodies in the present study coupled with the
249 induction of FoxP3, TGF- β and IL-10 (Fig. 4) suggests the involvement of both
250 mechanisms. In higher vertebrates, FOXP3 is a key transcription factor of regulatory
251 T cells (Tregs) while TGF- β is known to induce T cells including Tregs [24,25]. IL-10
252 on the other hand is an anti-inflammatory cytokine that has been shown to contribute
253 towards the induction of immune tolerance [24]. These genes have also been
254 described in fish although their functions relative to immune tolerance remain to be
255 characterized.

256 While the induction of tolerance may be testimony that much of the un-encapsulated
257 IPNV antigens were taken up, meaning they survived the hostile acidic environment
258 in the stomach, this finding underlines the importance of encapsulation as an aid to
259 stimulating the immune response of fish. It is noteworthy that the doses of vaccines
260 administered during the 2nd boost were lower per body weight of fish compared to the
261 1st boost since the fish had gained weight by the time they received the second boost.
262 The effect of this was not addressed but should be a subject of future studies.

263

264 Finally, the findings of the present study can be summarized as follows: 1) Parenteral
265 prime with oil-adjuvanted vaccine followed by oral boost with ENCAP results in a the
266 augmentation of both the systemic and mucosal immune responses; 2) Mucosal (gut)
267 immunity is primarily primed by oral administration of antigens; 3) Oral prime and
268 boost with ENCAP results in transient augmentation of mucosal immune responses

269 and 4) Oral priming and boosting with UNENCAP results in the induction of
270 tolerance.
271

272 **4.0 Materials and Methods**

273 This study was approved by the Norwegian Animal Research Authority. Prior to
274 sampling, the fish was anaesthetised with Finquel® (Scanvacc) at 100 mg/L in order
275 to prevent suffering.

276

277 **4.1 Cell culture**

278 Asian grouper strain K (AGK) cells and Chinook salmon embryo cells (CHSE-214;
279 ATCC CRL-1681) [26] were maintained with L-15 medium (Invitrogen)
280 supplemented with 10% L-glutamine and 1µl/ml of gentamicin. In addition the
281 medium used with the former also contained 7.5% fetal bovine serum (FBS) and these
282 cells were kept at 28°C while the medium for CHSE cells contained 10% FBS and the
283 cells were maintained at 20 °C.

284

285 **4.2 Fish**

286 The experiment was conducted at EWOS Innovation AS facilities in Dirdal, Norway.
287 Healthy Atlantic salmon growers reared in sea water were used. The fish had been
288 vaccinated with ALPHA JECT micro® 6 (PHARMAQ) about a year prior to the first
289 boost treatment and were kept at a water temperature of 12°C throughout the
290 experimental duration.

291

292 **4.3 Vaccine preparations**

293 **4.3.1 Antigen preparation**

294 A recombinant Sp strain of IPNV (rNVI-15PTA) [10] was used and was prepared as
295 reported previously (Chen et al., 2013). Briefly, approximately 80% confluent AGK
296 cells maintained in L15 media as described above but with 2% FBS were inoculated

297 with IPNV using MOI=0.1 followed by incubation at 15° C. Note: CHSE or RTG-2
298 cells can be used as alternatives in the absence of AGK cells, with post-culturing
299 concentration to increase virus amounts if necessary. The virus was harvested
300 following full CPE by centrifugation of the suspension at 2500 x g followed by
301 recovery of the supernatant. Titration of the virus was by end point dilution and the
302 titer measured using the Spearman–Karber’s 50% tissue culture infectious dose
303 (TCID₅₀) in CHSE-214 cells.

304

305 The virus was inactivated with formalin (0.5% final concentration equal to 0.2%
306 formaldehyde) at room temperature for 48 hours with continuous stirring using a
307 magnetic stirrer. Thereafter formalin was removed by dialysis. Inactivation was
308 confirmed by inoculating confluent CHSE-214 cells while formalin residual effects
309 were tested by incubating cells with excessive inactivated virus and assessing for
310 toxicity.

311

312 **4.3.2 Antigen encapsulation and feed preparation**

313 The treatment groups of this study comprised either of the following feeding regimes:
314 1) untreated feed (control); 2) feed containing unencapsulated IPNV (in suspension);
315 3) feed containing alginate-encapsulated IPNV antigens.

316

317 Oral boost feeds (OBFs) were prepared by applying an oil mixture (OM) to Ewos
318 Opal 200 base pellet (BP) in a vacuum infusion coating process. OMs were
319 formulated by mixing IPNV Ag suspension (10⁹ TCID₅₀/g), phosphate buffered saline
320 (PBS), (2.70×10¹⁰ TCID₅₀/g) with fish oil. Mixing was performed by using a
321 high-performance disperser (Model T25, IKA® Werke GmbH & Co., Germany) at

322 ambient temperature. The OBF were composed with the aim of generating feeds with
323 an antigen level of 4.01×10^7 TCID₅₀/g. This level was selected due to an expected
324 daily feed intake of 3.56g/fish during the first oral boost period. For the same reason,
325 the targeted antigen level in the second OBF was 2.99×10^7 TCID₅₀/g. Control feeds
326 were produced by mixing PBS with fish oil in advance of applying to BP in the
327 vacuum infusion coating process.

328

329 **4.4 Trial design and oral boosting**

330 As part of a larger study examining responses of Atlantic salmon to different alginate
331 formulations, 360 healthy Atlantic salmon weighing approximately 200g each were
332 distributed by dip netting and sequential allocation into 9 circular 500L tanks
333 containing sea water 10 weeks prior to the start of the primary oral boost. A
334 description of the fish is given in section 4.2. The tanks were randomly divided into
335 three groups (Unencap, Encap, and Control), with three tanks being assigned to each
336 group (Figure 5).

337

338 The fish were fed with Ewos Opal 200 diet for 10 weeks prior to the first boost and
339 also until the second boost. All fish groups were fed ad-libitum. During primary
340 boosting, normal feed was replaced by OBFs for 7 days. After 7 weeks, the fish were
341 sampled. Sampling was performed on 10 fish from each tank by first anaesthetizing
342 the fish with Finquel® (Argent Laboratories) at 100mg/L. The following samples
343 were collected, blood in heparin tubes for serum extraction; head kidney, spleen and
344 hind gut in both RNAlater® (Invitrogen) and formalin.

345

346 Following sampling, a secondary boost was performed as described above. From then
347 on, the fish were fed with Ewos Opal 500. The second sampling was done 4 weeks
348 after the secondary boost.

349

350 **4.5 Feed intake assessment**

351 Unconsumed feed was collected during both boost periods to calculate feed intake.
352 Uneaten pellets were spilled out of the tanks within 10 min post feeding and filtered
353 off from the outlet water using an automatic collection system. Residual pellets were
354 removed from the filters and put into a drying cabinet for 24 h at 70 °C. Amount of
355 feed consumed was calculated as the difference between the dry weight of the feed
356 served and the dry weight of unconsumed feed, expressed as the mass of feed per
357 week per fish.

358

359

360 **4.7 Enzyme-linked immunosorbent assay (ELISA)**

361 Blood samples were centrifuged at 2500 x g for 10 min immediately after sampling.
362 Thereafter, the serum was aspirated and transferred to new tubes that was the kept at
363 -80°C until required.

364 ELISA was done as previously described [26] with minor modifications. Briefly, the
365 wells of ELISA plates (Immunoplates, Nunc Maxisorb, Denmark) were coated with
366 100µl of polyclonal anti-IPNV [27] diluted 1:2000 in coating buffer (0.1M Carbonate
367 buffer pH9.6) and then incubated at 4 °C overnight. The plates were washed prior to
368 the incubation of 200µl of 5% dry milk per well for 2 hrs at room temperature. All
369 washing steps were done in triplicate with 200µl PBST/well, all dilutions were with
370 1% dry milk and all incubation was at room temperatures unless otherwise stated.

371 After washing, the wells were incubated with 100µl of IPNV supernatant (10^8
372 TCID₅₀/ml) for 2 hours. Following another washing step, serum samples diluted 1:40
373 were then added to the wells and then incubated at 4 °C overnight. After washing,
374 100µl of mouse antibody against rainbow trout IgM [28] diluted in 1:5000 was
375 incubated for 2 hours. Following another wash, 100µl of a 1:1000 dilution of
376 peroxidase conjugated anti-mouse Ig (DAKO, Denmark) was incubated in each well
377 for 1 hour. 100µl of OPD substrate (O-phenylenediamine dihydrochloride, DAKO)
378 diluted in water was added to each well after washing. This reaction was incubated for
379 15 min following which the reaction was stopped by the addition of 50µl/well 1M
380 H₂SO₄. Results were analyzed by using an ELISA reader (TECAN, Genios) at
381 492nm.

382

383 **4.8 RNA isolation and quantitative real-time RT-PCR**

384 Total RNA was isolated by using the RNeasy Plus minikit (Qiagen) according to the
385 manufacturer's instructions, and the concentration of RNA was determined by using
386 the Nanodrop ND1000 (NanoDrop Technologies).

387

388 Quantitative PCR was performed by using QuantiFast SYBR Green RT-PCR Kit
389 (Qiagen) and the LightCycler 480 system (Roche). For each gene, 50 ng of RNA was
390 used as a template in a mixture of specific primers (250 µM) (Table 2) and QuantiFast
391 SYBR Green RT-PCR master mix in a total volume of 20 µl. The mixtures were first
392 incubated at 50°C for 10 min, then 95°C for 5 min, followed by 40 amplification
393 cycles (10 s at 95°C; 30 s at 60°C and 8s at 72°C). The sequences of primers used are
394 given in Table 2.

395 The $2^{-\Delta\Delta CT}$ method was used to calculate the gene products as described elsewhere [29]
396 and is the relative mRNA expression representing the fold induction over the control
397 group. All quantifications were normalized to β -actin.

398

399 **4.9 Statistical analysis**

400 The amount of feed intake for the three groups, gene expression and Elisa results were
401 analyzed using Student's t test. F test was used to determine if the variances of
402 population were equal or not. The threshold for significance was $p < 0.05$ for both
403 Student's t test and F test.

404

405 Reference List

406

- 407 1. Taksdal T, Strangeland K, Dannevig B (1997) Induction of infectious pancreatic
408 necrosis (IPN) in Atlantic salmon *Salmo salar* and brook trout *Salvelinus*
409 *fontinalis* by bath challenge of fry with infectious pancreatic necrosis
410 virus (IPNV) serotype SP. Dis Aquat Org 28: 39-44.
- 411 2. McKnight IJ, Roberts RJ (1976) The pathology of infectious pancreatic necrosis.
412 I. The sequential histopathology of the naturally occurring condition. Br
413 Vet J 132: 76-85.
- 414 3. Adelman M, Kollner B, Bergmann SM, Fischer U, Lange B, Weitschies W,
415 Enzmann PJ, Fichtner D (2008) Development of an oral vaccine for
416 immunisation of rainbow trout (*Oncorhynchus mykiss*) against viral
417 haemorrhagic septicaemia. Vaccine 26: 837-844..
- 418 4. Weiner HL (2001) Oral tolerance: immune mechanisms and the generation of
419 Th3-type TGF-beta-secreting regulatory cells. Microbes Infect 3:
420 947-954.
- 421 5. Rombout JH, Lamers CH, Helfrich MH, Dekker A, Taverne-Thiele JJ (1985)
422 Uptake and transport of intact macromolecules in the intestinal
423 epithelium of carp (*Cyprinus carpio* L.) and the possible immunological
424 implications. Cell Tissue Res 239: 519-530.

- 425 6. de las Heras AI, Rodriguez Saint-Jean S, Perez-Prieto SI (2010) Immunogenic
426 and protective effects of an oral DNA vaccine against infectious
427 pancreatic necrosis virus in fish. *Fish Shellfish Immunol* 28: 562-570.
- 428 7. Biering E, Salonijs K (2014) DNA Vaccines. In: Gudding RLA, Evensen O,
429 editors. *Fish Vaccination*. John Wiley & Sons. pp. 47-55.
- 430 8. Holm A, Rippke BE, Noda K (2014) Legal Requirements and Authorization of
431 Fish Vaccines. In: Gudding RLA, Evensen O, editors. *Fish Vaccination*.
432 John Wiley & Sons. pp. 128-139.
- 433 9. Evensen Ø, Brudeseth B, Mutoloki S (2004) The vaccine formulation and its
434 role in inflammatory processes in fish - effectc and adverse effects. *Dev*
435 *Biol Stand* 121:117-125.
- 436 10. Munang'andu HM, Fredriksen BN, Mutoloki S, Dalmo RA, Evensen O (2013)
437 Antigen dose and humoral immune response correspond with protection
438 for inactivated infectious pancreatic necrosis virus vaccines in Atlantic
439 salmon (*Salmo salar* L). *Vet Res* 44: 7.
- 440 11. Romalde JL, Luzardo-Alvarez A, Ravelo C, Toranzo AE, Blanco-Wendez J
441 (2004) Oral immunization using alginate microparticles as a useful
442 strategy for booster vaccination against fish lactococcosis. *Aquaculture*
443 236: 119-129.
- 444 12. Espenes A, Press CM, Reitan LJ, Landsverk T (1996) The trapping of
445 intravenously injected extracellular products from *Aeromonas*
446 *salmonicida* in head kidney and spleen of vaccinated and nonvaccinated
447 Atlantic salmon, *Salmo salar* L. *Fish Shellfish Immunol* 6: 413-426.
- 448 13. Munang'andu HM, Sandtro A, Mutoloki S, Brudeseth BE, Santi N, Evensen O
449 (2013) Immunogenicity and cross protective ability of the central VP2
450 amino acids of infectious pancreatic necrosis virus in Atlantic salmon
451 (*Salmo salar* L.). *Plos One* 8: e54263.
- 452 14. Gonnella PA, Chen Y, Inobe J, Komagata Y, Quartulli M, Weiner HL (1998) In
453 situ immune response in gut-associated lymphoid tissue (GALT)
454 following oral antigen in TCR-transgenic mice. *J Immunol* 160:
455 4708-4718.

- 456 15. Sarei F, Dounighi NM, Zolfagharian H, Khaki P, Bidhendi SM (2013) Alginate
457 Nanoparticles as a Promising Adjuvant and Vaccine Delivery System.
458 Indian J Pharm Sci 75: 442-449. 10.4103/0250-474X.119829
459 [doi];IJPhS-75-442 [pii].
- 460 16. Salvador A, Igartua M, Hernandez RM, Pedraz JL (2012) Combination of
461 immune stimulating adjuvants with poly(lactide-co-glycolide)
462 microspheres enhances the immune response of vaccines. Vaccine 30:
463 589-596.
- 464 17. Maurice S, Nussinovitch A, Jaffe N, Shoseyov O, Gertler A (2004) Oral
465 immunization of *Carassius auratus* with modified recombinant A-layer
466 proteins entrapped in alginate beads. Vaccine 23: 450-459.
- 467 18. Mutwiri G, Bowersock T, Kidane A, Sanchez M, Gerdtts V, Babiuk LA, Griebel
468 P (2002) Induction of mucosal immune responses following enteric
469 immunization with antigen delivered in alginate microspheres. Vet
470 Immunol Immunopathol 87: 269-276. S0165242702000521 [pii].
- 471 19. Thinh NH, Kuo TY, Hung LT, Loc TH, Chen SC, Evensen O, Schuurman HJ
472 (2009) Combined immersion and oral vaccination of Vietnamese catfish
473 (*Pangasianodon hypophthalmus*) confers protection against mortality
474 caused by *Edwardsiella ictaluri*. Fish Shellfish Immunol 27: 773-776.
- 475 20. Tobar JA, Jerez S, Caruffo M, Bravo C, Contreras F, Bucarey SA, Harel M
476 (2011) Oral vaccination of Atlantic salmon (*Salmo salar*) against
477 salmonid rickettsial septicaemia. Vaccine 29: 2336-2340.
- 478 21. Rombout JHWM, van den Berg AA, van den Berg CTGA, Witte P, Egberts E
479 (1989) Immunological importance of the second gut segment of carp. III.
480 Systemic and/or mucosal immune responses after immunization with
481 soluble or particulate antigen. J Fish Biol 35: 179-186.
- 482 22. Joosten PHM, Tiemersma E, Threels A, CaumartinDhieux C, Rombout JHWM
483 (1997) Oral vaccination of fish against *Vibrio anguillarum* using alginate
484 microparticles. Fish Shellfish Immunol 7: 471-485.
- 485 23. Berzofsky JA, Ahlers JD, Derby MA, Pendleton CD, Arichi T, Belyakov IM
486 (1999) Approaches to improve engineered vaccines for human
487 immunodeficiency virus and other viruses that cause chronic infections.
488 Immunol Rev 170: 151-172.

- 489 24. Weiner HL, da Cunha AP, Quintana F, Wu H (2011) Oral tolerance. *Immunol*
490 *Rev* 241: 241-259.
- 491 25. Matsuo A, Oshiumi H, Tsujita T, Mitani H, Kasai H, Yoshimizu M, Matsumoto
492 M, Seya T (2008) Teleost TLR22 recognizes RNA duplex to induce IFN
493 and protect cells from birnaviruses. *J Immunol* 181: 3474-3485.
- 494 26. Munang'andu HM, Fredriksen BN, Mutoloki S, Brudeseth B, Kuo TY, Marjara
495 IS, Dalmo RA, Evensen O (2012) Comparison of vaccine efficacy for
496 different antigen delivery systems for infectious pancreatic necrosis virus
497 vaccines in Atlantic salmon (*Salmo salar* L.) in a cohabitation challenge
498 model. *Vaccine* 30: 4007-4016.
- 499 27. Evensen O, Rimstad E (1990) Immunohistochemical identification of infectious
500 pancreatic necrosis virus in paraffin-embedded tissues of Atlantic
501 salmon (*Salmo salar*). *J Vet Diagn Invest* 2: 288-293.
- 502 28. Thuvander A, Fossum C, Lorenzen N (1990) Monoclonal antibodies to
503 salmonid immunoglobulin: characterization and applicability in
504 immunoassays. *Dev Comp Immunol* 14: 415-423.
- 505 29. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using
506 real-time quantitative PCR and the 2⁻(-Delta Delta C(T)) Method.
507 *Methods* 25: 402-408.
508
509

510 **Figures Legends**

511 Figure 1. Infectious pancreatic necrosis virus (IPNV) mRNA expressed by real time
512 RT-PCR in selected organs of Atlantic salmon following oral boost with different
513 antigen preparations. This assay was used as a surrogate marker of retained
514 formalin-inactivated IPNV antigens in the present study. All fish were vaccinated
515 with an oil-based vaccine one year prior to the start of this study. The control fish
516 received no booster oral antigens. n=30; *statistically significant $p < 0.05$.

517

518 Figure 2. Infectious pancreatic necrosis virus-specific serum antibody levels in orally
519 boosted groups of Atlantic salmon relative to un-boosted controls. Antibodies were
520 assessed by ELISA and the results were obtained by using a plate reader (TECAN,
521 Genios) at a wavelength of 492nm. n=30; *statistically significant $p < 0.05$.

522

523 Figure 3. Mean relative expression of A) CD4; B) GATA3; C) IgT; and D) IgM genes
524 of fish orally boosted with different antigen preparations compared to un-boosted
525 controls. Real-time RT-PCR. n=30; *statistically significant $p < 0.05$.

526

527 Figure 4. Mean relative expression of A) FOXP3; B) TGF- β and C) IL-10 genes in
528 fish orally boosted with different antigen preparations compared to un-boosted
529 controls. Real-time RT-PCR. n=30; *statistically significant $p < 0.05$.

530

531 Figure 5. Schematic illustration of the trial plan used in the present study. Atlantic
532 salmon growers previously (1 year) vaccinated against IPNV were split into three
533 groups. Each group was further divided into three replicates (tanks) that were boosted
534 twice orally for one week. Sampling was at 7 weeks post primary boost (a day before

535 the second boost) and at the end of the trial. Ten fish from each tank (30 fish per
 536 group) were sampled at each time point.

537

538 **TABLES**

539 Table 1: Fish size in unit of mass (g), Weekly feed intake (FI) per fish, weekly IPNV
 540 antigen dose per fish and weekly IPNV antigen (Ag) dose per unit of fish mass
 541 (dose/kg).

542

Period	Group	Feed	Fish size (g) ±SD	Feed intake (g/fish/week) ±SD	IPNV Ag dose (TCID ₅₀ /fish/week) ±SD	IPNV Ag dose (TCID ₅₀ /kg/week) ±SD
Primary boost	Control	CF-1	395±92	24.7±0.4	0.00	0.00
	Unencap	OBF-1	375±82	23.9±2.4	9.6×10 ⁸ ±1×10 ⁸	2.6×10 ⁹ ±6×10 ⁸
	Encap	OBF-2	426±121	23.1±0.9	9.3×10 ⁸ ±4×10 ⁷	2.2×10 ⁹ ±6×10 ⁸
Second boost	Control	CF-2	846±135	39.6±0.4	0.00	0.00
	Unencap	OBF-4	796±126	37.3±3.9	1.1×10 ⁹ ±1×10 ⁸	1.4×10 ⁹ ±3×10 ⁸
	Encap	OBF-5	782±105	38.0±1.3	1.1×10 ⁹ ±4×10 ⁷	1.5×10 ⁹ ±2×10 ⁸

543

544

545 Table 2. Sequences of primers used in this study.

Genes	Accession number	Primer sequence 5'-3'	D*
β-actin	BT047241.2	CCAGTCCTGCTCACTGAGGC	F
		GGTCTCAAACATGATCTGGGTCA	R
IgT	HQ379938.1	AGAGGTGAAGACACACCGGTCATT	F
		ACGGAGTAGTTGCCTTTCTGGGTT	R
CD4	DQ867019.1	GAGTACACCTGCGCTGTGGAAT	F
		GGTTGACCTCCTGACCTACAAAGG	R
GATA3	NM001171800.1	CCCAAGCGACGACTGTCT	F
		TCGTTTGACAGTTTGACACATGATG	R
IgM	AF228580.1	TGAGGAGAACTGTGGGCTACACT	F
		TGTTAATGACCACTGAATGTGCAT	R
FOXP3	HQ270469	AGCTGGCACAGCAGGAGTAT	F
		CGGGACAAGATCTGGGAGTA	R
TGF-β	BT059581.1	AGTTGCCTTGTGATTGTGGGA	F
		CTCTTCAGTAGTGGTTTGTCG	R
IL-10	AB118099.1	CGCTATGGACAGCATCCT	F
		AAGTGGTTGTTCTGCGTT	R
IPNV	NC_001915.1	ATGCCAAGATGATCCTGTCCACA	F
		TGCCTTTGAGGTTGGTAGGTCACT	R

546 D* direction of primer.

547

548




Figure 1




Figure 2





Figure 3a

Figure 3b







Figure 3c






Figure 4a




Figure 4b

C




Figure 5

